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ABSTRACT 
Purpose:  Neuroendocrine Tumours (NETs) are rare and therefore poorly understood. 
Their slow progression and general poor response to standard chemotherapy regimes 
implies that their tumour biology is significantly different from most common cancers. 
There  have  been  major  advances  in  the  past  few  decades  in  the  diagnosis  and 
management of these tumours which are perceived to be associated with improvements 
in quality and length of life. However, since most NETs have metastasised extensively 
by  the  time  of  diagnosis  it  is  a  major  challenge  indeed  to  try  and  effect  tumour 
regression – the ultimate goal of any anti-cancer therapy.                                                                      
 
Chapters: 2 & 3: The epidermal growth factor receptor (EGFR) is commonly expressed 
in human tumours and provides an important target for therapy.  Several classes of 
agents including small molecule inhibitors and antibodies are currently under clinical 
evaluation.  These agents have shown interaction with chemotherapeutic agents in vitro 
and in vivo.  However, the mechanisms of these interactions are not clearly understood, 
particularly  in  regards  to  NETs.    The  purpose  of  this  study  was  to  investigate  the 
expression of EGFR in NET tissue and to determine its mechanisms of action, as well as 
the effects of modulation of EGFR activation. 
Experimental Design (Chapter 2): Paraffin-embedded tumour tissue was available 
from 98 patients with NETs (39 foregut, 42 midgut, four hindgut, five paragangliomas, 
and four of unknown origin). Immunohistochemical evaluation was performed for the 
expression of EGFR, p-EGFR, p-Akt, and p-ERK1/2. 
Results: Ninety-six percent of tumour samples were positive for EGFR expression; 63% 
were positive for activated EGFR; 76% were positive for activated Akt; and 96% were 
positive for activated ERK1/2. Importantly, the histological score for the activation of 
Akt and ERK1/2 correlated with the histological score for activated EGFR. These data 
provide a rationale for considering EGFR inhibitors in the treatment of NETs. 
Additionally, direct inhibition of Akt and ERK1/2 may provide further therapeutic 
options in the treatment of NETs in the future. 
 
Experimental Design (Chapter 3):  The effects of the EGFR inhibitors gefitinib and 
erbitux were determined in several NET cell lines. The modulation of DNA-PK activity   2 
by  these  agents  was  quantitated  using  a  variety  of  techniques  including 
immunoprecipitations,  immunoblotting,  cellular  fraction  extractions  and 
immunohistochemistry.  
Results: Prolonged EGFR inhibition leads to reduction in DNAPKCS concentration in 
all  tested  NET  cell  lines  except  RIN,  which  displays  the  lowest  levels  of  EGFR 
expression. This reduction in DNAPKCS is likely to lead to sensitisation of NET cells to 
ionising radiation, which causes double-strand DNA breaks, DNAPKCS being crucial to 
their repair.   
There  are  direct  EGFR/DNAPKCS  interactions  in  NET  cell  lines,  which  can  be 
enhanced by EGFR inhibition. 
EGFR inhibition leads to transfer of DNAPKCS from the nucleus to the cytoplasm in 
SHP and BON cell lines but not in CRI, RIN, or NCI cell lines. This difference in the 
observed outcomes may be due to the lack of or mutations in intermediary proteins, 
though proof is needed for this hypothesis. The re-distribution of DNAPKCS is likely to 
lead  to  sensitisation  of  NET  cells  to  ionising  radiation,  which  causes  double-strand 
DNA breaks, DNAPKCS being crucial to their repair.   
 
Chapter 4: Surgery is at present the only therapy with the possibility of achieving a 
cure. Therefore optimising diagnostic modalities in order to discover the tumours early 
or to discover all the tumour lesions prior to surgery would be of use. The purpose of 
this  project  was  to  assess  the  role  of 
99mTc-depreotide  in  patients  with  negative  or 
weakly positive OctreoScan® (Krenning score ≤ 1; measured on a scale range 0-4). To 
determine the usefulness of 
99mTc-depreotide scintigraphy for highlighting lesions that 
may be missed by OctreoScan® and/or CT/MRI imaging. 
Experimental  Design:  Prospective  analysis  of  25  NET  patients,  with  negative  or 
weakly positive ¹¹¹In-pentetreotide scans, who were consecutively enrolled to undergo 
¹¹¹In-pentetreotide and 
99mTc-depreotide imaging. The results were compared with either 
CT or MRI scans.  
Results: Histology was available for 20 of 25 patients: of these 40% had high grade 
tumours  (cellular  proliferation  marker  Ki67  score  >  20%),  a  further  35%  had 
intermediate  grade  tumours  (Ki67  2-20%),  and  the  remainder  25%  had  low  grade 
tumours (Ki67<2%). 52% of patients had completely negative and 48% had weakly 
positive OctreoScan®. 32% of these same patients had significantly positive 
99mTc-  3 
depreotide scans (Krenning score ≥ 2), with the histology demonstrating intermediate or 
high grade tumours.  
 
Chapter 5: Some NETs follow an indolent course compared to others which display a 
rapidly  progressive  course  with  only  short-lived  response  to  therapy.  Being  able  to 
confidently predict the long-term prognosis is obviously desirable. The  aims of this 
project  were  to  determine  the  diagnostic  and  prognostic  value  of  serum  alpha-
fetoprotein (AFP) and human chorionic gonadotrophin beta (hCGβ) in NETs.  
Patients and methods: a database  containing biochemical, histological, and survival 
data on 360 NET patients was constructed. This data was statistically assessed, using 
SPSS statistics package, to determine the utility of commonly measured tumour markers 
with particular emphasis on AFP and hCGβ. 
Results: AFP and hCGβ were raised in 9.5% and 12.3% of patients respectively, and 
jointly  raised  in  9.1%  of  patients  in  whom  it  was  measured.  AFP  levels  associated 
strongly and positively with tumour grade, serum CgA, hCGβ levels and worse survival. 
hCGβ levels also associated strongly and positively with serum CgA,  AFP levels and 
worsening survival.  
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INTRODUCTION 
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1.1  Neuroendocrine Tumours (NETs) 
The neuroendocrine system consists of neuronal cells in the central and peripheral 
nervous system, endocrine cells disseminated in the mucosa of hollow organs, and 
endocrine cells in the classical endocrine glands. Greater than a dozen neuroendocrine 
cells have been described in humans, sharing common morphological, biochemical, and 
ultra-structural features. Malignant transformation of these cells may give rise to a 
variety of tumours (fig 1.1) (Hofsli E 2006). 
 
Figure 1.1: Malignant transformation of the body’s neuroendocrine cells can give rise 
to a variety of neuroendocrine tumours. 
 
Despite the low incidence of NETs, their prevalence is relatively high, reflecting their 
lower malignant potential compared to the common epithelial cancers, a higher grade of 
differentiation, and a slower growth rate (Hofsli E 2006). 
Diagnosis of neuroendocrine tumours is often delayed as their presentation is similar to 
common  conditions  such  as  irritable  bowel  syndrome.  Diagnosis  is  rarely  made 
clinically and usually requires sophisticated laboratory and imaging techniques. In some 
cases,  multiple  peptides  or  hormones  are  responsible  for  symptoms  or  syndromic 
features, and several organs and/or multiple tumours may be involved in the disease 
state, confounding the clinical diagnosis. However, the secretory products these tumours   18 
make,  and  the  clinical  syndromes  that  are  subsequently  produced,  can  be  used  to 
classify these gastroenteropancreatic or neuroendocrine tumours (table 1.1). 
 
Table 1.1  
Classification and leading symptoms of the most frequent endocrine tumours of the 
gastrointestinal tract. (Arnold R
a 2005) 
Name 
(syndrome) 
Leading 
symptoms 
Hormone 
responsible 
Other 
hormones in 
the tumour 
Malignancy 
(%) 
Localisatio
n of 
primary 
Extra-
pancreatic 
localization 
Insulinoma  Hypoglycaemia  Insulin  Glucagon, PP  5–10  Pancreas  Very rare 
Gastrinoma 
(Zollinger–
Ellison 
syndrome) 
Peptic ulcers, 
diarrhoea, 
reflux disease 
Gastrin 
Insulin, PP, 
glucagon, 
ACTH, 
somatostatin, 
chromogranin A 
>90  Pancreas 
Duodenum, 
stomach, 
mesentery 
Carcinoid 
syndrome 
Flushing, 
diarrhoea, 
bronchial 
obstruction 
Serotonin 
Tachykinins, 
prostaglandins, 
chromogranin A 
100  Ileum  Pancreas 
(rare) 
VIPoma 
(Verner-
Morrison 
syndrome), 
pancreatic 
cholera 
Intractable 
diarrhoea, 
hypokalaemia 
VIP, PHI 
PP, glucagon, 
somatostatin, 
chromogranin A 
75  Pancreas   
Glucagonoma 
Erythema 
necrolyticans 
migrans, 
diabetes 
Glucagon 
PP, insulin, 
somatostatin, 
chromogranin A 
50  Pancreas  Rare 
Somato-
statinoma 
Diabetes, 
steatorrhoea, 
gallstones 
Somatostatin  PP, insulin, 
calcitonin  50  Pancreas  Duodenum 
ACTH - Adrenocorticotrophic hormone;  
CRH - corticotrophin-releasing hormone;  
GHRH - growth hormone-releasing hormone;  
PHI - peptide histidine isoleucine;  
PP - pancreatic peptide;  
VIP - vasoactive intestinal polypeptide. 
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1.1.1  Incidence and Mortality 
The data from 6 European countries and USA demonstrates that neuroendocrine 
tumours (table 1.2) are rare with an incidence of 2 to 4 per 100,000, with the lowest 
incidence in Italy, the region of Tuscany, and the highest in the USA, especially among 
the black population. In Europe, there is slightly increased preponderance of women, 
although this may just reflect the increased use of laparoscopy for pelvic conditions 
leading to increased discovery of NETs (table 1.2). (Taal BG 2004)  
 
Table  1.2:  Age-standardised  incidence  of  neuroendocrine  tumours  per  100,000 
inhabitants (Taal BG 2004) 
 
 
 
 
Table 1.3. Primary site and stage of carcinoid tumours in the Netherlands, 1989-1996 
(Taal BG 2004) 
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Carcinoid tumours account for more than half the incidence of NETs (figure 1.2). They 
also account for 13 – 34% of all tumours of the small bowel and 17 – 46% of all 
malignant tumours of the small bowel. They derive from primitive stem cells known as 
enterochromaffin cells which are generally found in the gut wall. Carcinoids may also 
occur in the bronchus, pancreas, rectum, ovary, lung, and elsewhere. They frequently 
metastasize to the regional lymph nodes, liver, and less commonly, to the bones. The 
likelihood of metastases is related to the size of the tumour so that the incidence of 
metastases is less than 15% for tumours smaller than 1cm but rises to 95% for tumours 
greater than 2cm (Vinik AI et al).  
 
Figure 1.2 Neuroendocrine tumours of the gastrointestinal tract: Annual incidence 10 
cases  per  million  (from  Vinik  AI  et  al.  Neoplasms  of  the  gastroenteropancreatic 
endocrine system. In: Holland JF, Bast JR Jr, Morton DL et al, eds. Cancer Medicine, 
Vol 1, 4
th ed. Baltimore: Williams and Wilkins; 1997: 1605-41.)  
 
Carcinoid patients invariably have a long history of vague abdominal symptoms. These 
symptoms persist with a median latency to correct diagnosis of greater than 9 years by 
which time the tumour has metastasized, causing flushing and diarrhoea and slow but 
relentless progression to the patient’s death (fig 1.3).    21 
Figure  1.3:  Natural  history  of  carcinoid  tumours  (from  Vinik  AI  et  al.  Use  of 
somatostatin analog in the management of carcinoid syndrome. Am J Dig Dis Sci. 34: 
14-27, 1989.) 
 
In general, the 5-year survival from neuroendocrine tumours is superior to that from 
metastatic  adenocarcinoma,  and  has  significantly  improved  in  recent  years.  In  the 
Netherlands, patients treated from 1992 onwards fared better than those treated between 
1980  and  1991.  This  may  be  due  to  the  wide  availability  of  octreotide  since  1992, 
whereas the continued positive trend (fig. 1.4) may be related to better supportive care. 
 
Fig. 1.4: Survival in the Netherlands of patients with metastatic carcinoid tumours according to year of 
diagnosis. (Vinik AI et al)   22 
1.2 Diagnosis 
1.2.1 Tumour markers 
A firm diagnosis of NET is dependent on the results from a combination of tests. The 
initial investigations tend to be biochemical in nature; divided into general and specific 
tests and ectopic hormones. The general tests for NETs include: serum chromogranins 
and urinary 5 Hydroxy Indole Acetic Acid. In addition some centres test for neurokinin-
A, hCGβ (human chorionic gonadotrophin-β), ACTH and GHRH. Specific peptides for 
NETs  include:  serum  gastrin,  insulin/C-peptide,  glucagons,  vasoactive  vasointestinal 
peptide, pancreatic polypeptide, and somatostatin.  
Measurement of circulating peptides and amines in patients with
 NETs is helpful on 
three counts.
  
1.  In making the initial diagnosis.
  
2.  In the assessment of treatment.
  
3.  For prognosticating.
  
There is evidence to suggest that CgA and neurokinin-A have prognostic significance. 
However, the value of measuring other tumour markers, such as α-fetoprotein and 
hCGβ is not clear (Turner et al 2006) 
We developed and subsequently analyzed a large database of Royal Free patients in 
order to clarify the prognostic potential of these latter tumour markers. 
 
1.2.2 Imaging  
The optimum imaging modality depends on whether it is to be
 used in detecting disease 
in a patient suspected of a NET or
 for assessing the extent of disease in a known case.
  
1.2.2.1 Imaging in suspected primary 
Gastric, duodenal, chest, and colonic primary sites are easier
 to find as they are likely to 
be discovered at endoscopy or CT scanning. Barium series and CT scans may be normal 
but will
 show larger lesions (for example midgut carcinoid changes including fixation, 
separation, thickening, and angulation,
 and often calcification at the centre of a 
"starburst" appearance
 of the desmoplastic reaction). SSRS (somatostatin receptor 
scintigraphy, usually octreoscan®) may be useful in tumours greater than 1cm diameter   23 
and expressing SSTR2 (see 1.2.2.2) mesenteric
 angiography may also be useful.
 A small 
primary, such as an intestinal NET, may not be seen on imaging
 and thus a patient with 
abdominal pain and change in bowel habit
 over many years is often labelled as having 
irritable bowel
 syndrome. 
The so called non-functioning pancreatic NETs which do not have an associated 
syndrome, due to over-secretion of a hormone such as insulin or gastrin, are usually 
detected late in
 the course of the disease and seen on CT, MRI, or SSRS. Functioning
 
pancreatic NETs may be identified earlier, due to their associated syndromes such as 
repeated episodes of hypoglycaemia and Zollinger Elison syndrome. The potential
 for 
surgical cure necessitates accurate localisation which may
 be performed using CT, MRI, 
endoscopic ultrasound, often together with SSRS, and
 in some centres digital 
subtraction angiography with intra-arterial calcium stimulation. 
1.2.2.2 Imaging for detecting the primary tumour when the patient has already 
presented with metastases 
Investigations for localising the primary site
 may include:
 ultrasound scans of the 
abdomen, testes, and ovaries; endoscopic ultrasound; CT
 scan of the chest (bronchial 
carcinoid), abdomen, and pelvis;
 endoscopy-colonoscopy and gastroscopy; barium 
studies; and nuclear
 medicine functional imaging. In one series, primary tumours
 were 
localised in 81–96% of cases using radiological and/or
 nuclear medicine imaging, 
although opinion is divided on whether locating
 the primary in the setting of metastatic 
disease changes prognosis. Endoscopic ultrasound is a useful diagnostic investigation
 in 
a patient with a suspected pancreatic NET. Its sensitivity
 may be less with 
extrapancreatic gastrinomas (80% of gastrinomas
 in MEN1 are found in the duodenum) 
for which an upper gastrointestinal
 endoscopy and CT or MRI should be performed 
first. 
Neuroendocrine tumours express somatostatin receptors (SSTR)
 and this has led to the 
development of radiolabelled somatostatin
 analogues for diagnostic imaging 
(somatostatin receptor scintigraphy – SSRS). There are five receptor subtypes,
 of which 
only subtype 2 and 5 are targeted for imaging by Octreoscan®. With the exception of 
insulinomas (with only 50% of
 this tumour group expressing SSTR2), SSRS plays a 
central role in locating
 and assessing the tumour site in gastroenteropancreatic NETs   24 
with reported sensitivity of up
 to 90%. The sensitivity could be further
 enhanced by the 
use of single positron emission computed tomography
 and fusion imaging with CT.  
Unfortunately, a negative octreoscan not only reduces diagnostic efficiency but also 
limits treatment options based on somatostatin analogues as at least moderately 
positive SSTR imaging is required for SSTR targeted radiotherapy, an important 
modality of anti-NET therapy. 
Hence there is a need for improving the sensitivity of SSTR scintigraphy. 
1.3 Management  
As with other cancers, such as breast or colon, the best chances of cure are when the 
disease is diagnosed at an early stage and is surgically removed in its entirety. Once 
distant  metastases  have  developed,  the  chances  of  a  cure,  surgical  or  otherwise  are 
remote.  Treatment  is  then  aimed  at  providing  symptom  palliation,  and  if  possible, 
prolonging  survival.  There  is,  therefore,  a  need  to  understand  the  biology  of  these 
tumours  in  order  to  decide  on  the  best  treatment  regimens,  from  those  currently 
available to patients with other tumours, as well as to develop novel therapies specific 
for NET patients. 
When the tumour is un-resectable the treatment has two objectives:  
1) To control symptoms, produced by hormone secretion, and thereby improve quality 
of life;  
2) To extend survival by effecting tumour reduction or limiting tumour growth.  
 
Chemotherapy has shown efficacy in managing NETs of foregut, including pancreatic 
origin, but is of limited benefit in mid-gut and hind-gut carcinoid tumours [4-6]. This 
has led to the search for novel agents capable of slowing the progress of NETs as well 
as providing symptom control. With the exception of pancreatic and high grade NETs, 
the majority of NETs are relatively insensitive to chemotherapeutic agents. The main 
aim of anti-NET therapy in these cases, until recently, has been to provide symptom 
control using somatostatin analogues. In the last 2 decades there has been a significant 
expansion in the available options of anti-tumour therapy, but as with other cancers 
there continues to be a great need for new and more potent treatments. 
Current treatment options for metastatic NETs are (also see figure 1.5):   25 
1)  Surgery: removal of the primary, tumour debulking, and in rare cases liver 
transplantation. 
2)  Monitoring only: if tumour is inoperable, asymptomatic and observed to be 
radiologically, biologically, and clinically stable. 
3)  Biotherapy: Somatostatin analogue and/or interferon therapy – if tumour is 
symptomatic,  due  to  hormone  production,  but  radiologically  stable.  It  can 
temporarily stabilise the tumour in majority of patients treated and may even 
cause tumour regression in a small minority. 
4)  Chemotherapy: in a subgroup of progressive NETs known to be sensitive to 
this form of therapy. 
5)  Intravenously administered targeted radiotherapy for chemo-resistant NETs: 
using either radiolabelled-mIBG or radiolabelled somatostatin analogues. 
6)  Intra-arterially administered selective internal radiotherapy (SIRT; considered 
experimental  and  only  available  in  specialist  centres):  using  radiolabelled 
somatostatin analogues, usually when the bulk of the tumour is confined to the 
liver. 
7)  Ablative methods: trans-arterial chemoembolisation, radiofrequency ablation, 
ethanol ablation.  
 
 
Figure 1.5: An algorhythmn for treating neuroendocrine tumours (Arnold R
a 2005) 
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1.3.1 Biotherapy:  
1.3.1.1 Somatostatin analogues 
Somatostatin (SS) is a natural polypeptide which circulates as physiologically active 
somatostatin-14 and somatostatin-28. It is a powerful inhibitor of endocrine and 
exocrine function affecting, amongst others, the release of insulin, gastrin, glucagon, 
gastric secretions, and pancreatic secretions. These inhibitory effects are the core basis 
for the role of somatostatin and its analogues in providing symptom control in NET 
patients. SS has also been shown to have apoptotic and cytostatic effects on various 
tumour cell types [Chen C 1992, Buscail L et al 1994, Buscail L et al 1995, Liebmann C 
2001]. 
SS acts through G-protein linked cell surface somatostatin receptors, of which there are 
five subtypes, 1-5. Both SS14 and SS28 are known to bind to all somatostatin receptor 
(SSTR) subtypes with high affinity. Binding to SSTR1 increases mitogen activated 
protein kinase (MAPK) activity, which would be expected to lead to cellular 
proliferation, but the final outcome is anti-proliferative due to induction of cell-cycle 
arrest. SSTR2 stimulation leads to activation of SHP-1 followed by trans-inactivation of 
EGFR and decrease in MAPK activity. SHP-1 also appears to be responsible for 
inducing cell-cycle arrest in response to SSTR2 activation. SSTR3 induces apoptosis by 
increasing the p53 level. SSTR4 is unusual in that its activation leads to cellular 
proliferation, achieved via activation of MAPK. SSTR5 mediates cell-cycle arrest by 
activation of a protein tyrosine phosphatase [Chen C 1992, Buscail L et al 1994, Buscail 
L et al 1995, Liebmann C 2001].  
SS and its analogues (octreotide™ and lanreotide™) have been shown to exert an 
indirect antiproliferative effect on various normal and cancerous cells, both in vitro and 
in vivo, through numerous mechanisms: by the inhibition of release of growth factors 
and trophic hormones (GH, IGF-1, insulin, gastrin, EGF); inhibition of angiogenic 
processes (endothelial cell proliferation, VEGF release, monocyte activity), and 
immunomodulatory effect (lymphocyte proliferation, interleukin or cytokine release, 
natural killer cell activity) [Buscail L et al 2002].  
 
The use of radio-labelled somatostatin analogues for imaging and detection of mRNA 
expression with in-situ hybridisation or reverse transcription-polymerase chain reaction 
has allowed the characterisation of the expression of somatostatin receptors in a large 
variety of human tumours, including NETs. Full range of SSTR subtypes can be   27 
expressed by tumours but SSTR2 appears to be the most prevalent, with 80-90% of 
NETs expressing SSTR2 [Jonas S et al 1995, Benali N et al 2000, Nilsson O et al 1998, 
Shi W et al 1998, Reubi JC et al 1987, Thulin L et al 1978].  
 
The beneficial effect of SS in symptom control was initially described in the late 1970s. 
However, it has a half life of two minutes thereby necessitating a continuous infusion 
which, together with the occurrence of rebound symptoms upon treatment cessation, 
made it impractical for clinical use in the outpatient setting. Over the last two decades 
the availability of longer acting SS analogues has greatly facilitated their use for the 
control of symptoms in patients with carcinoid syndrome and other functioning NETs. 
Inhibition of tumour growth and occasional decrease in tumour size has also been 
reported [Saltz L et al 1993, Arnold R et al 1996]. 
 
1.3.1.2 IFN alpha treatment in NETs 
Interferons (IFNs) are biological response modulating agents which have been shown to 
have an effect in a number of tumour types, including melanoma and lymphoma. IFN-α 
is produced by a subset of cells in human peripheral blood in response to various viruses 
and bacteria and has a variety of biological functions. IFNs exert their anti-tumour 
effects through the modulation of multiple cellular mechanisms, including proliferation, 
differentiation, apoptosis, and angiogenesis. There are a number of types of interferon, 
three of which (alpha, beta, and gamma) have been extensively clinically investigated. 
IFNs were initially obtained from human leukocytes which limited their availability. 
Later recombinant interferon alpha became available thereby allowing its use in larger 
numbers of patients. IFNs have been used alone or in combination with chemotherapy 
and somatostatin analogues in mainly carcinoid subgroup of NETs.  
 
Analysis of pooled data, from published studies, indicates median symptomatic and 
biochemical response   rates of 40 – 70% and 44% respectively, with median tumour 
response rate of 11%. Disease stabilisation is reported in median 35% of patients, with 
tumour progression in 15 – 20%. Median duration of response is 32 months [Oberg K 
1991]. There is no clear dose/response relationship as shown by the lack of improved 
response by high dose interferon [Moertel CG et al 1989]. The recommended doses of 
recombinant IFNα are 3 – 9MIU every day or every other day, median 5MIU every 
other day, by sub-cutaneous injection. However, the dose should be titrated according to   28 
the sex, age, and weight of the patient [Eriksson B 1993, Oberg K 1992]. The leukocyte 
count can also be used to titrate IFN dose, by aiming to reduce the leukocyte count to 
<3.0 x 10
9 / litre. This approach does not increase the risk of infection [Oberg K  2000].  
 
IFN therapy is commonly associated with flu-like symptoms which tend to be short 
lived, lasting for a week or so, and can be treated with paracetamol. Chronic fatigue 
syndrome and depression, of various grades, can develop in up to 50% of patients. 
These side-effects are more difficult to manage and may lead to cessation of treatment. 
Serotonin uptake inhibitors have shown efficacy in treating IFN associated depression 
and therefore may help improve compliance [Benedetti F et al 2004]. Autoimmune 
manifestations are seen in 15 – 20% of patients, with majority developing thyroid 
dysfunction, which in turn may contribute to fatigue. More severe autoimmune 
reactions include the SLE syndrome and polymyositis. 1/3
rd of patients develop mild 
derangement of liver enzymes which only occasionally require treatment withdrawal 
[Oberg K 2000].  
 
 
1.3.2  Chemotherapy 
NETs have usually metastasized to the lymph nodes, liver, bone, brain, and other sites 
by the time of diagnosis. Tumour progression is related to the degree of differentiation: 
well differentiated NETs display slow progression and prolonged survival; and poorly 
differentiated  NETs  display  rapid  progression  and  short  survival.  Systemic 
chemotherapy would be expected to play a major role in the management of metastatic 
NETs.  However,  experience  has  shown  that  chemotherapy  is  only  effective  in  a 
subgroup of NET patients, mainly: well differentiated NETs of the pancreas, and poorly 
differentiated NETs of any origin (Arnold R 2005). 
 
1.3.2.1 Well differentiated neuroendocrine tumours of the pancreas 
Many chemotherapeutic substances have been trialled in NET patients. Amongst these 
are carboplatin, chlorozotocin, DTIC, doxorubicin, etoposide, streptozocin (STZ), and 
paclitaxel. Objective response rates have generally been low apart from for treatment 
with STZ. 
Streptozocin was isolated from Streptomyces organisms in 1956 and was shown to have 
anti-microbial and anti-tumour activity. During pre-clinical toxicology studies, it was   29 
discovered to cause hyperglycaemia in rats and dogs. This was subsequently shown to 
be due to rapid islet-cell degranulation by STZ, leading to permanent diabetes mellitus. 
These findings led to the focus of STZ use in patients with pancreatic islet cell tumours. 
STZ was first used to treat patients with multiple hormone producing metastatic islet 
cell tumours producing clinical effects including hypoglycaemic episodes (Varva JJ et al 
1959, Rakieten N et al 1963, Evans JS et al 1965). STZ displayed a beneficial effect on 
the  clinical  symptoms  of  hypoglycaemia  as  well  as  demonstrating  objective  tumour 
response.  Later  studies  confirmed  monotherapy  with  STZ  to  be  equally  effective  in 
functioning and non-functioning tumours, with a response rate of about 36% (Moertel 
CG et al 1980). 
Streptozocin  combinations:  STZ  in  combination  with  5-fluorouracil  (5-FU)  showed 
significantly improved response rate as compared to STZ alone. An overall response 
rate of 63% v 36% was observed (with complete response rate of 33% v 12%) for 
combination v mono-therapy respectively. The response was similar for functioning and 
non-functioning tumours (Moertel CG et al 1980). STZ is also given in combination 
with  doxorubicin  and  has  been  shown  to  produce  the  best  response  rates,  although 
associated  with  severe  side-effects  including  long-lasting  nausea  and  vomiting, 
haematological toxicity, and heart failure, which limit its use (Moertel CG et al 1992). 
 
1.3.2.2 Well differentiated tumours of the gastrointestinal tract 
The sensitivity of gastrointestinal neuroendocrine tumours to chemotherapeutic agents 
is  low.  The  median  reported  response  rate  to  therapies  such  as  actinomycin  D, 
carboplatin,  cisplatin,  doxorubicin,  DTIC,  etoposide,  mitomycin  C,  paclitaxel,  STZ, 
STZ + 5-FU, STZ + cyclophosphamide, STZ + doxorubicin, 5-FU + doxorubicin + 
cisplatin,  dacarbazine  +  5-FU,  and  others  is  17%.  Chemotherapy,  therefore,  is  not 
recommended for the treatment of these patients at present (Jensen RT 2001). 
 
1.3.2.3 Poorly differentiated tumours of the gastrointestinal tract 
A  small  group  of  patients  with  poorly  differentiated  neuroendocrine  tumours  of  the 
gastrointestinal tract were treated with a combination of etoposide + cisplatin. In 12 of 
18 patients, with anaplastic NETs, objective tumour regression was seen, with disease 
stabilisation for a median of 11 months (Moertel CG 1986). 
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1.3.3  Somatostatin receptor targeted radionuclide therapy 
Radiotherapy  is  an  established  form  of  treatment  for  many  tumour  types  including 
gastrointestinal cancers. Radiation causes DNA and cell-membrane damage leading to 
activation of various pathways that end in activation of executioner caspases and cell 
apoptosis (figure 1.6). 
 
Figure 1.6: Radiation induced apoptosis occurs via multiple pathways, some of which 
are energy dependant. ATP dependant steps are indicated by the stars. SAPK – stress 
activated protein kinase pathway. cs – ceramide synthase. MRN – Mre11-Rad50-Nbs1. 
(Hunter A et al 2006).  
 
 
 
The majority of neroendocrine tumours express SSTRs with SSTR2 being the most 
frequently expressed subtype. In patients with un-resectable neuroendocrine tumours of 
the gastrointestinal tract, there is now reasonable evidence to support SSTR targeted 
radiotherapy. This “magic bullet” form of treatment has been rapidly developing over 
the past 2 decades.  
SSTR  targeted  radiotherapy  was  developed  from  SSTR  targeted  scintigraphy  by 
increasing the radiation dose of the administered radiolabelled somatostatin analogue in 
an attempt to cause tumour shrinkage. Since then, several radiolabelled SSTR targeting 
agents  have  been  developed  using  a  range  of  radionuclides  with  variable  physical   31 
characteristics (
111In, 
90Y, 
177Lu being the commonest), chelating agents (such as DTPA 
and DOTA) and somatostatin analogues (such as octreotide, octreotate, and lanreotide). 
These components, variously combined, give a range of affinities for SSTRs, though 
they all bind preferentially to SSTR2 as opposed to other SSTR subtypes (table 1.4).   
 
 
Table 1.4: Affinity profile (IC50) for human somatostatin receptors hSSTR1-5 of a 
series of somatostatin analogues (Jaap J.M et al 2005).  
 
 
[
90Y-DOTA-Tyr3]octreotide  for  instance  has  been  shown  to  be  effective  in  treating 
moderate to large metastases (≥1 cm
2; 7-9cm
2), in rat models, as 
90Y emits high energy 
β-particles which have a maximum tissue penetration range of 12mm and can therefore 
seriously damage approximately 600 cells surrounding the index cell, hopefully leading 
to cell apoptosis (table 1.5).  
[
177Lu-DOTA0-Tyr3]octreotate has an order of magnitude greater binding affinity for 
SSTR2. This agent has shown good results in the treatment of smaller tumours (≤1 cm2) 
as radiation from 
177Lu has a shorter tissue penetration range (2mm; 100 cells) than 
90Y 
(table 1.5).  
[
90Y-DOTA]lanreotide shows high affinity for SSTR2 and SSTR5. It has been shown to 
be  as  effective  as  [
90Y-DOTA-Tyr3]octreotide  in  the  treatment  of  metastatic 
gastrointestinal neuroendocrine tumours. This reagent may become important in treating   32 
patients whose tumours either do not express SSTR2, or have lost SSTR2 expression 
during  progression  from  a  low-grade  tumour  to  high-grade  tumour,  but  continue  to 
express SSTR5 (Virgolini I et al 2002). 
 
Table  1.5:  Physical  characteristics  of  the  radionuclides  used  in  peptide  receptor 
radionuclide therapy (Jaap J.M et al 2005). 
 
 
All these reagents are useful in controlling tumour progression, but treatment rarely 
leads to cure.  
Failure of radiotherapy induced DNA damage to cause apoptosis is an important 
mechanism for limiting disease response. 
Encouraging radiotherapy induced apoptosis by blocking anti-apoptosis / cell-repair 
pathways should therefore improve response rates. Discovery of relevant cell repair 
mechanisms, which could be suitable for pharmacological manipulation, is part of the 
remit of this research thesis. 
 
1.3.4 Chemoembolisation of liver metastases  
Neuroendocrine tumour patients usually have liver metastases by the time of diagnosis. 
Often the bulk of tumour burden lies in the liver. When possible, surgery is the best 
form of treatment for liver metastases. However, a high proportion of patients have 
diffuse bi-lobar disease not amenable to surgery. Systemic chemotherapy can be given 
in  these  cases,  especially  when  the  disease  is  progressive  and/or  symptomatic,  and 
shows  reasonable  results  in  patients  with  pancreatic  primaries.  Patients  with  liver 
metastases from midgut primaries, however, do not respond well to chemotherapy and 
their 5-year survival rate is reported to be 0-40%. Liver metastases can be responsible 
for endocrine hyperfunction resulting in symptoms, such as carcinoid syndrome, which   33 
can be difficult to control. Somatostatin analogues may be efficacious in controlling 
these  symptoms  but  their  effect  tends  to  wear  out  usually  with  time,  due  either  to 
tachyphylaxis or tumour progression. 
Vascular occlusion aiming at selective ischaemia induction of hepatic metastases has 
been in use for some time. This initially consisted of surgical ligation of hepatic artery 
to produce transient or intermittent hepatic ischaemia. These methods were commonly 
associated with severe complications as well as high treatment associated mortality.  
 
1.3.5 Sequential hepatic artery embolization 
 
A percutaneous technique, for radiologically guided hepatic artery embolization, has 
been developed. Portal vein patency has to be demonstrated and tumour vasculature 
visualised. Selective catheterization of hepatic artery branches is achieved followed by 
contrast injection and embolization of fragments of absorbable gelatine sponge. This 
technique has been efficacious in neuroendocrine tumour metastases to the liver, as well 
as  advanced  non-resectable  hepatocellular  carcinoma  and  liver  metastases  from 
colorectal cancer. (O’Toole & Ruszniewski 2005).   
 
1.3.6 Trans-catheter arterial chemoembolization (TACE) 
 
This  employs  the  same  technique  as  hepatic  artery  embolisation,  but  in  addition  an 
emulsion  made  from  a  cytotoxic  drug  (e.g.  adriamycin  50mg/m2  or  STZ  1.5g/m2) 
dissolved in 10ml of normal saline and combined with 10ml of iodized oil (Lipoidol®) 
is injected prior to embolization with gelatine sponge 2-3mm particles or microspheres 
(Embospher®).  Patients  need  to  be  pre-medicated  with  intravenous  hydration  and 
antibiotics, somatostatin analogues (in cases of carcinoid syndrome in order to prevent 
carcinoid  crises),  anti-emetics,  and  analgesia.  STZ  administration  requires  a  general 
anaesthetic because of the severe pain associated with the administration of this acidic 
agent. The results from various studies are encouraging (O’Toole & Ruszniewski 2005; 
table 1.6). 
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Table 1.6: Symptoms and hormonal secretion (O’Toole & Ruszniewski 2005). 
 
 
 
1.4 Promising fields for study in the management of NETs: 
Modulation  of  DNA-damage  repair  mechanisms  through  better 
understanding of EGFR/DNA-PKCS interactions 
 
 
1.4.1  Intrinsic causes of DNA Damage 
The integrity of genomic DNA is constantly under threat. DNA damage can result from 
the  action  of  endogenous  reactive  oxygen  species  (ROS)  such  as  hydroxyl  radicals, 
hydrogen peroxide or superoxide anions. Errors in replication and recombination as well 
as environmental agents such as ultraviolet (UV) light from the sun, ionising radiation 
and genotoxins such as cigarette smoke, can also result in DNA damage in the form of 
single-strand (SSB’s) or double-strand breaks (DSB’s) (Norbury & Zhivotovsky 2004). 
If for any reason the DNA cannot be repaired, mutations may result and the risk of 
cancer increases (Hoeijmakers 2001).  
 
1.4.2  DNA-Interactive Chemotherapeutic Agents 
While unicellular organisms respond to the presence of DNA lesions by activating cell 
cycle  checkpoint  and  repair  mechanisms,  multicellular  animals  have  the  additional 
possibility of eliminating the damaged cells by triggering programmed cell death or 
“apoptosis”.   35 
Anti-cancer agents targeting DNA are some of the most potent treatments in clinical 
practice. They have improved patient survival particularly when used in combination 
with drugs employing differing mechanisms for their anti-tumour activity. They act by 
relatively selectively targeting cells types with a rapid turnover such as cancer cells, 
bone  marrow  and  the  gut  lining.  These  chemotherapeutic  agents  can  be  classed 
according to the nature of their molecular interactions with DNA and the subsequent 
modifications they induce. Figure 1.7 summarises these different interactions namely, 
DNA  strand  crosslinking,  intercalation,  DNA  strand  breaking  and  code  reading 
molecules (Hurley 2002). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7: Classes of DNA-interactive agents and their molecular interactions with 
DNA. 
Source: Adapted from L. Hurley, Nature Reviews Cancer, 2002. 
 
1.4.3  Cellular Response to DNA Damage  
The cell-cycle infrastructure is able to detect DNA damage at specific checkpoints in 
G1, S, G2 and M phases allowing repair of lesions before they become permanent (Zhou 
& Elledge 2000). If the damage is too severe, apoptosis will be initiated at the expense 
of the whole cell. 
Short-term damage to DNA as a result of disrupted DNA metabolism and longer-term 
effects  by  way  of  irreversible  mutations  contributing  to  oncogenesis  and  cannot  be 
reversed by way of a single repair process. No one system can cope with the variety of 
lesions  and  so  at  least  four  main  damage  repair  systems  are  known  to  exist 
(Hoeijmakers  2001).  These  are:  Nucleotide  Excision  Repair,  Base  Excision  Repair, 
Homologous Recombination and Non-Homologous End Joining.    36 
Common  damage  detection  and  signal  transduction  mechanisms  are  shared  between 
pathways governing DNA repair, cell cycle checkpoint activation and apoptosis. By 
allowing the survival and proliferation of cells with damaged DNA, failure of these 
processes contributes to tumourigenesis and resistance to cancer therapies (Igney and 
Krammer 2002). 
 
 
1.4.4 DNA-Dependent Protein Kinase (DNA-PK) and its role in NHEJ  
DNA-PK is a nuclear serine/threonine kinase with a molecular mass of ~460 kDa that is 
involved in non-homologous end-joining (NHEJ) of DNA double-strand breaks, and 
therefore is a key player in DNA damage repair. It is made up of a regulatory subunit, 
containing the Ku70/80 subunits, and a catalytic subunit, DNA-PKCS (Smith & Jackson 
1999; Collis et al. 2005). Electron microscopy shows that DNA-PKCS is divided into 
two large regions, labelled as ‘head’ and ‘palm’ connected by a third region labelled 
‘arm’ (Figure 1.8B) (Brewerton et al. 2004).  
DNA-DNA-PKCS  binding  to  DNA  greatly  stimulates  DNA-PKCS  activity  with  the 
phosphorylation of one of its natural substrates, the XRCC4 protein. This indicates that 
DNA interaction is functionally relevant to DNA-PKCS (Boskovic et al. 2003; Collis et 
al. 2005).  
DNA binding to DNA-PKCS induces conformational changes causing the palm domain 
to  bend,  coming  into  contact  with  the  head  and  exposing  a  small  channel  able  to 
accommodate double-stranded DNA. These structural movements are likely to play a 
role in the activation of DNA-PKCS kinase activity upon DNA binding (Martensson & 
Hammarsten 2002).    37 
Figure 1.8: 3D structure of DNA-PKCS and its DNA-bound complex. 
Source: O. Llorca & L.H. Pearl, Micron, 2004. 
 
DNA-PKCS may also act as a scaffold protein to aid the localisation of DNA repair 
proteins to the site of damage (Collis et al. 2005). DNA-PKCS, as well as Ku, is found at 
the ends of chromosomes, suggesting a further role for DNA-PKCS in the maintenance 
of telomeric stability  and the prevention of chromosomal end fusion  (Espejel 2004; 
Rebuzzini et al. 2004). 
DNA-PKCS and the Ku subunits associate directly with each other even in the absence 
of DNA, and can each bind DNA end structures independently (Lieber et al. 2003). It 
has been suggested that the Ku component of DNA-PK is probably the initial DNA 
double strand breaks (DSBs) sensor in vivo (Collis et al. 2005). It is proposed that Ku 
binds to DNA termini generated at the site of damage to recruit DNA-PKCS, which is   38 
activated upon DNA binding although the key target for phosphorylation by DNA-PKCS 
is  unclear  (Llorca  &  Pearl  2004).  Proteins  phosphorylated  by  DNA-PKCS  include 
regulators  of  the  cellular  DNA  damage  response  such  as  p53,  as  well  as  other 
components of the NHEJ complex such as Artemis, XRCC4 and Ku, as well as DNA-
PKCS itself (Lieber et al. 2003). Once the catalytic subunit of DNA-PK is supporting the 
DNA,  Ku  then  moves  to  a  more  internal  position  where  the  DNA-PKCS  probably 
contributes to hold the two DNA ends together (DeFazio et al. 2002). To finish, the 
XRCC4-DNA-ligase-IV  complex  is  recruited  by  DNA-PK  and  ligation  is  achieved 
(figure 1.9). 
 
Fig. 1.9: Model for non-homologous recombination DNA repair (NHEJ). (A) The 
catalytic subunit of the DNA-dependent protein kinase (DNA-PKcs) is the major 
orchestrator of NHEJ repair in mammalian cells. DNA-PKcs is a large molecule with a 
C-terminal region containing conserved domains named as FAT, FATC and the region 
with homology to the kinase of domain of PI3-kinases (PI3K). It has been postulated 
that the N-terminal portion of DNA-PKcs consists of helical repeats with a low degree 
of conservation. (B) Present models propose that the two Ku subunits are among the 
first proteins to recognise damaged DNA and help recruit DNA-PKcs to the site of 
damage, which in turn acts as scaffolding for other repair factors, included the 
XRCC4/ligase IV complex. DNA-PKcs kinase is activated upon DNA binding and 
phosphorylates substrates that participate in the adequate progression of DNA repair.  
Source: O. Llorca & L.H. Pearl, Micron, 2004. 
 
Role of DNA-PK in DNA repair mechanisms in Neuroendocrine Tumours 
No significant body of work has been published in this field, to date.  
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1.5 Epidermal Growth Factor Receptor (EGFR) 
EGFR was the 1
st cell surface receptor to be linked directly to cancer. The finding that 
EGFR is ligand-dependant tyrosine kinase and that the product of the v-erbB oncogene 
from  avian  erythroblastosis  virus  is  a  truncated  form  of  EGFR,  revolutionised  both 
growth factor and cancer biology. Many cancers are promoted by EGFR activation, 
which can result from mutations of the receptor (leading to constituitive activation), 
EGFR over expression, or from EGFR stimulation through autocrine loops. 
EGFR is a member of the ErbB family of receptors which include: EGFR itself, ErbB2 
(HER2/Neu),  ErbB3  (HER3)  and  ErbB4  (HER4).  Since  its  discovery  more  than  40 
years ago (Cohen 1960), EGFR ligand epidermal growth factor (EGF) has provided 
numerous puzzles for scientists. Recently, major advances in understanding of EGF 
action have come from crystallographic studies of EGFR family of receptor, yielding 
several surprises. A dramatic conformational transition was shown to occur upon ligand 
binding; a receptor-mediated mode of dimerization was identified; and a “preactivated” 
state was defined for the ErbB2 monomer. By combining the information gained from 
the  recent  structural  studies,  models  for  the  allosteric  regulation  of  EGFR  family 
members have been developed. These models have greatly improved our understanding 
of  ErbB  receptor  signaling  and  have  created  opportunities  for  the  design  of  new 
anticancer agents. 
 
1.5.1 ErbB receptors are activated by ligand-induced dimerization 
It is well established that growth factor binding to the extracellular region of EGFR 
promotes dimerization of the monomeric receptor and increases the tyrosine kinase 
activity of its intracellular domain (Schlessinger 2000). Receptor molecules in the 
ligand-induced EGFR dimer become tyrosine autophosphorylated. The resulting 
phosphotyrosines recruit the SH2 domains of multiple downstream signalling 
molecules, thus initiating an array of intracellular signalling pathways (Schlessinger 
2000). Biological activity of EGFR family members is modulated by receptor display, 
ligand availability, ligand/receptor affinity, and competency. EGFR appears to exist in 
two different affinity classes at the cell surface (Ullrich and Schlessinger 1990), with 
2%–5% of receptors binding EGF with high affinity (KD < 0.1 nM) and 95%–98% 
binding with lower affinity (KD 6–12 nM). The affinity classes are thought to represent 
different receptor conformations and/or oligomers.    40 
1.5.2 Growth Factor Ligands that Regulate the Four ErbB Receptors 
EGFR is regulated by a family of at least seven distinct peptide ligands (Groenen et al. 
1994 and Harris et al. 2003), including EGF, transforming growth factor-α (TGF-α), 
amphiregulin, betacellulin, epigen, epiregulin, and heparin binding EGF-like growth 
factor (HB-EGF). ErbB2 has no known direct activating ligand (Citri et al. 2003), while 
ErbB3 and/or ErbB4 function as receptors for the four known neuregulins (NRGs) 
(Falls 2003). All EGFR ligands are expressed as type I integral membrane proteins 
(Harris et al. 2003) and are proteolytically processed to yield the 49–85 amino acid 
mature growth factor that consists largely of the EGF-like domain (Harris et al. 2003). 
The bioactive core of mature NRG isoforms is also their EGF-like domain (Falls 2003).   
1.5.3 Domain Organisation and Relationships with the ErbB Receptor Family 
The four ErbB receptors are closely related single-chain modular glycoproteins with an 
extracellular ligand binding region (620 residues), a single transmembrane domain (23 
residues), and an intracellular tyrosine kinase domain (260 residues) that is flanked by 
juxta-membrane (40 residues) and C-terminal (232 residues) regulatory regions (Figure 
1.10). It is intriguing that this family includes an orphan receptor that nonetheless has 
robust tyrosine kinase activity (ErbB2) and a demonstrated NRG receptor (ErbB3) that 
lacks tyrosine kinase activity (Guy et al. 1994). Each ErbB receptor is thought to have a 
distinct physiological role, which can be modified by ligand-induced formation of ErbB 
receptor hetero-oligomers that are capable of generating unique signalling responses 
(Holbro et al. 2003 and Yarden and Sliwkowski 2001). Thus, the signalling 
characteristics of the 4 ErbB receptors are strongly interdependent.  
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Figure 1.10: Domain Organization of ErbB Receptors.  
 
1.5.4 ErbB Receptor Signalling  
A bow-tie structure of the ErbB signalling is presented in Figure 1.11. The input of 
multiple  growth  factors  that  function  through  eight  potential  receptor  hetero-  or 
homodimers  activates  common  signalling  cascades.  This  results  in  the  specific 
activation of transcription factors that lead to the selected cell fate. The ligands consist 
of 13 growth factors that directly bind to three receptors, ErbB1, ErbB3 and ErbB4. The 
specificity  of  ligand–receptor  interactions  displays  remarkable  redundancy.  For 
example, betacellulin binds to and activates both ErbB1 and ErbB4, whereas epiregulin 
binds to ErbB1, ErbB3  and ErbB4. The multiplicity of ErbB ligands feeds into the 
combinatorial nature of the ErbB network, in which homo- or hetero-dimeric receptors 
can be formed, thereby establishing a high level of complexity. Biochemical evidence 
attributes to each ligand-driven receptor dimer distinct functional properties in terms of 
binding  affinity,  endocytic  routing  and  effector  activation  (Citri  A,  and   Yarden  Y 
2006).   42 
 
 
Figure  1.11:  A  reductionist  view  of  the  bow-tie-architectured  signalling  network  is 
represented. The heart of the system is a collection of biochemical interactions, which 
are tightly coupled to each other and interface with two sets of components: three input 
modules, each comprising an ErbB receptor tyrosine kinase; and a large group of partly 
redundant ligand growth factors. The output of the core process is translated to gene 
expression through multiple transcription factors. Depending on the exact combination 
of transcription factors and the cellular context, the output of the network regulates cell 
behaviour. The system maintains two steady states, for which inter-conversions depend 
on  ligand  binding.  The  fail-safe  action  of  the  system  is  conferred  by  structural 
modularity and functional redundancy, along with rich and stringent system controls. 
An important positive regulator is ErbB2, a co-receptor. Heterodimerization between 
ErbB2 and any of the three ErbB input modules enhances and prolongs the respective 
output.  ErbB2  is  chaperoned  and  catalytically  suppressed  by  heat-shock  protein-90 
(HSP90). On the other hand, a ubiquitin ligase that is involved in receptor degradation, 
Cbl, controls an important negative-feedback loop. Several activation-dependent control 
loops fine-tune. These include transcription of ErbB ligands (positive regulation) and 
newly  synthesized  negative  regulators  such  as  mitogen-inducible  gene-6 
(MIG6)/receptor-associated late transducer (RALT), sprouty (SPRY) and leucine-rich 
repeats and immunoglobulin-like domains-1 (LRIG1).  
EGF  -  epidermal  growth  factor;  EGR1  -  early  growth  response-1;  NRG1/2/3/4, 
neuregulin-1/2/3/4; TGFα - transforming growth factor-α. 
(Citri A, and  Yarden Y 2006). 
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1.5.5 System Controls of the ErbB Signalling Network  
The ErbB network has evolved positive- and negative-feedback circuits in order to 
dynamically control the amplitude, kinetics and frequency of output signals, 
1.5.5.1 Positive-feedback loops.  
Positive-feedback loops enhance the amplitude and prolong the active state of signalling 
pathways. In the case of ErbB, the output of the main switch, namely binding of the 
ligand to the primary receptor, is tuned by the identity of the secondary receptor. ErbB2 
can be considered as an important positive regulator; it functions as the preferred 
secondary receptor, and ErbB2-containing heterodimers evade negative regulation 
(Baulida J et al 1996, Worthylake R 1999,  Lenferink AE et al 1998). 
  
Another important mechanism of positive feedback is based on autocrine and paracrine 
loops, in which EGF-like ligands, as well as angiogenic factors, are produced following 
receptor activation. ErbB-mediated activation of the Ras–MAPK pathway strongly 
induces the transcription of multiple ErbB ligands, including TGFα and HB-EGF 
(Schulze A et al 2001). Similarly, transactivation of ErbB1/EGFR by G-protein-coupled 
receptors occurs through the stimulation of surface proteinases, generating mature, 
active HB-EGF (Schafer B 2004).
  
1.5.5.2 Negative-feedback loops.  
Multiple molecular mechanisms, including post-translational modifications, 
compartmentalization, catalytic inactivation and steric hindrance, lead to signal 
attenuation. It is useful to distinguish between general attenuation, which functions at 
the level of the ligand–receptor complex, and pathway-specific inactivation such as 
inactivation of SOS through phosphorylation by the downstream MAPK. Furthermore, 
negative regulators either pre-exist, or they are newly synthesized following stimulation 
of ErbBs by their respective ligands. 
Pre-existing attenuators primarily control receptor dephosphorylation and degradation. 
Receptor internalization coupled to degradation is considered the most effective, 
irreversible process that robustly attenuates signalling by targeting surface receptors for 
degradation in lysosomes (see below, and Wiley HS 2003). Another general mechanism 
of signal attenuation that functions at the receptor level is instigated by tyrosine   44 
phosphatases such as density-enhanced phosphatase-1, which dephosphorylates ErbB1 
as well as other RTKs (Berset TA et al 2005), and protein tyrosine phosphatase-1B, 
which dephosphorylates RTKs in endosomes (Haj FG 2002). 
Unlike pre-existing attenuators, the level of expression of newly synthesized attenuators 
rises after stimulation, reaching a peak within an hour of the initial stimulation and 
thereby defining the window of active signalling. Transcriptional up-regulation of this 
group of attenuators affects multiple processes. For example, EGF treatment induces 
expression of the suppressor of cytokine signalling-5 (SOCS5) that leads to a marked 
reduction in the levels of the receptor by promoting ErbB1 degradation (Kario E et al 
2005). A further example of a negative-feedback loop that functions downstream of the 
receptor and is common to many mitogens, including ErbB ligands, involves the 
inducible expression of dual-specificity phosphatases of MAPKs, which thereby defines 
the time frame of MAPK activation.   
1.5.6 Loss of System Control 
Several pathological conditions (for example, cancer, psoriasis and atherosclerosis) 
harness the ErbB network by de-regulating its essential hubs. Gain-of-function 
perturbations may incapacitate system controls in diverse malignancies (see below and 
Figure 12; Box 3).  
 
1.5.6.1 Kinase-domain mutations and deletions.  
Certain heterozygous, somatically acquired ErbB1 mutations in lung cancer correlate 
with clinical responses to ErbB1-specific kinase inhibitors (Lynch TJ et al 2004, Paez 
JG et al 2004, Pao W. et al 2004). These aberrations, which include deletions, insertions 
and missense point mutations that stabilize interactions with ATP and kinase inhibitors, 
concentrate in regulatory regions that surround the ATP-binding cleft of ErbB1. 
ErbB1 mutants have been associated with enhanced autophosphorylation and cell 
survival; this finding provides an explanation as to why kinase inhibitors selectively 
induce the apoptosis of mutant-expressing cells (Tracy S et al 2004,
 Sordella R et al 
2004). Along with pathway-selective activation, ligand-induced downregulation of 
ErbB1 mutants seems impaired (Lynch TJ et al 2004, and the association with ErbB3   45 
seems enhanced (Engelman JA et al2005), which is in line with multiple mechanisms of 
network dysregulation. Although occurring significantly less frequently, cancer-
associated kinase-domain mutations have also been reported in ErbB2 (Shigematsu H et 
al 2005). Consistent with the importance of receptor heterodimers, mutations in ErbB1 
and ErbB2 have not been detected in the same tumours.   
1.5.6.2 Large deletions in ErbB1.  
Brain tumours, especially gliomas, display multiple rearrangements within the ErbB1 
gene, including large deletions, point mutations and insertional mutations (Ekstrand A J 
et al 1992). Up to 20% of glioblastomas show ErbB1 rearrangements and up to 40% of 
glioma tumours over-express the ErbB1 receptor (Ekstrand AJ et al 1991, Liu L et al 
2005). The most frequent mutant, EGFRvIII, lacks the dimerization arm and an 
essential part of the ligand-binding domain (Ekstrand A J et al 1992), yet this mutant is 
constitutively active at the plasma membrane and evades downregulation (Huang HS et 
al1997), thereby bypassing system controls.  
1.5.6.3 Receptor over-expression.  
ErbB1 over-expression due to gene amplification or increased translation has been 
reported in diverse tumours, such as lung, pancreas and breast lesions (Nicholson RI et 
al 2001). In head and neck cancer, ErbB1 over-expression is observed in at least 80% of 
tumours (Ford AC & Grandis JR 2003), and correlates with a reduction in patient 
survival rates. Likewise, over-expression of ErbB2 has been reported in breast, lung, 
pancreas, colon, endometrium and ovarian cancer (Ross JS et al 2003), and it has been 
associated with a poor prognosis for breast and ovarian cancer patients (Slamon D J et 
al 1989). Along with high basal auto-phosphorylation, receptor over-expression delays 
ligand-induced degradation because of the limited capacity of clathrin-mediated 
endocytosis.   
1.5.6.4 Autocrine mechanisms.  
Co-expression of an ErbB protein and one or more of its ligands might establish an 
autocrine loop that drives uncontrolled cell growth. In cancer patients, the autocrine 
production of TGFα or EGF is associated with reduced survival (Hirai T et al 1998,
 
Tateishi M et al 1990).     46 
 
 
Figure 1.12: Mutiple pathways to oncogenesis. a | Over-expression of ErbB receptors, 
owing primarily to gene amplification, results in the exaggerated activation of signalling 
pathways and delayed endocytosis. ErbB1 over-expression has been observed in 80% of 
head and neck tumours (Ford AC & Grandis JR 2003); it correlates with poor prognosis 
and resistance to therapy. ErbB2 over-expression has been found in breast, lung, 
pancreas, colon, endometrial and ovarian cancer and it has been frequently associated 
with an adverse prognostic value (Ross JS et al 2003, Slamon D J et al1989). b | Large 
deletions within ErbB1 that are commonly found in brain tumours create constitutively 
active protein products that lack parts of the ligand-binding domain, or the C-terminal 
tail (Shigematsu H et al 2005, Ekstrand A J et al 1992). c | Multiple short deletions within 
the 3–αC loop of the ErbB1 kinase domain, as well as within the activation loop, P-loop 
and αC–4 loop (all marked in red) have been observed in lung cancer. Likewise, 
mutations of Gly719 and Leu858 are common. These aberrations affect regulatory 
regions and result in enhanced kinase activity, or altered substrate specificity. The 
presence of these diverse mutations predicts significant clinical responses to specific 
kinase inhibitors (Lynch TJ et al 2004, Paez JG et al 2004). d | Small duplications 
within the kinase domain of ErbB2 have been detected in lung cancer and other 
malignancies. This is an infrequent event of unclear functionality (Shigematsu H et al 
2005). However, all the mutations that have been identified reside within the αC–4 loop. 
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1.5.7 Various clinically useful options are now available to target the ErbB 
system: 
 
Figure 1.13: The ErbB system can be targeted through multiple means. AKT/PKB, 
AKT/protein kinase B; EGF, epidermal growth factor; MAPK, mitogen-activated 
protein kinase; P, phosphate; PI3K, phosphatidylinositol 3-kinase (Citri A, and  Yarden 
Y 2006). 
1.5.7.1 Monoclonal antibodies 
Therapeutic antibodies function by recruiting cytotoxic lymphocytes (Clynes RA et al 
2000), as well as through direct effects on signalling in the target tumour cell (Nagata Y 
et al 2004). Antibodies in use at present are trastuzumab (Herceptin; Genentech; which 
targets ErbB2) for treatment of breast tumours, and cetuximab (Erbitux; Bristol Myers 
Squibb (BMS)/ImClone; which targets ErbB1) for treatment of colorectal cancer. Novel 
experimental therapeutic approaches target the heterodimerization of ErbB2 
(Omnitarg/pertuzumab), or use antibody combinations (Spiridon CI et al 2002)
 to 
promote receptor degradation (Friedman LM et al 2005).   
1.5.7.2 Tyrosine-kinase inhibitors 
These small molecules block the nucleotide-binding pocket of ErbB proteins. Two 
ErbB1-specific drugs, gefitinib (Iressa; AstraZeneca) and erlotinib (Tarceva; 
Genentech/OSI), were recently approved for the treatment of non-small-cell lung 
cancer, and have been shown to be effective against tumours that express catalytically 
hyperactive ErbB1 mutants (Lynch TJ et al 2004, Paez JG et al 2004). A more effective 
strategy may be to use dual-specificity inhibitors, such as Lapatinib (GlaxoSmithKline),   48 
CI-1033 (Pfizer) and EKB-569 (Wyeth-Ayerst Research), thereby targeting both ErbB1 
and ErbB2 (Xia W et al 2002).   
1.5.7.3 Inhibitors of heat-shock protein-90 (HSP90) 
ErbB2 is strictly dependent on the HSP90 chaperone complex for maintenance of its 
stability, identifying an Achilles heel of the ErbB system (Neckers L & Ivy SP 2003). 
The clinical efficacy of HSP90 inhibitors, such as 17-N-allylamino-17-
demethoxygeldanamycin (17-AAG), is under evaluation. However, a novel approach 
for the specific targeting of ErbB2 for proteasomal degradation involves the use of 
kinase inhibitors that dissociate HSP90 from ErbB2 (Citri A et al 2002).   
1.5.7.4 Drug combination 
Genetic heterogeneity and cellular dynamics are thought to underlie tumour resistance 
to drugs, but combinations of non-cross-resistant treatment regimens might prevent its 
recurrence (Goldie JH & Coldman AJ 1979). Therapeutic strategies that target various 
components of the ErbB signalling network might be beneficial (Ye D et al 1999). 
Integration of anti-ErbB drugs with conventional anti-cancer chemotherapy and 
radiotherapy have been shown to improve outcome (Slamon DJ et al 2001)
 and 
overcome drug resistance (Shou J et al 2004).  
1.6 Epidermal growth factor receptor and DNA double strand break 
repair 
Cancer management often includes radiotherapy which, though effective, rarely leads to 
cure on its own. Combined treatment with two DNA-damaging agents, physical 
(ionising radiation) and chemical (e.g. alkylating agent), enhances the lethal effect in 
cancer cells but at the same time considerably increases the adverse effects due to 
damage to normal tissues. An efficacious and better tolerated option may be to combine 
X-ray therapy with drugs of low general toxicity that would specifically enhance the 
lethal effect of local irradiation. Of special interest is the relationship between cellular 
signalling and DSB (DNA double strand break) repair, which may be amenable to 
manipulation in order to improve radio-sensitivity of tumours in vivo (Schmidt-Ullrich 
RK 2000). Numerous reports point to a high efficiency of radio-sensitisation by   49 
inhibition of growth factor-dependent receptor tyrosine kinases (RTKs) (Szumiel I 
2006). 
These kinases appear to be suitable targets for therapy, as most aggressive and invasive 
human cancers over-express them (e.g. Nagane M et al 2001, Ohgaki H 2005). In 
monotherapy of cancers with over-expressed RTKs, improvement in outcomes is 
achieved by using specific receptor antibodies and RTK inhibitors (RTKI; e.g. Raben D 
et al 2004, Barker FG et al 2
nd 2001], Chinnaiyan P et al 2005 ). RTKs, of special 
interest include the receptor kinases of the ErbB family, including EGFR, which form 
homo- or heterodimers after binding ligands (Ohgaki H 2005). 
EGFR activation by ionising radiation is an important part of the radioprotective cellular 
defence system. One effect of reactive oxygen species generated by ionising radiation is 
inactivation of a redox-sensitive, cysteine-based protein-tyrosine phosphatase. This 
causes a shift in the equilibrium between the phosphorylated and dephosphorylated 
forms of EGFR and stimulates the kinase activity of the receptor in a ligand-
independent manner. The same mechanism operates in the case of UV-A, UV-B, UV-C, 
hydrogen peroxide (Knebel A 1996) and pro-oxidant chemical agents, e.g. menadione 
(Abdelmohsen K et al 2003).  
Another possible mechanism of EGFR activation in the irradiated cell is by upregulation 
of autocrine/paracrine secretion of EGFR ligands (Dent P et al 2003) and Shvartsman 
SY et al 2002.  
After exposure to X- or γ-ray doses 1–5 Gy (a dose range used in cancer radiotherapy), 
multiple signalling pathways are activated; among them, EGFR activation and increased 
signalling through the Ras–MAPK pathway take place (review in (Dent P et al 2003). 
This EGFR initiated signalling is the source of anti-apoptotic (survival) signals and of 
increased cellular radioresistance, as measured by survival or chromosomal aberration 
frequency. The latter end-point very often is applied to estimate the response to 
irradiation and it shows the cell's ability to repair DNA. 
In concert with the initiation of signalling pathways and EGFR internalisation, nuclear 
translocation of DSB repair proteins, including DNA-PKCS from the cytoplasmic stores 
takes place. This ensures an immediate increase in activity of the main repair system   50 
necessary after X-irradiation, NHEJ. Efficiency of such defence may vary between cell 
types, depending on the status of EGFR, on how many supplementary DNA-PK 
subunits are stored for use under stress conditions, to what extent does the cell rely on 
D-NHEJ for DSB repair (this also depends on position in the cell cycle) and how 
effective is the translocation machinery. Figure 1.14 presents a diagram of the events 
that are believed to take place in the X-irradiated cell and involve EGFR and DNA-PK 
actions and interactions.  
 
Figure 1.14: Diagram representing the hypothetical relations between EGFR activation 
and DSB repair (Szumiel I 2006). 
Although there is evidence to support the existence of direct and indirect EGFR/DNA-
PK interactions modulating DNA double strand break repair, much further work is 
needed to confirm the reported observations and to define the pre-requirements for 
EGFR–DNA-PK interaction. Furthermore, very little is known about DNA damage 
repair in neuroendocrine tumours or cell lines. 
Understanding the mechanism of action of EGFR inhibitors is important in devising a 
rationale for combined radio- and chemotherapy since these inhibitors are being 
increasingly applied in combination with DNA-damaging agents. It may be expected 
that their efficiency can be enhanced by a suitable drug combination, thus representing a 
significant contribution to cancer therapy.    51 
1.7 EGFR and Neuroendocrine Tumours 
EGFR has been shown to be expressed by neuroendocrine tumours, in various small 
scale studies (see chapter 2). Furthermore, a recent study of neuroendocrine tumour cell 
lines has demonstrated promising effects of EGFR inhibition using the EGFR-specific 
tyrosine kinase inhibitor gefitinib. In human insulinoma (CM) cells, in human 
pancreatic carcinoid (BON) cells and in NE tumour cells of the gut (STC-1), gefitinib 
induced a time- and dose-dependent growth inhibition by almost 100%. The anti-
proliferative potency of gefitinib correlated with the proliferation rate of the tumour 
cells. The IC(50) value of gefitinib was 4.7+/-0.6 microM in the fast-growing CM cells, 
still 16.8+/-0.4 microM in the moderate-growing BON cells, and up to 31.5+/-2.5 
microM in the slow-growing STC-1 cells. Similarly, the induction of apoptosis and cell-
cycle arrest by gefitinib differed according to growth characteristics: fast-growing CM 
cells displayed a strong G0/G1 arrest in response to gefitinib, while no significant cell-
cycle alterations were seen in the slow-growing STC-1. Conversely, the proapoptotic 
effects of gefitinib, as determined by caspase-3 activation and DNA fragmentation, 
were most pronounced in the slow-growing STC-1 cells. Thus, EGFR-TK inhibition 
appears to be a promising novel approach for the treatment of NE tumour disease. 
(Höpfner M et al 2003) 
 
 
1.7.1 Rationale for studying EGFR in NETs 
Current  options  for  treatment  of  NET  patients,  such  as  targeted  radiotherapy  and 
chemo-embolisation, should theoretically lead to marked reductions in tumour lesions 
and prolonged disease control. However, their efficacy is curtailed by dose limiting side 
effects and emergence of therapy resistant tumour clones.  
The general aim of anti-tumour therapies is to induce sufficient tumour cell damage to 
activate tumour apoptosis pathways. However, not all severely damaged tumour cells 
follow this pathway. Some tumour cells are able to circumvent apoptosis through the 
activation of powerful signals which lead to cell repair and survival. Many studies point 
to EGFR activation, through ligand-dependent as well as ligand-independent means, to 
be a key factor in cell repair and survival. These insights are further reinforced by phase 
III clinical trials demonstrating improvements in tumour response rates and survival 
when anti-EGFR therapy is combined with chemotherapy or radiotherapy. Furthermore,   52 
combination  therapy  does  not  lead  to  potentiation  of  chemotherapy/radiotherapy-
associated side effects, although it can be responsible for the development of severe 
acne in some patients.  
EGFR has been shown to be over-expressed in most tumour-types, when tested for. 
Moreover, its over-expression is related to impaired survival. EGFR, therefore, seems 
to be an excellent subject for further study in relation to NETs. 
 
1.8  Aims of this thesis 
 
1) Determine the role of EGFR expression and activation in neuroendocrine tumours by 
analysing histological samples from NET patients.  
2) Study the molecular pathways mediating the effects of EGFR activation, using 
neuroendocrine tumour cell lines.  
3) Improve sensitivity of somatostatin receptor targeted scintigraphy imaging. 
4) Determine prognostic value of alpha-fetoprotein, hCGβ, and other commonly 
measured tumour markers in neuroendocrine tumours. 
 
 
Chapter 2: 
Epidermal growth factor receptor expression and activation in neuroendocrine 
tumours 
EGFR is over-expressed by most tumour types in which it has been tested. Furthermore, 
it is suggested that expression is related to worse prognosis. Using cell lines with 
neuroendocrine differentiation EGFR has been demonstrated to act through cellular 
activation pathways in which Akt and ERK1/2 activation forms a key step. This chapter 
details the immunohistochemical study of neuroendocrine tumour tissue. Consecutive 
tumour slides from 96 patients were used to determine the expression of EGFR, its 
activation, and the activation of Akt and ERK1/2, molecules involved in the 
downstream signalling following EGFR activation.  
Furthermore, the effects of EGFR expression, its activation, and the activation of Akt 
and ERK1/2 were correlated with survival.  
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Chapter 3: 
Effects of EGFR inhibition on EGFR/DNA-PKCS interactions in neuroendocrine 
tumour cell lines  
EGFR inhibition has been shown to impair survival and proliferation in cell lines with 
neuroendocrine differentiation. This chapter details experiments performed to determine 
the molecular mechanisms for these effects. In particular the effects of EGFR inhibition 
and the subsequent EGFR/DNA-PK interactions were studied using 
immunoprecipitation and western blotting techniques. Also, the effects of EGFR 
inhibition and the subsequent effect on DNA-PK protein expression and localisation 
were studied using immunoblotting, immunofluorescence as well as nuclear 
fractionation and western blotting techniques. 
 
Chapter 4: 
The role of 
99mTechnetium-depreotide in the management of neuroendocrine 
tumours  
This chapter details the role of 
99mTechnetium-depreotide, a somatostatin analogue, in 
imaging neuroendocrine tumours which are negative with ‘standard’ 
111In-pentetreotide 
(OctreoScan®) scintigraphy. There are 5 somatostatin receptor subtypes (1-5) with 
SSTR2 being the most widely expressed in NETs and commonly utilised for diagnostic 
and treatment purposes. However OctreoScan® is not always positive highlighting the 
lack of SSTR2 by some NETs.  
99mTechnetium-depreotide has an expanded SSTR 
subtype affinity, through binding SSTR sub-types 2/3/5, and may be positive in 
OctreoScan® negative cases. We examined the frequency, strength, and pattern of 
positivity of 
99mTechnetium-depreotide scans in OctreoScan® negative patients in order 
to determine the utility of 
99mTechnetium-depreotide in improving the sensitivity of 
SSTR scintigraphy as an imaging modality. 
 
Chapter 5: 
The role of alpha-fetoprotein and hCGβ as prognostic tumour markers in 
neuroendocrine tumours. 
Many generalised and specific serum and urinary biochemical markers are measured in 
NET patients. Some of these markers, such as CgA, 5HIAA gastrin, insulin etc, are 
helpful in arriving at the diagnosis of NET. They may also alert the physician to 
changes in tumour biology, as well as informing on the efficacy of any given anti-  54 
tumour therapy. CgA and neurokinin-A in particular may also provide prognostic 
information. 
Current internationally accepted guidelines for the management of NETs also 
recommend the measurement of serum alpha fetoprotein and human chorionic 
gonadotrophin-β. However their role and value in NET management is not clear. We 
have analysed, using the large Royal Free Hospital NET database, the prognostic 
significance of these two tumour markers. 
 
Chapter 6: 
Discussion and conclusion 
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2.1  Introduction 
Epidermal growth factor receptor (EGFR), the first ErbB receptor family member to be 
described and sequenced (Ullrich A et al 2004), is a large (175kDa) membrane 
glycoprotein with a trans-membrane lipophilic segment and a cytoplasmic tyrosine 
kinase segment flanked by regulatory segments (Lazarides E 1984, Schlessinger J 1998, 
Yarden Y 2001, Groenen LC et al 1994). The ErbB receptor family comprise 3 other 
related receptors: ErbB2 (HER2/neu); ErbB3 and ErbB4 (Yarden Y 2001). EGFR 
ligands, such as EGF and TGFα, are synthesised as membrane-anchored precursor 
forms which are shed by metalloproteinase-cleavage to generate soluble ligands. Both 
the membrane anchored isoforms and the soluble growth factors may act as biologically 
active ligands, thereby inducing: juxtacrine, autocrine, paracrine, and/or endocrine 
signalling (Singh AB 2005). Ligand binding leads to receptor activation and auto-
phosphorylation of tyrosine residues located in the carboxyl region of the receptor, and 
results in the recruitment and phosphorylation of several intracellular substrates (Ullrich 
A et al 2004, Cochet C et al 1988, Heldin CH 1995, Schlessinger J 1992, Pazin MJ 
1992, Ullrich A 1990).  
Two major pathways mediating EGFR signalling require the activation of intracellular 
signalling molecules ERK1/2 and PKB/Akt, leading to enhanced: cell survival; 
proliferation; transformation and motility (Schlessinger J 2000). Over-expression of 
EGFR and its natural ligands results in activation of these receptors through autocrine 
stimulation, leading to increased cell growth signalling in many types of cancer (Rusch 
V et al 1996, Hirono Y et al 1995). This is likely to be the reason for the association of 
EGFR over-expression with early recurrence, metastasis, and significantly lower patient 
survival (Lei W et al 1995).  
EGFR inhibition, by either humanised anti-EGFR antibodies or orally active small 
molecule ATP-competitive inhibitors of the receptor tyrosine kinase (tyrosine kinase 
inhibitors [TKIs]), is now possible. This approach was successful in vitro, using tumour 
cell lines, and in-vivo, using human tumour cells grafted into athymic mice (Shintani S 
et al 2003, Friedmann B et al 2004). Subsequent clinical studies have been promising. 
In particular cetuximab, a humanised anti-EGFR antibody, in combination with 
radiotherapy for locoregionally advanced head and neck cancer and in combination with 
irinotecan in colon cancer, has provided improved response and survival rates. 
Meanwhile the small molecule receptor TKIs, gefitinib and erlotinib, have demonstrated   57 
activity in non-small cell lung cancer (Bonner JA et al 2004, Cunningham D et al 2004, 
Lynch TJ et al 2004, Paez JG et al 2004).  
Neuroendocrine tumours (NETs) are an often slowly progressing heterogeneous group 
of tumours that have been postulated to originate from a common precursor cell 
population (Rindi G et al 2001). NETs can be subdivided, according to the site of origin, 
into tumours of the foregut (medullary thyroid cancer, bronchus, pancreas, stomach, 
proximal duodenum), midgut (distal duodenum, jejunum, ileum, appendix, and 
proximal colon), and hindgut (distal colon and rectum). They tend to be diagnosed fairly 
late in the course of the disease often having already metastasised (Perry RR 1995, 
Gibril F et al 1995). Somatostatin analogues are the mainstay of symptomatic treatment, 
but these agents have minor anti-tumour effect. Chemotherapy has shown efficacy in 
managing NETs of foregut, including pancreatic, origin but is of limited benefit in mid-
gut and hindgut carcinoid tumours (Modlin IM 1997, Oberg K et al 1987, Moertel CG 
et al 1992). Often treatments such as alpha interferon and radionuclide therapy (i.e.
131I-
mIBG and 
90Y-DOTA octreotide) may be useful, but objective response rates are 
disappointing. When the tumour is unresectable, treatment is aimed at extending 
survival by affecting tumour reduction or limiting tumour growth. Thus there is need for 
new agents capable of reversing or slowing the progress of NETs.  
EGFR has been shown, in small studies, to be expressed by NETs. Further work with 
neuroendocrine tumour cell lines has shown that inhibition of EGFR or interference 
with the intracellular transduction of EGFR-activation related signalling causes potent 
anti-tumour effects related to inhibition of the downstream signalling molecules ERK 
and Akt (Hopfner M et al 2003, Song C et al 2002, Peghini PL et al 2002).  
The aim of this study was to assess EGFR expression in tumour tissue from NET 
patients and to determine the activation of the downstream signalling molecules 
ERK1/2 and Akt, which are mediators of cell survival and proliferation signals. 
 
 
2.2  Patients and Methods 
Human breast cancer tissue was used to determine the optimum pre-treatment 
conditions and to determine optimum antibody concentrations for use. Human breast 
cancer tissue was also used for control purposes as it is known to express EGFR and is 
easily available (figure 2.1). Consecutive samples of formalin fixed paraffin embedded   58 
tumour tissue were available from 98 patients with a histologically confirmed diagnosis 
of neuroendocrine tumour. Tumour tissue was available from 77 patients who had 
undergone an operation and tumour resection with a further 21 samples from tumour 
biopsies. All major NET subtypes were represented: foregut – 39 patients; midgut – 42 
patients; hindgut – 4 patients; paraganglioma – 5 patients; and NETs of unknown origin 
– 4 patients.   
The study was performed under the auspices of the Royal Free Hospital Pathology 
Department ethics recommendations for studies on archive histology samples. 3µm 
sections of tumour tissue were de-waxed in xylene for 10 minutes, dehydrated in 
alcohol and then rinsed in distilled water for 5 minutes. Endogenous peroxidase activity 
was blocked by incubation in 1% hydrogen peroxide, diluted in acetone, for 10 minutes. 
Pre-treatment: slides were placed in a plastic rack, immersed fully in pre-heated citrate 
buffer and micro-waved at full power for 5 minutes (for EGFR IHC), 5 minutes (for 
ERK IHC) and 10 minutes (for p-EGFR IHC). No pre-treatment was necessary for Akt 
IHC. Sections were sequentially incubated with avidin and biotin solutions for 10 
minutes each in order to block avidin binding protein. Non-specific binding was 
minimised by incubating the sections with 10% normal goat serum, in phosphate 
buffered saline (PBS), for 30 minutes. PBS was used for washing the sections between 
each stage.  
Primary antibodies:  
1] anti-phospho-AKT antibody ab8932, specific for S473 phosphorylated AKT, was 
purchased from Abcam Ltd Cambridge, UK. 
2] anti-EGFR rabbit polyclonal antibody ab2430 (immunogen: synthetic peptide 
EDMDDVVDADEY, corresponding to C terminal amino acids 1005 – 1016 of EGFR) 
was purchased from Abcam Ltd, Cambridge, UK.  
3] anti-phospho-EGFR mouse monoclonal antibody 1H12, specific for Tyr1068 
phosphorylated EGFR and manufactured by Cell Signalling Technology, was purchased 
from New England Biolabs UK Ltd, Hitchin, UK. 
4] anti-diphosphorylatedERK1&2 mouse monoclonal antibody (M9692) was obtained 
from Sigma-Aldridge Co Ltd, Gillingham, UK.   
Antibodies were used at 1 in 100 dilutions in PBS, except for anti-phosphoEGFR, 
which was used at 1 in 500 dilution. All primary antibodies were incubated overnight at 
4°C. Biotinylated 2° antibody (DAKO StreptABComplex / HRP Duet, mouse / rabbit;   59 
DK – 2600 Glostrup, Denmark) was used at 1 in 100 dilution, with the slides being 
incubated for 30 minutes. The antibody binding was visualised by using DAB 
peroxidase substrate kit from Vector Laboratories Inc. The sections were counterstained 
with Mayer’s haematoxylin for 5 minutes.  
Breast carcinoma stained strongly positive for all four antibodies and was therefore used 
for optimising the pre-treatment and staining methods and subsequently used as control 
tissue for all four antibodies. The negative controls consisted of i) omitting the primary 
antibody; ii) using species and sub-type matched, but non-specific, control antibodies. 
Cytotoxicity of drugs alone or in combination was determined by the Sulphorhodamine 
B (SRB) proliferation assay as described in Section 2.4.1. Experiments were largely 
carried out on MCF-7 cells. This is a human breast adenocarcinoma cell line established 
from a pleural effusion from a 69 year female Caucasian (Soule et al., 1973). The line 
exhibits  some  features  of  differentiated  mammary  epithelium  including  oestradiol 
synthesis and may carry B or C type retrovirus (Zhang et al., 1993). Cells express the 
wild-type and variant oestrogen receptors as well as the progesterone receptor (ECACC, 
86012803). MCF-7 cells express functional EGFR of a magnitude of approximately 
250,000 EGF binding sites per cell (Ciardiello et al., 1999). 
 
2.2.1  Histological Interpretation 
Tumours were classified according to their site of origin, level of differentiation, and 
their mitotic index. Two examiners (Richard Frow [trainee histopathologist] and Tahir 
Shah) performed the interpretation of immunohistochemical staining for EGFR, p-
EGFR, p-Akt, and p-ERK1/2. The examiners were blinded to the identity of the 
samples, and their findings were compared for the level of concordance. Any discordant 
results were then reviewed to reach agreement or determine an average value for the 
disputed sections. Quality control advice was provided by Professor Dhillon 
(histopathologist). The intensity of staining was compared to the intensity of staining of 
positive controls for each protein tested. Slides were graded for the density of staining: 
0 = negative; 1 = weak staining; 2 = moderate staining; 3 = strong staining. The 
percentage of tumour cells staining positive were determined by randomly selecting 10 
high power fields per slide, when possible, and determining the average percentage of 
positive staining cells. The extent of tumour staining was scored as follows: 1 = <25% 
cells staining positive; 2 = 25-75% of cells positive; 3 = >75% positive. The product of   60 
the density of staining and the percentage of tumour cells staining positive was used as 
the histological score giving final values of 0, 1, 2, 3, 4, 6, and 9 (Iddon J et al 2000 32).  
 
2.3  Results 
Tumour tissue was available from 98 patients with histologically confirmed diagnosis of 
NET. 94 of 98 (96%) patients were positive for EGFR expression. The staining was 
predominantly cytoplasmic and perinuclear in the tumour cells. Vascular endothelial 
cells also stained positive and acted as additional internal positive controls.62 of 98 
(63%) patients were positive for p-EGFR expression. The staining was primarily 
cytoplasmic, with strong positive staining of vascular endothelium.74 of 98 (76%) were 
positive for p-Akt. The tumour cells displayed positive cytoplasmic staining, together 
with strong positive staining of vascular endothelium. 94 of 98 (96%) were positive for 
p-ERK1/2. The tumour cells displayed nuclear as well as cytoplasmic staining together 
with positive staining of vascular endothelium (figure 2.2). 
Staining for all 4 markers tested was generally restricted to tumour cells. However, 
strong positive staining was seen in blood vessels throughout the tissue samples, 
including in areas of normal tissue. Tumour grade could be assessed for 76 of 98 
patients who had tissue available for MIB-1 staining. Of these 47 were classified as low 
grade; 9 as intermediate grade; and, 20 as high grade. Multi-variant statistical analysis 
did not show any correlation between tumour grade, EGFR expression, EGFR 
activation and either Akt activation or ERK1/2 activation.  
Results for the 4 markers were subdivided according to histological scores for purposes 
of statistical comparisons (figure 2.3). This revealed correlations between the 
histological scores (i.e. the strength and extent of extent) for activated EGFR and 
activated forms of Akt as well as ERK1/2:  
p-EGFR and p-Akt – correlation coefficient = 0.386, p = > 0.0001 
p-EGFR and p-ERK1/2 – correlation coefficient = 0.322, p value = 0.001  
Furthermore, there was correlation between the histological score for p-Akt and           
p-ERK1/2, with correlation coefficient of 0.466 and p value of > 0.0001.  
There was no correlation between the immunostaining data and tumour grade.  
The majority of tissue samples were less than 4 years old, and statistically there was no 
deterioration in the quality of staining of the samples greater than 4 years old as 
compared to the newer samples.     61 
 
 
 
Figure  2.1:  Immunohistochemical  staining  of  breast  carcinoma  as  controls,  200X 
magnification.  Representative  negative  controls:  I-  with  the  omission  of  primary 
antibody;  and  II  -  with  non-specific  antibody  used  as  the  primary.  Representative 
positive controls: A – EGFR; B – pEGFR; C – pAkt; D – pERK1/2. 
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Figure 2.2: Immunohistochemical staining images, 200X magnification with close ups 
(insets) to demonstrate  staining patterns. Consecutive tumour tissue slides, from the 
same  field,  of  a  pancreatic  neuroendocrine  tumour  liver  metastasis:  A  –  EGFR: 
cytoplasmic  and  perinuclear  staining;  B  –  p-EGFR:  cytoplasmic  and  perinuclear 
staining;  C  –  p-Akt:  cytoplasmic  staining;  D  –  p-ERK1/2:  nuclear  and  cytoplasmic 
staining. 
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Figure  2.3:  Breakdown  of  tumour  samples  according  to  the  overall  score  for  the 
immunohistochemical  staining.  The  method  of  scoring  for  immunohistochemical 
staining is described in the methods. IHC score – immunohistochemical score 
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2.4  Discussion 
EGFR plays an important role in regulating cellular processes such as proliferation, 
differentiation, and survival and is central to the maintenance of normal epidermal 
tissues where its expression is highly regulated. When its function becomes deregulated, 
leading to increased signalling through molecules such as Akt and ERK1/2, it 
contributes to the growth and survival of cancer cells and as such is recognised as an 
important target for cancer therapy. Indeed EGFR is prominently expressed in a variety 
of human solid tumours, including colorectal cancer, head and neck squamous cell 
cancer and non-small cell lung cancer (Grandis et al 1996, Goldstein 2001, V. Rusch et 
al 1997). Although the relationship between EGFR status and prognosis is not 
completely understood, EGFR expression in tumours is usually associated with more 
aggressive disease, increased resistance to chemotherapy and radiotherapy, increased 
metastasis, poor clinical prognosis and decreased survival (Neskovic-Konstantinovic et 
al 1999, Nicholson et al 2001, Ang et al 2002).  
We undertook a large-scale immunohistochemical study of the expression of EGFR in 
order to assess the EGFR associated cellular activation pathways, in tumour tissue from 
98 NET patients.  
Tumour samples were available either from primary sites or from a site of metastasis. 
Paired tissue samples from primary site as well as from synchronous metastases were 
not usually available, which prevented a comparative study of EGFR expression in 
primary versus secondary sites. Immunostaining demonstrated expression of EGFR in a 
high proportion of the NET tissue samples studied, as well as its activation in the 
majority of these cases, with the pattern of EGFR expression being perinuclear and 
cytoplasmic. Although EGFR is classically reported to have a membranous distribution, 
its expression has been shown to be mainly cytoplasmic in a previous 
immunohistochemical staining study of lung neuroendocrine tumour tissue (Rusch VW 
et al 1996). Also, recent data on patterns of EGFR expression in A549 human bronchial 
carcinoma cells has demonstrated a perinuclear distribution during unstressed growth 
conditions (Dittmann K et al 2005).   
The modulation of EGFR signalling pathways by gefitinib has been shown to lead to 
dephosphorylation and transcriptional down-regulation of ERK1/2 in NET cell lines 
(Hopfner M et al 2003). Furthermore, disruption of EGFR signalling can significantly   65 
attenuate EGFR mediated activation of ERK1/2 and Akt in cell lines (Song C et al 
2002). This study demonstrates the activation of Akt and ERK1/2 in NET tissue, and 
shows this activation to be related to activation of EGFR. Thus providing evidence for 
similar cellular activation mechanisms in NETs to those previously reported in dynamic 
studies using neuroendocrine tumour cell lines (Hopfner M et al 2003,  Song C et al 
2002). We also assessed the degree of correlation, between the histological score for p-
EGFR and the activated forms of downstream signalling molecules, p-Akt and p-
ERK1/2. This demonstrated a moderate but highly statistically significant linkage. The 
moderate nature can be explained by the fact that these intracellular signalling 
molecules are mediators of messages from multiple origins including, but not exclusive 
to, EGFR. Furthermore, the higher correlation coefficient between the activated forms 
of Akt and ERK1/2 can be taken as evidence that EGFR activation leads to the 
simultaneous activation of the two separate signalling pathways involving Akt and 
ERK1/2, as predicted from dynamic studies of EGFR activation pathways using cellular 
models (Song C et al 2002). Additionally, a recent IHC study of EGFR expression and 
activation in NET tissue has demonstrated that the presence of EGFR in its activated 
form is a predictor for poor prognosis, not the overall expression of EGFR (Papouchado 
et al 2005). These findings, together with our large-scale study demonstrating 
downstream signalling following EGFR activation, highlight the importance of EGFR 
signalling in NETs as well as confirming the importance of EGFR as target for anti-
tumour therapy. This work also highlights Akt/PKB and ERK1/2, two molecules well 
known to be involved in tumour cell survival and proliferation, as future targets for anti-
tumour therapy in NET patients.  
 
EGFR expression and activity, and therefore its influence on cancer cell survival, can be 
amplified by a number of mechanisms other than increased receptor expression (C.L. 
Arteaga 2002). These include an increase in ligand expression, interaction with human 
epidermal receptor-2 (HER2) to form highly stable and potent EGFR–HER2 
heterodimers, and the expression of constitutively activated mutant EGFRs. Further 
work is under way by our group to characterise the expression of the entire EGFR 
family of receptors and their relationship to tumour characteristics as well as patient 
survival. 
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Further advances in EGFR targeted anti-tumour therapy may follow the full 
characterisation of EGFR mutations, including the commonly occurring EGFRvIII 
deletion mutation, which can determine tumour behaviour as well as response to anti-
EGFR therapy. Assessment for the presence of a number of mutations occurring at the 
region encoding for the ATP binding site of EGFR, which result in enhanced EGFR 
activation as well as a higher susceptibility to TKIs (Lynch TJ et al 2004, Paez JG et al 
2004), has also been carried out. These ATP binding site mutations, however, have been 
shown not to occur in neuroendocrine tumours (Gilbert JA et al 2005), whereas the role 
of EGFRvIII in neuroendocrine tumours is yet to be determined.  
Small molecule inhibitors of Akt and ERK1/2 are also currently under development. 
The demonstration of activated Akt in a majority of NET samples and activated ERK1/2 
in virtually all the NET tissue samples signals a promising future for the role of Akt and 
ERK1/2 inhibitors in the treatment of NET patients.   
In conclusion we have demonstrated expression of EGFR by NET tissue, the presence 
of activated EGFR and the subsequent activation of intracellular signalling pathways as 
demonstrated by the immunostaining for p-Akt and p-ERK1/2 in our NET tissue 
samples. This data provides a basis for the trial of anti-EGFR therapy in NET patients. 
Furthermore, the availability of specific inhibitors of ERK1/2 and Akt makes them 
attractive targets for assessment in neuroendocrine tumours.  
 
Rationale for using immunohistochemistry: 
Several standard techniques are available for the detection of EGFR expression in 
tumours, including protein expression assays (e.g., IHC, Western blot analysis, enzyme-
linked immunosorbent assay (ELISA), fluorescence-activated cell sorting (FACS), RNA 
transcript assays (e.g., Northern blot analysis, reverse transcriptase polymerase chain 
reaction (RT-PCR) and DNA assays (e.g., quantitative PCR, Southern blot analysis and 
fluorescence in situ hybridisation (FISH). However these methods have their drawbacks 
such as loss of tumour architecture, technically difficult and requiring specialist 
equipment, or not being able to measure the protein product directly. 
IHC is the most commonly used method for determining EGFR expression, which has 
been used in the majority of published studies for EGFR expression in human tumours. 
Its widespread use is mainly due to it being a relatively quick technique that utilises 
commonly available reagents and equipment. Unlike extractive methods, IHC also has   67 
the benefit of preserving cellular morphology and tissue integrity and this can provide 
additional, important information regarding the distribution of the target molecule 
within the tissue sample.  
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CHAPTER 3 
GEFITINIB AND EGFR/DNA-PKCS INTERACTIONS IN 
NEUROENDOCRINE TUMOUR CELL LINES    69 
3.1  Introduction 
Combined treatment with DNA-damaging agents, physical (ionising radiation) and 
chemical (e.g. alkylating agent), enhances their lethal effect in cancer cells but at the 
expense of considerably increased adverse effects due to damage to the normal tissues. 
A possible improvement in outcomes of combined therapy may be achieved by 
combining X-rays treatment with drugs of low general toxicity that would specifically 
enhance the lethal effect of local irradiation without significantly increasing side-
effects. Of particular interest is the relationship between cellular signalling and DSB 
(DNA double strand break) repair, because they might be applied for modulating 
radiosensitivity in vivo (Schmidt-Ullrich RK et al 2000). Numerous reports (Harari PM 
2000 & 2001, Friedmann B et al 2004, Raben D et al 2004) point to enhanced 
radiosensitisation by inhibition of growth factor-dependent receptor tyrosine kinases 
(RTKs) such as those of the ErbB family.   
The DNA-dependent protein kinase (DNA-PK) is a serine/threonine kinase that consists 
of a 350-kDa catalytic subunit and a
 heterodimeric regulatory complex Ku70/80 and can 
in vitro phosphorylate
 a number of transcription factors and DNA binding proteins, 
including
 p53, the RNA polymerase II carboxyl-terminal domain, replication
 factor A, 
and the Ku (Carter T et al 1990, Jackson SP 1995, Weaver DT 1995, Reeves WH 1997). 
DNA-PK is believed to play
 a major role in repairing double strand DNA breaks and 
V(D)J recombination,
 as mutations of DNA-PKCS (catalytic subunit) cause both x-ray 
sensitivity and defective
 V(D)J recombination (Baselga J et al 1993, Reeves WH 1997). 
Since efficient DNA repair may
 require growth factor signaling (John Mendelsohn 
1997, Haimovitz-Friedman A 1991), it became of interest
 to explore any linkage 
between EGFR-mediated signaling and DNA-PK
 pathway.   
 
 
  3.1.1  Stimulation of EGFR by DNA damage 
The model of how cells are killed by ionising radiation and their association with events 
at the plasma membrane are of great interest (Perry RR 1995). In light of the recent 
experimental data, EGFR activation by ionising radiation is considered to be an 
important part of the radioprotective cellular defence system.    70 
One effect of reactive oxygen species generated by ionising radiation is inactivation of a 
redox-sensitive, cysteine-based protein-tyrosine phosphatase. Inactivation of 
phosphatase causes a shift in the equilibrium between the phosphorylated and 
dephosphorylated forms of EGFR and stimulates the kinase activity of the receptor in a 
ligand-independent manner (Chiarugi P 2003). Another possible mechanism of EGFR 
activation in the irradiated cell is by upregulation of autocrine/paracrine secretion of 
EGFR ligands (Dent P 2003, Shvartsman SY 2002). 
 
 
 
3.1.2  Initiation of the Signalling Kinase Cascade 
Exposure to DNA damaging therapies leads to activation of multiple signalling 
pathways; among them, are EGFR activation and increased signalling through the Ras–
MAPK pathway (Dent P 2003). Other EGFR/ERBB downstream signalling pathways 
involved include:  
• phosphatidylinositol 3-OH kinase–protein kinase B (PI3K–PKB) (Shah T et al 2006) 
• phospholipase C (PLC) γ-calmodulin-dependent kinase (CaMK) – protein kinase C 
(PKC) 
• janus-activated kinase 2 – signal transducer and activator of transcription (JAK–
STAT). 
Stimulated signalling results in enhanced proliferation of cells surviving despite 
cytotoxic treatment, clonogenic cells, and consequently tumour repopulation–an  
important cause of treatment failure – becomes accelerated. The same signalling 
initiated by EGFR is the source of anti-apoptotic (survival) signals and of increased 
cellular radio-resistance, as measured by survival.  
There are several methods to interfere with the signalling initiated by EGFR, following 
DNA damage, leading to decreased cellular radio-resistance. The most clinically 
advanced methods are:    71 
(a) blockade of the extracellular part of the receptor molecule with monoclonal antibody 
against the ligand-binding domain, which prevent ligand binding and receptor 
activation, e.g. chimeric antibody cetuximab (Lammering G et al 2003)  
(b) inhibition of the receptor kinase, using small molecule tyrosine kinase inhibitors that 
compete with ATP e.g. gefitinib (Harari PM 2004)  
The addition of gefitinib has been shown to increase inhibition of proliferation, induce 
apoptosis, and increase antitumor activity in vitro and in vivo when combined with a 
variety  of  chemotherapeutic  agents.  Similarly,  combination  with  radiation 
synergistically increases inhibition of proliferation and pro-apoptotic effects in vitro and 
increases tumour growth delay in the treatment of human tumour xenografts (Bianco et 
al 2002; Solomon et al 2003; Giocanti et al 2004). 
 
3.1.3  EGFR / DNA-PKCS Interactions  
The study of EGFR/DNA-PKCS interactions has been a very active field of research 
leading to numerous insights into tumour biology. The initial study of EGFR inhibition 
with mAb 225 showed direct binding of DNA-PKCS to EGFR, leading to sequestration 
of DNA-PKCS in the cytoplasm thereby reducing intra-nuclear DNA-PKCS. This 
reduction in the level of DNA-PKCS in the
 nucleus is important, as it implies a direct 
role of EGFR-signalling
 in maintenance of the nuclear levels of DNA-PKCS, and 
interference
 in EGFR signalling may result in the impairment of DNA
 repair activity in 
the nuclei of anti-EGFR mAb-225 treated cells. (Bandyopadhyay D et al 1998) 
Since then there have been many  published studies not only  on the mechanisms of 
EGFR/DNA-PKCS  interactions,  under  varying  circumstances,  but  also  into  EGFR’s 
various other roles including as a transcription factor. Two recent publications from our 
lab  detail  the  effects  of  EGFR  inhibition,  using  a  small  molecule  tyrosine  kinase 
inhibitor gefitinib, on EGFR / DNA-PKCS interactions and the downstream effects on 
DNA  damage  repair,  cellular  proliferation  and  survival.  The  first  study  revealed  a 
synergistic  effect  on  growth  inhibition  when  gefitinib  treatment  was  given  in 
combination  with  cisplatin  or  etoposide.  There  was  delayed  repair  of  DNA  strand 
breaks  after  treatment  with  etoposide  combined  with  gefitinib,  and  repair  of  DNA   72 
interstrand crosslinks produced by cisplatin was delayed when concomitantly treated 
with gefitinib. Immunoprecipitation of cell extracts demonstrated that after exposure to 
gefitinib, there was increased association between EGFR and DNA-PKCS (Friedmann B 
et al 2004). 
The second study specifically investigated the effects of EGFR inhibition by gefitinib 
on functional activity of DNA-PKCS in cancer cell lines and the interaction between 
EGFR and DNA-PKCS. DNA-PKCS activity was quantitated and expression measured 
by  immunoblotting  following  gefitinib  treatment.  Immunoprecipitation  experiments 
were  done  with  and  without  gefitinib  in  breast  carcinoma  MCF-7  cells,  the  AR42J 
pancreas cell line with high EGFR, and human MDA-453 breast cancer cell line with 
low  EGFR  expression.  Nuclear  and  cytoplasmic  extracts  were  immunoblotted  with 
antibody to DNA-PKCS to determine if gefitinib treatment altered cellular expression. 
Gefitinib treatment reduced DNA-PKCS activity in MCF-7 and AR42J but not MDA-
453 cells. Immunoprecipitation experiments showed interactions between EGFR and 
DNA-PKCS  in  a  dose  dependent  and  time  dependent  manner  following  gefitinib 
treatment in MCF-7 and AR42J but not MDA-453 cells. Gefitinib treatment reduced 
nuclear expression and increased cytosolic expression of DNA-PKCS MCF-7 and AR42J 
but not MDA-453 cells. Thus the study concluded that gefitinib treatment modulates 
EGFR and DNA-PKCS association leading to decreased function of DNA-PKCS. This is 
likely  to  be  an  important  factor  in  sensitising  cancer  to  chemo  and  radiotherapy 
following treatment with inhibitors of the EGFR pathway. (Friedmann BJ et al 2006) 
 
 
3.1.4  Study of EGFR / DNA-PKCS Interactions in NET cell lines 
Neuroendocrine tumours (NETs) are a heterogeneous and rare group of tumours and 
hence their tumour biology is poorly understood. They tend to be diagnosed fairly late 
in the course of the disease often having already metastasised (Perry RR 1995, Modlin 
IM 1997). Treatments such as alpha interferon and radionuclide therapy (i.e.
131I-mIBG 
and 
90Y-DOTA octreotide) may be useful, but objective response rates are 
disappointing. When the tumour is unresectable treatment is aimed at extending survival 
by effecting tumour reduction or limiting tumour growth. Thus there is need for new 
agents capable of reversing or slowing the progress of NETs.  
Our  large  IHC  study  demonstrating  expression  of  EGFR,  its  activation,  and  the   73 
activation of molecules known to be key members of downstream signalling pathways, 
namely PKB/Akt and ERK1/2, together with recent publication of an IHC study using 
tumour tissue from NET patients confirming the poor prognosis associated with EGFR 
activation, has placed the spotlight on EGFR as a likely target for therapy in NETs. 
Preliminary work in our laboratory with neuroendocrine tumour cell lines showed that 
gefitinib could sensitise the cells to the effects of chemotherapy. The promising results 
with MCF-7 and AR42J cell lines encouraged us to look at EGFR related pathways in 
these neuroendocrine tumour cell lines in order to gain new insights into the role of 
EGFR in NETs.  
 
This chapter details work to:  
1.  Determine the expression of EGFR in neuroendocrine tumour cell lines. 
2.  Determine the expression of DNA-PKCS in neuroendocrine tumour cell lines. 
3.  Determine the effects of gefitinib on EGFR activation in neuroendocrine tumour 
cell lines.  
4.  Determine  the  effect  of  gefitinib  and  cetuximab  on  EGFR  /  DNA-PKCS 
interactions in neuroendocrine tumour cell lines.  
5.  Determine the effect of EGFR inhibition on DNA-PKCS. 
 
3.2  MATERIALS 
3.2.1  Chemical Reagents and Drug Source 
All reagents and disposables were obtained from Sigma Chemical Co., Poole, UK or 
VWR International Ltd., Poole, UK unless otherwise stated. 
Cytotoxic drugs (Table 3.1) were prepared as stocks in advance, or as fresh prior to 
individual  experiments  depending  on  stability  and  activity  in  solution  as  well  as 
experimental parameters. The concentration ranges used for experiments were modified 
based on previous personal communications on the cytotoxicity of individual agents 
where necessary.  
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Table 3.1: Drugs used in this study. 
 
3.2.2  Experimental Cell Lines 
African green monkey kidney cell line Cos-7 cells were grown in Dulbecco’s MEM 
(DMEM).  
Cell lines used were obtained as shown in Table 3.2. All tissue culture media were 
supplied by Autogen Bioclear, Calne, UK and were supplemented with 10% Foetal calf 
serum (FCS) (previously heat-inactivated for 30 minutes at 57
oC) and 1% glutamine. 
The growth medium described for the routine propagation of exponentially growing cell 
lines is referred to as complete growth medium throughout. Antibodies used are listed in 
table 3.3.  
Cell Line  Origin  Culture 
Conditions  Supplier 
MCF-7 
Human Breast 
Adenocarcinoma – Pleural 
effusion with hormone 
receptors. 69 year old 
Caucasian female. 
Dulbecco’s 
Minimal Essential 
Medium (DMEM) 
Cancer Research UK 
London Research 
Institute. 
A431  Human epithelial 
carcinoma cell line  
DMEM & 10% 
FBS 
Cancer Research UK 
London Research 
Institute. 
NCI-H727  Pulmonary carcinoid 
tumour 
RPMI + glutamine 
+ 10% FCS 
Cancer Research UK 
London Research 
Institute. 
SHP-77  Pulmonary carcinoid 
tumour 
RPMI + glutamine 
+ 10% FCS 
Cancer Research UK 
London Research 
Institute. 
CRI-G1  Rat islet-cell tumour  DMEM + 10%FCS 
Cancer Research UK 
London Research 
Institute. 
RIN-5F  Rat islet-cell tumour  RPMI + 10%FCS 
Cancer Research UK 
London Research 
Institute. 
BON  Human pancreatic 
carcinoid 
DMEM/F12K + 
10%FCS 
 
Table 3.2: Cell lines used in this study. 
Drug  Chemical Structure  Stock 
Solution   Solvent  Supplier 
Gefitinib 
(Iressa
TM, 
ZD1839)   
10mM  DMSO  AstraZeneca 
Cetuximab        Merck 
Pharmaceuticals   75 
Primary Antibodies 
Antibody  Description  Supplier  Antibody  Description  Supplier 
EGFR 
170KDa 
Mouse, 
Monoclonal 
Santa Cruz, 
UK 
PKBα/ 
AKT 
60KDa 
Mouse, 
Monoclonal  Abcam, UK 
EGFR 
170KDa 
Rabbit, 
Polyclonal  Abcam, UK 
P-AKT 
(Ser-473) 
70KDa 
Rabbit, 
Polyclonal  Abcam, UK 
P-EGFR 
(Tyr-845) 
175KDa 
Rabbit, 
Polyclonal 
Cell Signaling 
Technology, 
USA 
MAPK 
38KDa 
Mouse, 
Monoclonal  Abcam, UK 
P-EGFR 
(Tyr-1045) 
175KDa 
Rabbit, 
Polyclonal 
Cell Signaling 
Technology, 
USA 
P-MAPK 
43KDa 
Rabbit, 
Polyclonal  Abcam, UK 
P-EGFR 
(Tyr-1068) 
175KDa 
Rabbit, 
Polyclonal 
Cell Signaling 
Technology, 
USA 
Bax 
22KDa 
Mouse, 
Monoclonal 
BD 
Biosciences, 
UK 
P-EGFR 
(PY20) 
175KDa 
Mouse, 
Monoclonal 
BD 
Biosciences, 
UK 
Bcl-2 
26KDa 
Rabbit, 
Polyclonal 
BD 
Biosciences, 
UK 
DNA-PKCS 
460KDa 
Mouse, 
Monoclonal  Sigma, UK  BclXL 
29KDa 
Mouse, 
Monoclonal 
BD 
Biosciences, 
UK 
Ku70 
70KDa 
Goat, 
Monoclonal  Abcam, UK  Lamin B1 
67KDa 
Mouse 
Monoclonal  Abcam, UK 
Her-2 
185KDa 
Mouse, 
Monoclonal  Abcam, UK  α-Tubulin 
170KDa 
Mouse, 
Monoclonal  Sigma, UK 
Secondary Antibodies 
Antibody  Supplier  Antibody  Supplier 
HRP-Conjugated Rabbit 
Anti-Goat  Abcam, UK 
HRP-Conjugated Goat 
Anti-Rabbit  Abcam, UK 
HRP-Conjugated Goat 
Anti-Mouse 
BD 
Biosciences, 
UK 
Table 3.3: Primary and secondary antibodies used in this study. 
 
 
3.3  METHODS 
3.3.1  Tissue Culture 
3.3.1.1 Maintenance of Cell Lines 
All cell lines were grown in 50cm
2 (T50) flasks and maintained at 37
oC with 5% CO2 in 
dry incubators (Forma Scientific, UK). All procedures were carried out in Class II MDH 
biological safety cabinet (Intermed MDH, UK) using aseptic techniques. Exponentially 
growing  cells  were  maintained  at  a  cell  concentration  according  to  the  European 
Collection of Cell Cultures (ECACC), Salisbury, UK.    76 
Cells were routinely passaged at 90% confluence (biweekly). To this end, cells were 
washed  with 10ml of 0.01M phosphate buffered saline (PBS) to remove serum. To 
detach the cells from the flask 5ml of 1X Trypsin/EDTA (Autogen Bioclear, Calne, 
UK) was then added for 5 minutes at 37
oC. 5ml of complete growth medium was then 
added to inactivate the trypsin and the cell suspension was pelleted by centrifugation at 
1,500rpm for 5 minutes at room temperature. Cells were then resuspended in complete 
growth  medium  and  re-plated  at  an  appropriate  passage  ratio  for  the  cell  line.  The 
passage number was increased by one. Cells were discarded after approximately 25 
passages and fresh cells were taken from the initial passage number used. 
 
3.3.1.2 Cell Count 
Trypsinised cells were resuspended in 10ml of complete growth medium and counted 
using a haemocytometer. To this end, 20µl of cell suspension was mixed with trypan 
blue (Sigma, UK) to exclude dead cells and the cell number was determined for each of 
five separate 1mm
2 fields. The average was multiplied by 1x10
4 to give the number of 
cells per ml of suspension. 
 
3.3.1.3 Determination of Cell Doubling Time 
Cells were seeded out at an initial total cell number of 1x10
5 cells per 25cm
2 (T25) flask 
containing 10ml of complete growth medium with an individual flask for every time-
point.  Cells  were  trypsinised,  centrifuged,  resuspended  and  counted  using  a 
haemocytometer as described above and the subsequent concentration used to determine 
the  total  cell  count  per  flask.  Further  samples  were  taken  every  24  hours  until 
confluence.  The  doubling  time  of  each  cell  line  was  calculated  by  reading  off  the 
exponential portion of the growth curve derived by plotting number of hours against 
total number of cells counted. 
 
3.3.1.4 Mycoplasma Testing 
Cell cultures were routinely tested for Mycoplasma contamination every 6 months. The 
human breast cancer cell line, MCF-7 cells were grown in Dulbecco’s MEM (DMEM) 
supplemented with 10% FCS and 1% glutamine. They were maintained at 37
oC with 
5% CO2. A total number of 5x10
4 MCF-7 cells were seeded onto a sterile coverslip 
placed in a flat bottom Falcon tube. Cells were allowed to adhere to the coverslips for   77 
24 hours at 37
oC with 5% CO2. Previously, the cell lines to be Mycoplasma tested had 
been set up such that the cells reached confluency concurrently with the set-up of the 
Mycoplasma test. Thus, from a flask containing a confluent cell population to be tested, 
500µl  of  the  supernatant  growth  medium  was  removed  and  transferred  to  the 
Mycoplasma testing tube. The cell-free supernatant must not contain additives such as 
hydrocortisone,  cholera  toxin  or  antibiotics  that  might  interfere  with  Mycoplasma 
growth. The MCF-7 cells were incubated until they reached confluence after 5 days. 
The medium was removed and the cells washed once with 0.01M PBS. The cells were 
then  fixed  in  absolute methanol  for  5  minutes  and  subsequently  washed  twice  with 
0.01M PBS and stained with 5µg/ml of Hoechst 33258 dissolved in 0.01M PBS for 10 
minutes. Following two more washes with 0.01M PBS, the coverslips were carefully 
removed from the Mycoplasma testing tube, placed cell surface upwards on a glass 
microscope  slide  and  covered  with  a  coverslip.  Analysis  was  performed  under  a 
fluorescent  microscope  using  a  x40  objective  and  ultra-violet  (UV)  illumination. 
Control  cells  showed  intense  blue-white  staining  of  the  nuclei  only.  Mycoplasma 
infected cells would have been covered in a fine lawn of speckles all over. 
 
3.3.1.5 EGFR ihibition with gefitinib 
Cell lines were grown in 80ml flasks until approximately 70% confluent. They were 
then serum starved for 16 hours (overnight). Cellular inhibition was performed by 
adding concentrated gifitinib, from stock solution, in order to obtain the desired final 
concentrations (C, 1um, 5um, and 10 um etc). Cells were incubated with gefitinib for 3 
hours, followed by EGF activation for 30 minutes. 
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3.3.2  Protein Extraction 
3.3.2.1 Total Cell Lysis 
Cells cultured and treated in 75cm
2 (T75) flasks were washed twice in PBS at room 
temperature, drained well and placed in ice. To lyse the cells, 500µl RIPA buffer (1% 
deoxycholic acid, 1% Triton X-100, 0.1% SDS, 250 mM NaCl, 50 mM Tris pH 7.5, 100 
µg/ml  AEBSF,  17µg/ml  aprotinin,  1µg/ml  leupeptin,  1µg/ml  pepstatin,  5µM 
fenvalerate,  5µM  potassium  bisperoxo  (1,10-phenanthroline)  oxovanadate  (V) 
(BpVphen)  and  1µM  okadaic  acid)  was  added  to  each  flask  for  10  minutes  with 
occasional rocking. Cells were then scraped into a 1.5ml Eppendorf tube using a cell 
scraper (VWR International Ltd.) and centrifuged at 13,000rpm for 10 minutes at 4
oC. 
The supernatant (containing total cell protein) was then carefully transferred to a fresh 
tube and the pellet discarded. This is the total cell lysate and can be stored at -80
oC. 
 
3.3.2.2 Protein Assay 
To  determine  the  protein  concentration  of  a  particular  total  cell  lysate,  the  Biorad 
Protein Assay kit was used. Briefly, 2µl of each lysate is added to 18µl H2O.  In a 
separate Eppendorf, 20µl Reagent S is mixed with 1ml Reagent A. 100µl of this is 
added to each 20µl lysate sample mixed well with a short spin. 800µl Reagent B is then 
added to each and incubated at room temperature for 15 minutes. The optical density 
(O.D.) for each sample is then read on a spectrophotometer (Beam PU 8600 Series 
UV/Vis Single, Philips
®) at 750nm and the protein concentration determined using the 
following formula: 
O.D. x25 =[ ]/µl (i.e. µg/µl) 
 
 
3.3.3  Co-Immunoprecipitation 
The  topic  of  co-immunoprecipitation  (Co-IP)  is  best  preceded  by  a  discussion  of 
immunoprecipitation (IP) to help frame an understanding of the principles involved. 
Immunoprecipitation is one of the most widely used methods for antigen detection and 
purification. An important characteristic of IP reactions is their potential to deliver not 
only the target protein but also other macromolecules that interact with the target. 
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The principles of immunoprecipitation (see appendix 1; page 92) 
Protein G Sepharose™ 4 Fast Flow is protein G immobilised by the CNBr method to 
Sepharose  4  Fast  Flow.  Protein  G  binds  to  the  Fc  region  of  IgG  from  a  variety  of 
mammalian species. Protein G Sepharose 4 Fast Flow may be used to isolate and purify 
classes, subclasses and fragments of immunoglobulins from any biological fluid or cell 
culture medium. Since only the Fc region is involved in binding, the Fab region is still 
available for binding antigen. Hence, Protein G Sepharose 4 Fast Flow is extremely 
useful  for  isolation  of  immune  complexes.  The  potential  applications  of  protein  G 
include almost all of the current and projected applications of protein A. Protein G and 
protein A, however, have different IgG binding specificities, dependent on the origin of 
the IgG. Compared to protein A, protein G binds more strongly to polyclonal IgG, for 
example, from cow, sheep and horse. Furthermore, unlike protein A, protein G binds 
polyclonal rat IgG, human IgG3 and mouse IgG1 (Table 3.4). In this study, only Protein 
G Sepharose was used. 
 
Species  Protein G  Protein A 
Human IgG1  ++  ++ 
Human IgG2  ++  ++ 
Human IgG3  ++  - 
Human IgG4  ++  ++ 
Rabbit  ++  ++ 
Cow  ++  + 
Horse  ++  - 
Goat  ++  + 
Guinea Pig  +  ++ 
Sheep  ++  - 
Dog  +  ++ 
Pig  ++  ++ 
Rat  -  - 
Mouse  +  + 
Chicken  -  - 
Table 3.4: Relative binding strength of polyclonal IgG from various species to free 
protein G and protein A, as measured in a competitive ELISA test. 
Source: Amersham Biosciences Instruction Manual 71-7083-00 Edition AF 
 
Protein  Sepharose  G
TM  4  Fast  Flow  (Amersham  Biosciences,  Sweden)  beads  were 
prepared by washing as follows: Taking the required volume of Protein Sepharose G
TM 
the supernatant (slurry) was removed by centrifugation at 13,000rpm for 15 seconds at 
4
oC. The pellet was then resuspended in a volume of PBS equal to the volume of the   80 
bead pellet for a total of 5 times. For each sample, 25 – 45µl of Protein Sepharose G
TM 
was then added to 500 – 1000µg of protein taken from the total cell lysate. (To ensure 
that the beads themselves were being collected, the nib of the pipette tip was cut off.) 
The appropriate antibody at a final concentration of 4µg was then added to each sample 
and then placed on a rotation wheel at 4
oC and left overnight. The supernatant was 
removed by centrifugation at 13,000rpm for 15 seconds at 4
oC and rested upright on ice 
for approximately 10 minutes. This lead to a level pellet at the bottom of the epindorph 
tube. This can be stored at -80
oC for future analysis as it is still a total cell lysate with 
the immunoprecipitated protein depleted and is a useful control for confirming that the 
immunoprecipitation  has  purified  the  required  protein.  The  pellet  was  washed  three 
times  by  resuspending  in  100µl  RIPA  buffer  and  centrifuging  at  13,000rpm  for  15 
seconds at 4
oC. The pellet contained the Protein Sepharose beads attached to the Fc 
segments of antibody, which in turn were bound to the purified antigen (protein) and 
anything else that may be associated to the antigen. This complex can be stored at -80
oC 
for further analysis at a future date if necessary.  
The antibodies used for immunoprecipitations were the rabbit polyclonal anti-EGFR 
antibody which cross-reacts with human, mouse and rat; and the mouse monoclonal 
anti-DNA-PKCS antibody which cross-reacts with human and rat. Both were purchased 
from Abcam Limited, Cambridgeshire, UK (Harlow & Lane, 1999). 
 
3.3.3.1 Troubleshooting 
Whilst the immunoprecipitation technique is well defined and allows for a clear and 
concise study of specific proteins and their characteristics, optimisation is variable and 
dependent on a number of factors such as protein of interest and antibodies used. In this 
study, modifications to the methodology were made to obtain the best results and were 
as follows: 
 
1.  The Protein Sepharose G
TM beads were not originally washed in PBS prior to use. 
Supplied in a preservative this masked the beads activity and therefore yielded a 
poor protein binding affinity. 
2.  The final concentration of antibodies used was increased from 2 to 4µg. 
3.  Initial rotation time was 2h which did not allow for sufficient antibody-protein 
binding. This was then increased to16h.   81 
4.  Following  rotation,  pellets  were  initially  washed  once  with  RIPA  buffer.  This 
gave variable results due to contamination with DNA-PK which is usually present 
in  cells  at  much  higher  concentration  than  EGFR.  Number  of  washes  was 
increased to three times giving far greater consistency. 
5.  Immunoprecipitates  were  originally  resuspended  in  50µl  RIPA  buffer.  This 
diluted the protein concentration too much and so samples were resuspended in 
15µl of RIPA/running buffer. 
 
3.3.4  Nuclear and Cytosolic Extraction 
To separate out nuclear and cytosolic components of total cell lysates, the TransFactor
® 
Extraction Kit (Clontech Laboratories, UK) was used according to the manufacturer’s 
instructions.  Briefly,  all  steps  were  performed  at  4
oC  unless  otherwise  specified. 
Reagents  were  pre-cooled  to  4
oC,  and  not  used  until  fully  defrosted.  Cells  were 
collected and transferred to an Eppendorf tube centrifuged at 13,000rpm for 10 minutes 
at 4
oC and the supernatant discarded. The pellet was then washed twice in PBS and the 
pellet size estimated. Lysis buffer was prepared as follows: 150ml 10x Pre-lysis Buffer 
(Hypotonic) (100mM HEPES pH 7.9, 15mM MgCl2, 100mM KCl), 15ml 0.1M DTT, 
15ml  Protease  Inhibitor  Cocktail  (Aprotinin,  Pepstatin  A,  Bestatin,  trans-
Epoxysuccinyl-Lleucylamido  (4-guanidino)  butane,  and  4-(2-aminoethyl) 
benzenesulfonyl  fluoride  hydrochloride  in  DMSO)  and  1.32ml  ddH2O.  Cells  were 
resuspended in a volume of lysis buffer equal to five times the cell pellet volume and 
incubated on ice for 15 minutes. Following centrifugation at 13,000rpm for 10 minutes 
at 4
oC, the supernatant was carefully removed and the pellet resuspended in a volume of 
lysis buffer equal to twice the cell pellet volume. 
The suspension was then slowly drawn into a syringe through a narrow-gauge (No. 27) 
needle and then ejected with a single rapid stroke. This was repeated ten times and 
centrifuged at 13,000rpm for 10 minutes at 4
oC. The supernatant was then transferred to 
a fresh Eppendorf tube and is the cytosolic fraction. This can be snap-frozen and stored 
at -70
oC. 
Extraction Buffer was prepared as follows: 147ml Pre-extraction Buffer (20mM HEPES 
pH 7.9, 1.5mM MgCl2, 0.42M NaCl, 0.2mM EDTA, 25% (v/v) glycerol), 1.5ml 0.1M 
DTT and 1.5ml Protease Inhibitor Cocktail. The crude nuclear pellet was resuspended 
in  a  volume  of  Extraction  Buffer  equal  to  two-thirds  of  the  cell  pellet  volume.  To   82 
disrupt the nuclei, the suspension was then syringed as before and placed on a shaker at 
low speed for 30 min at 4
oC. The nuclear suspension was then centrifuged at 13,000rpm 
for 10 minutes at 4
oC. The supernatant or nuclear fraction, was transferred to a fresh 
Eppendorf tube and can be snap-frozen and stored at -80
oC.  
For determination of the protein concentrations within both the nuclear and cytosolic 
extractions, the protein assay detailed in Section 2.7.2 was used. 
 
3.3.4.1 Troubleshooting 
A  number  of  obstacles  were  overcome  whilst  performing  the  nuclear  and  cytosolic 
extractions: 
 
1.  Initial low protein concentrations were due to improper measurement of cell pellet 
volume. 
2.  Protein activities were at first not present because some of the proteins of interest 
are highly susceptible to proteolytic degradation. With practice, work efficiency 
decreased the time of initial purification steps whilst keeping all reagents on ice at 
all times.  
3.  There was difficulty drawing cell lysates into the syringe. This was because of a 
compact cell pellet and was overcome by using a pipette tip to disperse them. 
 
3.3.5  Immunoblotting 
  3.3.5.1 Electrophoresis 
Protein  concentrations  of  total  cell  lysates  were  determined  using  the  protein  assay 
outlined in Section 2.7.2. For each sample the required volume containing 30-50µg of 
protein was transferred to a fresh Eppendorf tube. Loading (Laemmeli) buffer (4% SDS, 
10% β-Mercaptoethanol, 20% glycerol, 0.02% bromophenol-blue and 100mM Tris HCl 
(pH 6.8)) was then added to each lysate before heating at 95
oC for 4 minutes to denature 
the proteins. Samples were then centrifuged at 13,000rpm for 10 minutes at 4
oC and the 
pellet discarded. 
For  immunoprecipitates,  the  whole  pellet  containing  500  –  100µg  of  protein  was 
resuspended in loading buffer and boiled as above. Boiling allows for denaturing of and 
dissociation  between  the  proteins  and  the  antibodies  and  beads.  Following   83 
centrifugation,  the  pellet  containing  beads  and  antibody  was  discarded  and  the 
supernatant could be loaded for electrophoresis. 
The  NuPAGE
®  Electrophoresis  System  (Invitrogen,  UK)  was  used.  For  analysis  of 
proteins  with  a  molecular  weight  of  between  120  and  410  KDa,  lysates  and 
immunoprecipitates were loaded onto NuPAGE
® Novex 3-8% Gradient Tris-Acetate 
Pre-Cast Gels which were placed in the XCell SureLock
TM Mini-Cell (two gels per cell) 
and  included  an  appropriate  marker  (Kaleidoscope  pre-stained  standards,  BioRad, 
Hemel-Hempstead,  UK)  and  a  positive  protein  control  (A431+EGF  cell  lysate;  BD 
Biosciences, UK). Upper (200ml) and lower (600ml) buffer chambers were then filled 
with 1x NuPAGE
® Tris-Acetate SDS Running Buffer (diluted from a 20x stock: 50mM 
Tricine,  50mM  Tris  base,  0.1%  SDS,  pH  8.24)  and  Mini-Cells  were  run  at  150V 
constant at 4
oC for approximately 1h 30min (Expected 40-55 mA/gel at start; 25-40 
mA/gel at end). 
For analysis of proteins with a molecular weight of between 10 and 180 KDa lysates 
and immunoprecipitates were loaded onto NuPAGE
® Novex 4-12% Gradient Bis-Tris 
Pre-Cast Gels and placed in Mini-Cells as above. Upper (200ml) and lower (600ml) 
buffer  chambers  were  then  filled  with  1x  NuPAGE
®  MOPS  SDS  Running  Buffer 
(diluted from a 20x stock: 50mM MOPS, 50mM Tris base, 0.1% SDS, pH 7.7) and 
Mini-Cells were run at 200V constant at 4
oC for approximately 50min (Expected 100-
125 mA/gel at start; 60-80 mA/gel at end). 
 
3.3.5.2 Protein Transfer and Immunoblotting 
Proteins were electrically transferred to Immobilon
TM polyvinylidenedifluoride (PVDF) 
membranes (Millipore, UK). These extremely hydrophobic membranes will not wet in 
aqueous  solution  and  so  were  prepared  as  follows:  blots  were  immersed  in  100% 
methanol for three seconds and then placed in H2O for 2 minutes to elute the methanol. 
To equilibrate, membranes were then soaked in protein transfer buffer (diluted from a 
10x  stock:  3%  TrisBase,  14.4%  glycine  and  20%  methanol).  Gels  and  prepared 
membranes were then placed into the X-Cell II
TM Blot Module (Novex
®) as illustrated 
in Figure 3.1.   84 
 
Figure 3.1: Gel/Membrane sandwich for 2 gels. 
Source: NuPAGE
® Technical Guide, Invitrogen, UK 
 
Transfer was achieved at 40V for 2h using the XCell SureLock
TM Mini-Cell (two blots 
per cell) and filled with protein transfer buffer as described in the NuPAGE Novex
® 
protocol.  
Membranes  were  then  blocked  in  3%  casein  blocking  buffer  [(3%  skimmed  milk 
powder (Marvel, UK) in TBS-Tween (TBS-T) (20mM TrisBase, 0.15M NaCl pH 7.5 in 
Elga H2O with 0.1% Tween-20)] for at least 1 hour on a shaker at 4
oC. Membranes 
being probed for phosphorylated proteins were blocked in 5% Bovine Serum Albumin 
(BSA) in TBS-T. This is due to the fact that milk contains a number of phosphorylated 
proteins  which  interfere  with  a  phosphotyrosine  antibody’s  ability  to  bind  specific 
proteins of interest.  
Blots were then probed with primary antibody against proteins of interest for at least 2h 
on a roller at room temperature. Antibodies used in this study are detailed in Table 2.5. 
All  were  diluted  in  a  1:1  mix  of  either  Milk-TBS-T  or  BSA-TBS-T  and  TBS  as 
necessary. Following this membranes were washed three times for 5 minutes in TBS-T 
followed by three more washes for 5 minute with TBS. Membranes were then probed 
with an appropriate horseradish peroxidase conjugated secondary antibody for at least 
1h and washed as before. 
Immunocomplexes  were  visualised  using  the  enhanced  chemiluminescence  (ECL) 
system (Amersham Pharmacia, Little Chalfont, UK) by incubating the membranes in   85 
the ECL system solution for 1 minute before wrapping the moist blots in cling film and 
exposing  the  blots  to  Kodak  X-OMAT™LS  film  for  varying  exposure  times  (two 
seconds to 24h) (Sambrook et al., 1989).  
In order to remove or ‘strip’ pre-bound antibody, membranes were rehydrated in TBS 
for 5 minutes and placed in a hybridiser (Techne, UK) with 100ml of stripping buffer 
(100mM  β-Mercaptoethanol,  2%  SDS,  62.5mM  Tris-HCl,  pH  6.7)  and  left  for  30 
minutes at 50ºC. Membranes were then washed twice in TBS-T for ten minutes each, 
blocked and reprobed as described above. 
 
3.3.6  Densitometric Analysis 
To  mathematically  compare  the  intensity  of  particular  bands  produced  by 
immunoblotting,  densitometric  analysis  was  used.  Briefly,  blots  were  placed  in  the 
imaging densitometer (Imaging Densitometer GS-670 BioRad, UK) and the bands of 
interest  selected.  Intensity  was  then  measured  by  computer  and  the  background 
subtracted. Data is represented as a percentage of control band intensity. 
The screen-grab shown in Figure 3.2 illustrates the methodology. In this case V5 serves 
as a background, V1 is the control and bands V2-4 represent different drug treatments. 
 
Figure 3.2: Sample screen display of densitometric analysis as seen using the BioRad 
Imaging Densitometer Software. 
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3.3.7  Immunofluorescent Staining 
Exponentially growing cells were seeded at 2x10
4 cells per well on circular glass slides 
in 12 well plates (Nunclon, VWR) and incubated for 24h at 37
oC in 5% CO2. Cells 
were then treated as required, the media subsequently removed and the cells washed 
twice with cold PBS. Cells were then fixed using 500µL/well of 50% methanol/50% 
acetone mix at 4
oC for 8 minutes. Following this the slides were then washed twice with 
cold PBS and permeablised using 500µL/well of 0.5% TritonX-100 in PBS. Slides were 
then blocked in 3% casein blocking buffer [(3% skimmed milk powder (Marvel, UK) in 
TBS-Tween (TBS-T) (20mM TrisBase, 0.15M NaCl pH 7.5 in Elga H2O with 0.1% 
Tween-20)] overnight at 4
oC. 
Slides were then washed 3 times in cold PBS following which the cells were incubated 
with  anti-DNA-PKCS  antibody  for  1  hour.  Slides  were  then  washed  3  times  with 
washing  buffer  (0.1%  TritonX-100  in  PBS)  and  then  incubated  for  1  hour  at  room 
temperature with FITC-labelled secondary antibody: Alexa fluoro
 488 goat anti-mouse 
IgG (green). Nuclear counterstaining was performed using 2µg/ml Propidium Iodide 
(blue) for 3 minutes followed by destaining with distilled water for 20 minutes. 
The slides were viewed and photographed using a laser scanning confocal microscope. 
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3.4  RESULTS 
 
Expression of EGFR in neuroendocrine tumour cell lines 
Five cell lines, with neuroendocrine differentiation, were tested for EGFR expression. 
All five proved positive for EGFR expression as demonstrated below (figure 3.3). A431 
was used as positive control for EGFR in cell lysates. 
 
         A431               BON              NCI                RIN      SHP           CRI 
    
 
  Figure 3.3: EGFR expression in neuroendocrine tumour cell lines. A431 included 
  as positive control. 
 
 
 
 
 
 
 
Expression of DNA-PKCS in neuroendocrine tumour cell lines 
 
Five  cell  lines,  with  neuroendocrine  differentiation,  were  tested  for  DNA-PKCS 
expression. All five proved strongly positive for DNA-PKCS expression as demonstrated 
below (figure 3.4). A431 was used as positive control for DNA-PKCS in cell lysates. 
 
 
            A431             RIN             NCI     BON              SHP            CRI 
      
 
 
    Figure 3.4: DNA-PKCS expression in neuroendocrine tumour cell lines. A431 
included as positive control.   
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3.4.1  Gefitinib Treatments  
Cytotoxicity of gefitinib was determined by the Sulphorhodamine B (SRB) proliferation 
assay. Experiments were carried out in NET cell lines by Dr V Kostoula, a member of 
Dr Caplin and Dr Hochhauser’s research team. These experiments demonstrated IC50 
values  to  be  between  18  and  30  µM  (table  3.5).  Majority  of  EGFR  inhibition 
experiments, however, were performed at final concentrations of gefitinib of up to 10 
µM as these concentrations best represented the concentrations attainable in tumours, 
in-vivo.  
 
 
 
    Table 3.5     
Chemotherapy drug and gefitinib IC50s in µ µ µ µM 
   SHP-77  CRI-G1  NCI-H727  RIN-5F      BON 
Gefitinib  18  19  18  30  21 
 
Table 3.5: courtesy of V. Kostoula 
 
3.4.2  Gefitinib Treatment and EGFR/DNA-PKCS interactions in NET cell-lines 
 
A431 and NET cell lines were treated with gefitinib as detailed in methods (3.3.1.5). 
EGFR, expressed by all cell lines, was shown to be susceptible to inhibition by gefitinib 
(figure 3.5). Furthermore, gefitinib treatment led to dose dependent reduction in cellular 
DNA-PKCS concentration (figure 3.6). 
 
A431 cell-line 
Gefitinib concentration                        C                  10µM            20µM                  
                                                        p-EGFR 
                                                        EGFR 
 
Figure 3.5:  a representative western demonstrating the ability of gefitinib to inhibit 
EGFR. Arrow indicates phosphorylated EGFR, showing complete inhibition with 10 & 
20µM gefitinib.    89 
3.4.3 Effect of gefitinib treatment on cellular DNA-PKCS concentration 
     
BON  C                  1 µM              5 µM           10 µM gefitinib 
                       DNA-PKCS 
             α-tubulin 
 
NCI           C                   1 µM              5 µM grfitinib 
                      DNA-PKCS 
                      α-tubulin 
 
SHP                     C               1 µM              5 µM               10 µM gefitinib 
                      DNA-PKCS 
            α-tubulin 
 
CRI                      C                  2 µM                 10 µM gefitinib 
                     DNA-PKCS 
           α-tubulin 
 
 RIN       C                1 µM    5 µM        10 µM gefitinib                 
                    DNA-PKCS 
                    α-tubulin 
Figure  3.6:  Immunoblots  of  whole  cell  lysates  demonstrating  reduction  in  cellular 
DNA-PKCS concentration following gefitinib treatment in 4 of 5 neuroendocrine tumour 
cell lines. No reduction in cellular DNA-PKCS concentration was demonstrated in RIN 
cells. Concentration of Gefitinib used is displayed in µM 
3.4.3  Co-immunoprecipitation   90 
Having  demonstrated  EGFR  expression  and  down-regulation  of  cellular  DNA-PKCS 
levels following EGFR inhibition with gefitinib, the next step was to look for evidence 
of  direct  interaction  between  EGFR  and  DNA-PKCS.  Immunoprecipitation  technique 
was  employed  for  this  purpose.  Whole  cell  lysates  were  incubated  with  anti-EGFR 
antibodies to selectively pull out EGFR. These IP samples were then probed for EGFR 
and  subsequently  for  DNA-PKCS  to  determine  whether  there  is  a  direct  and  strong 
interaction  between  these  2  proteins  and  whether  EGFR  inhibition,  with  gefitinib, 
modulates these interactions. 
Experiments  were  performed  under  a  range  of  conditions.  The  variable  parameters 
included: 
i) Concentration of gefitinib: 1 – 30µM 
ii) Duration of gefitinib treatment: 3 – 24 hours 
iii) With or without serum starvation, prior to gefitinib treatment, in order to stimulate 
EGFR expression 
iv) With or without EGF stimulation 
 
Representative results for these experiments are shown below (figures 3.6 & 3.7). These 
experiments demonstrated successful EGFR IP with all NET cell lines used. When the 
membranes  were  probed  for  DNA-PKCS  it  was  found  to  be  consistently  present, 
suggesting its co-immunoprecipitation with EGFR. Gefitinib treatment increased DNA-
PKCS co-immunoprecipitation in A431 (control cell-line), and NCI, while BON also 
demonstrated a small increase (figure 7). However there was no demonstrable increase 
of DNA-PKCS co-immunoprecipitation in CRI, RIN, and SHP cell lines (SHP displayed 
in figures 3.6). 
Thus  far  we  had  demonstrated  that  EGFR  inhibition  leads  to  decreased  DNA-PKCS 
levels in neuroendocrine tumour cell-lines. We had also demonstrated that there is direct 
interaction between EGFR, a cell surface receptor molecule, and DNA-PKCS which is 
known  to  reside  mainly  in  the  nucleus.  Furthermore,  this  direct  EGFR/DNA-PKCS 
interaction can be modulated, in some cell types at least, such that there are increased 
EGFR/DNA-PKCS associations upon EGFR inhibition (figure 3.8).  
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     A431            DNA-PKCS (co-IP)            NCI           DNA-PKCS (co-IP) 
              0            1µM          10µM                     0           1µM          10µM 
              
  EGFR (IP)                       EGFR (IP) 
              
 
     SHP    DNA-PKCS (co-IP)                   BON     DNA-PKCS (co-IP) 
            0             1µM           10µM                    0            1µM           10µM                  
                  
  EGFR (IP)  EGFR (IP) 
               
Figure 3.7: Co-immunoprecipitation experiments in four cell lines: gefitinib treated cells were lysed and 
EGFR immunoprecipitated using anti-EGFR antibody. Protein transfer embranes were immunoblotted 
with anti-EGFR to confirm successful EGFR immunoprecipitation, and anti-DNA-PKCS to look for co-
iimunoprecipitation  of  DNA-PKCS  with  EGFR.  This  figure  demonstrates  co-immunoprecipitation  of 
DNA-PKCS with EGFR as well as an increase in EGFR/DNA-PKCS association upon EGFR inhibition in 
A431, NCI, and BON cell lines, but not SHP cell line (highlighted red).  
µM refers to gefitinib concentrations.  
 
 
Successful inhibition of EGFR with  gefitinib followed by immunoprecipitation with 
anti-EGFR antibodies was used to look for direct association of EGFR with DNA-PKCS. 
The above results confirm that DNA-PKCS is co-immunoprecipitated with EGFR, thus 
suggesting  a  direct  interaction  between  these  two  proteins.  Furthermore,  EGFR 
inhibition led to an increase in interactions between EGFR and DNA-PKCS in two of the 
five NET cell lines, namely NCI and BON, as well as in the control cell line A431. 
however, these results were not as impressive as those reported previously in A431 and 
other  cell  lines,  utilising  cetuximab  to  inhibit  EGFR.  We  therefore  repeated  the 
immunoprecipitation experiments, following EGFR inhibition with cetuximab, in NET 
and A431 cell lines. 
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3.4.4.1 Co-immunoprecipitation following cetuximab treatment 
 
 
CRI 
    +C             0             30          60 cetuximab 
   DNA-PKCS   
 EGFR-IP   
NCI 
    +C             0             30          60 cetuximab 
   DNA-PKCS   
 EGFR-IP   
BON 
    +C             0            30          60 cetuximab 
   DNA-PKCS   
 EGFR-IP  
SHP 
    +C            0             30          60 cetuximab 
   DNA-PKCS   
 EGFR-IP    
RIN 
    +C             0             30          60 cetuximab 
   DNA-PKCS   
 EGFR-IP    
A431 
    +C             0             30          60 cetuximab 
   DNA-PKCS   
 EGFR-IP  
 
 
As  can  be  seen  from  the  above  immunoblots  (figure  3.8),  EGFR  inhibition  with 
cetuximab did not lead to an increase in EGFR/DNA-PKCS interactions. These findings 
are in stark contrast to previously published data (Bandyopadhyay D et al 1998).  
Figure 3.8: 
Exponentially growing 
cells were treated with 
cetuximab (30 or 60 
µM). Cell lysates were 
prepared. Anti-EGFR 
immunoprecipitation 
was performed and the 
resultant samples were 
electrophoresed, 
transferred to 
membranes, and probed 
for EGFR (lower 
immunoblots). Protein 
transfer membranes 
were also probed for 
DNA-PKCS (upper 
immunoblots) in order 
to determine whether it 
was co-
imunoprecipitated with 
EGFR. No such 
association was seen in 
these experiments. 
+C consisted of A431 
cell lysate.   93 
3.4.5 Immunofluorescence  
 
These co-immunoprecipitation experiments thus demonstrated mixed results for direct 
EGFR/DNA-PKCS interaction in the NET cell-lines tested, under the stated conditions. 
However, EGFR/DNA-PKCS relationship has been shown to be a complex one having 
multiple components. For instance, EGFR inhibition has been shown to affect not only 
DNA-PKCS activity but also its intracellular translocation, between the nucleus and the 
cytosol  (Friedmann  BJ  et  al  2006).  One  very  powerful  and  informative  way  of 
observing  these  events  is  through  the  use  of  confocal  microscopy.  Utilising  this 
technique,  we  repeated  the  EGFR  inhibition  experiments  to  determine  the  effect  on 
DNA-PKCS localisation in NET cell-lines (figure 3.11). 
EGFR inhibition was shown to influence the localisation of DNA-PKCS in SHP cell-line 
(figure 3.10) and possibly BON cell-line (incomplete data only, therefore not shown) 
with DNA-PKCS translocation from the nucleus to the cytoplasm, but no effect was seen 
in NCI, CRI, and RIN cell lines. Thus, it appears that in some NET cell-lines EGFR 
inhibition leads to translocation of DNA-PKCS from the nucleus to the cytoplasm. This 
translocation may (as in the case of BON) or may not (as in the case of SHP) be due to 
increase in direct binding of EGFR to DNA-PKCS thereby leading to sequestration of 
DNA-PKCS in the cytoplasm.  
     
 
Figure 3.9: Nuclear separation and immunofluorescence experiments in mcf-7 cell line 
demonstrating export of nuclear into the cytoplasm upon EGFR inhibition with gefitinib 
(Friedmann BJ et al 2006). 
 
 
Control  
Gefitinib 
10 µM   94 
Further  evidence  for  these  immunofluorescence  findings  was  sought  using  a 
combination  of  cellular  fractionation,  to  separate  out  the  nuclear  and  cytosolic 
compartments, followed by western blotting to determine the relative concentrations of 
DNA-PKCS in these compartments. Cells had been cultured under same conditions as 
previously and treated with gefitinib as described for the co-immunoprecipitation and 
immunofluorescence experiments. 
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Figure 3.10 SHP cell-line: 
Results of immunofluorescence 
and cell fractionation 
experiments, following gefitinib 
treatment, to determine the 
effects on DNA-PKCS 
localisation. Gefitinib therapy 
led to a 20% increase in 
cytoplasmic DNA-PKCS in SHP 
cells as demonstrated by the 
photographs above, 
immunoblot, left, and 
densitometry graph, below.   96 
            CRI 
 CYTOPLASMIC           NUCLEAR 
      C              10               C             10 
     DNA-PKCS 
   
       LAMIN 
 
 
 
           NCI 
CYTOPLASMIC            NUCLEAR 
      C              10               C             10 
     DNA-PKCS 
 
  LAMIN 
 
                 
       RIN 
CYTOPLASMIC            NUCLEAR 
      C              10               C             10 
     DNA-PKCS 
 
  LAMIN 
 
Figure 3.11A: Results of cell 
fractionation experiments, 
following gefitinib treatment, to 
determine the effects on DNA-
PKCS localisation. Gefitinib 
therapy did not alter DNA-PKCS 
localisation in CRI. Lamin 
immunoblots are included to 
show efficient nuclear and 
cytoplasmic separation.  
Figure 3.11B: Results of cell 
fractionation experiments, 
following gefitinib treatment, to 
determine the effects on DNA-
PKCS localisation. Gefitinib 
therapy did not alter DNA-PKCS 
localisation in NCI cells. 
Figure 3.11C: Results of cell 
fractionation experiments, 
following gefitinib treatment, to 
determine the effects on DNA-
PKCS localisation. Gefitinib 
therapy did not alter DNA-PKCS 
localisation in RIN cells. 
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3.5  Discussion  
 
EGFR  is  a  major  tumour  behaviour  determinant,  with  increased  EGFR  expression 
associated  with  resistance  to  anti-tumour  therapy  and  poorer  prognosis.  The 
mechanisms underlying these observations are the subject of intense study. EGFR has 
been shown to be expressed to a much higher degree in cell lines derived from highly 
metastasising  tumours  as  opposed  to  cell  lines  derived  from  same  type  but  poorly 
metastasising tumours. Furthermore, the highly metastasising tumour derived cell lines 
express  higher  concentrations  of  anti-apoptotic  proteins  such  as  Bcl-2,  NFκB,  and 
MDM2. They also expressed lower concentrations of pro-apoptotic proteins such as 
Bax and p53.  
Our early experiments involving EGFR inhibition in NET cell lines had already shown 
promise with potentiation of chemotherapeutic  effects. This work is concerned with 
discovering the nature of EGFR/ DNA-PKCS interactions, if any, in NET cell lines. 
We initially tested for the expression of EGFR by NET cell lines (figure 3.3). All NET 
cell lines being grown in our laboratory were demonstrated to express EGFR, with RIN 
demonstrating the lowest, and CRI expressing the highest, concentration of the protein. 
All NET cell lines expressed large amounts of DNA-PKCS (figure 3.4). 
Bandyopadhyay et al had demonstrated direct EGFR/DNA-PKCS interactions with their 
work  using  cetuximab  to  inhibit  EGFR.  They  demonstrated  a  clear  association  of 
EGFR/DNA-PKCS upon cetuximab treatment. This work encouraged other groups to 
explore this modulation of double-strand DNA repair mechanism further. In particular, 
our group has concentrated on using gefitinib, a small molecule tyrosine kinase inhibitor 
of  EGFR,  to  understand  the  mechanisms  underlying  the  actions  of  EGFR.  We  had 
already made a number of new insights into EGFR biology using, amongst others the 
mcf-7 breast cancer cell line, demonstrating that EGFR inhibition with gefitinib leads to 
decreased overall concentration of DNA-PKCS, physical interaction between EGFR and 
DNA-PKCS leading to movement of DNA-PKCS from nucleus into cytoplasm, decreased 
DNA-PKCS  activity,  and  sensitisation  of  cells  to  ionising  radiation  as  well  as  DNA 
damaging chemotherapy (Friedmann B 2004 & 2006). In view of the limited knowledge 
available regarding the biology of NET cells, and our group’s major interest in these 
tumours, we decided to explore EGFR/DNA-PKCS interactions in NET cell lines.    98 
Co-immunoprecipitation  experiments  were  performed  in  NET  cell  lines  to  look  for 
EGFR/DNA-PKCS association and the effect of EGFR inhibition on it. Our experiments 
demonstrate that there is direct EGFR/DNA-PKCS association, and that the degree of 
association between these 2 proteins can be increased in some NET cell lines, namely 
NCI  and  BON,  by  EGFR  inhibition  using  gefitinib  (figure  3.5-3.7).  However  the 
baseline degree of association, and its increase following gefitinib treatment, is very 
small compared to the overwhelmingly huge quantity of DNA-PKCS that is expressed by 
all NET cell lines. Therefore the contribution of direct EGFR/DNA-PKCS association as 
a  means  of  reducing  nuclear  DNA-PKCS  concentration,  as  has  been  previously 
suggested,  is  probably  minimal.  Other  possible  effects  of  this  increased  association, 
such as switching off the activity of DNA-PKCS or tagging it for degradation need to be 
further studied in NET cell lines.  
This lack of a large increase in EGFR/DNA-PKCS interactions is in stark contrast to the 
initial  published  data  on  EGFR  inhibition,  using  cetuximab,  demonstrating  a  clear 
interaction between these two proteins following cetuximab treatment (Bandyopadhyay 
D  et  al  1998).  We  decided  to  repeat  the  immunoprecipitation  experiments  using 
cetuximab to inhibit EGFR in NET cell lines. However the results in this case were 
negative, that is to say there was lack of any enhancement in association between EGFR 
and DNA-PKCS following cetuximab treatment (figure 3.8). One possible explanation 
for this outcome may be that cetuximab induced EGFR/DNAPKCS interactions are cell 
type specific and the results of Bandyopadhyay et al are not reproducible in NET cell 
lines. However the results of our experiments were negative even in A453 cell-line, the 
same cell line as used in Bandyopadhyay et al’s experiments (figure 3.8). Upon review 
of Bandyopadhyay et al’s experiments a second, more likely explanation can be found 
which can attribute all the positive immunoprecipitation results to flawed experimental 
methodology.  
Those original experiments were performed by treating cells with cetuximab, preparing 
a cell lysate and immunoprecipitating out DNA-PKCS. However Western blot analysis 
revealed not only the 360kDa DNA-PKCS protein band but also a 170kDa protein band, 
which was confirmed to be EGFR. These experiments were taken as evidence of EGFR 
being co-immunoprecipitated with DNA-PKCS due to a direct attachment of EGFR to 
DNA-PKCS.  What  is  more  likely  is  that  cetuximab,  an  anti-EGFR  antibody  used  to 
inhibit EGFR, was in fact acting as an immunoprecipitating antibody. Thus instead of   99 
DNA-PKCS being immunoprecipitated and EGFR being co-immunoprecipitated, there 
were in fact two independent immunoprecipitation processes occurring. These same co-
immunoprecipitation methods have also been employed by K Dittman et al. Since we 
had treated with cetuximab, a high affinity anti-EGFR antibody, immunoprecipitated 
using another anti-EGFR antibody and then looked for DNA-PKCS, we showed that 
only EGFR on its own was pulled out of the cell lysate and that DNA-PKCS did not co-
immunoprecipitate with it. Incidentally, immunoprecipitation of EGFR was much more 
efficient from samples  already treated with cetuximab, despite the concentrations of 
EGFR being the same in the control and cetuximab treated samples, confirming the 
immunoprecipitating qualities of cetuximab.  
Despite these negative co-immunoprecipitation results with cetuximab therapy there is 
ample  evidence  to  suggest  that  EGFR  influences  DNA-PKCS:  Dote  et  al’s  data  on 
inhibition of heat shock protein 90 (Hsp90) indicates that the attenuation of repair of 
radiation induced DNA double strand breaks is due to inhibition of EGFR which then 
leads to decreased interaction of EGFR with DNA-PKCS in the nucleus resulting in 
decreased activation of DNA-PKCS; Jee Hyun Um et al demonstrated that EGFR and 
DNA-PKCS  activity  are  mutually  regulated  by  each  other;  Toulany  M  et  al  2005 
demonstrated decreased radiation induced DNA-PKCS autophosphorylation (and hence 
decreased activation) upon inhibition of EGFR or AKT in K-RAS mutated A549 cells, 
but not in tumour cells containing wild type K-RAS; K-RAS being a member of the 
small GTPase family and involved in EGFR activation induced cell signalling pathway; 
Joanne B Wedhaas et al 2006 demonstrated, using the Radelegans model of radiation 
induced reproductive cell death (a model
 of reproductive clonogen cell death in the 
nematode  Caenorhabditis
  elegan),  the  importance  of  EGFR/RAS/MAPK  network  in 
DNA repair post-irradiation. Dittman et al 2005 have demonstrated radiation induced 
translocation of EGFR to the cellular nucleus, its activation, its physical interaction with 
DNA-PKCS and the activation of DNA-PKCS. (Dittmann K et al 2005, Friedmann B et al 
2004 & 2006, Toulany M et al 2005 ; Wedhaas JB et al 2006).   
 
EGFR activation → ↑GRP association with SOS → ↑RAS-GTP binding → ↑activation 
of Raf → ↑activation of MEK → ↑activation of MAPK→ various cellular effects.    
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Published work from our laboratory and by others had also reported the export of DNA-
PKCS upon EGFR inhibition and had concluded that this was due to the direct binding of 
EGFR to DNA-PKCS (Friedmann BJ et al 2006). We looked for this effect in NET cell 
lines using confocal microscopy techniques as well as analysis of separated cytoplasmic 
and nuclear fractions to determine any changes in the concentration of DNA-PKCS in 
the two compartments upon EGFR inhibition. SHP and BON cell lines demonstrated 
significant changes in the distribution of DNA-PKCS upon EGFR inhibition such that 
gefitinib treatment led to movement of DNA-PKCS from the nucleus to the cytoplasm, 
as  observed  using  confocal  microscopy  (figure  3.10).  This  re-distribution  was 
confirmed for the SHP cell lines by Western blot analysis of separated nuclear and 
cytoplasmic  fractions  to  determine  the  relative  concentration  of  DNA-PKCS  with  or 
without gefitinib treatment (figure 3.10). Similar experiments were not performed using 
the BON cell line due to lack of time. No redistribution of DNA-PKCS was observed for 
the  remainder  of  NET  cell  lines  (figure  3.11).  While  the  discrepancy  between  the 
different cell-lines could possibly be explained by the low level of EGFR expression in 
the RIN cell-lines, as yet the reasons for differential outcomes observed in the other 
NET cell-lines is not clear. It is possible that these differences are due to differential 
expression of proteins which act as adaptors, such GRB2 and SHC, for interactions 
between  EGFR  and  other  proteins  or  possibly  due  to  mutations  in  a  range  of 
intermediary proteins, such as Ras, Raf, MEK etc. 
 
One possible mechanism of reduced  DNA damage repair has been attributed to the 
ability  of  EGFR  inhibitors  to  decrease  DNA-PKCS  concentration  and  activity.  We 
demonstrate here that prolonged exposure of NET cells to gefitinib leads to decrease in 
the concentration of DNA-PKCS. This effect was consistently reproduced in all NET cell 
lines except for RIN (figure 3.6). This lack of effect in RIN cells is likely to be due to 
the  much  lower  expression  of  EGFR  by  this  cell  line.  Reduction  in  DNA-PKCS 
concentration, upon EGFR inhibition with cetuximab, was not observed. This is likely 
to  be  due  to  the  much  shorter  treatment  period  with  cetuximab.  These  are  very 
encouraging results and confirm a very important mode of action of EGFR inhibition 
which is likely to impair non-homologous end joining, essential in double strand DNA 
break repair, for which DNA-PKCS is essential.   
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In  summary  EGFR  inhibition  in  NET  cell  lines  enhances  chemotherapy  related 
reduction  in  cellular  proliferation.  Previous  studies  in  non-NET  cell  lines  have 
demonstrated that EGFR/DNAPKCS interactions play a major role in sensitising cells to 
ionising radiation and DNA damaging radiotherapy. Analysis of the effects of EGFR 
inhibition with gefitinib reveals that: 
i)  There  are  direct  EGFR/DNAPKCS  interactions  in  NET  cell  lines,  which  can  be 
enhanced by EGFR inhibition. 
ii) EGFR inhibition leads to transfer of DNAPKCS from the nucleus to the cytoplasm in 
SHP and BON cell lines but not in CRI, RIN, or NCI cell lines. This difference in the 
observed outcomes may be due to the lack of or mutations in intermediary proteins, 
though proof is needed for this hypothesis. The re-distribution of DNAPKCS is likely to 
lead  to  sensitisation  of  NET  cells  to  ionising  radiation,  which  causes  double-strand 
DNA breaks, DNAPKCS being crucial to their repair.   
iii) Prolonged EGFR inhibition leads to reduction in DNAPKCS concentration in all 
tested NET cell lines except RIN, which displays the lowest levels of EGFR expression. 
This reduction in DNAPKCS is likely to lead to sensitisation of NET cells to ionising 
radiation, which causes double-strand DNA breaks, DNAPKCS being crucial to their 
repair.   
 
Further work is being performed to discover the mechanisms involved in the outcomes 
observed  following  EGFR  inhibition.  In  particular,  the  role  of  EGFR  inhibition  in 
sensitising NET cell lines to ionising radiation; the reasons for differences in DNAPKCS 
re-distribution following EGFR inhibition, in varying NET cell lines; the role of EGFR 
as a transcription factor etc are under study.   
 
 
 
 
3.5.1 APPENDIX 1 
The Immunoprecipitation (IP) Principle 
The principle of an IP is very simple (Figure 3.12). An antibody (monoclonal or 
polyclonal) against a specific target antigen is allowed to form an immune complex with 
that target in a sample, such as a cell lysate. The immune complex is then captured on a 
solid support to which either Protein A or Protein G has been immobilized (Protein A or 
G binds to the antibody, which is bound to its antigen). The process of capturing this   102 
complex from the solution is referred to as precipitation. Any proteins not “precipitated” 
by the immobilized Protein A or G support are washed away. Finally, components of 
the bound immune complex (both antigen and antibody) are eluted from the support and 
analyzed by SDS-PAGE (gel electrophoresis), often followed by Western blot detection 
to verify the identity of the antigen. 
 
Traditional immunoprecipitation involves the following steps: 
1.  Form the antigen-antibody complex (immune complex) by incubating specific 
antibody with the antigen-containing sample for 1 hour to several hours. 
2.  Capture the immune complex on an immobilized Protein A or Protein G agarose 
gel support by incubation for ≈16 hours. 
3.  Remove any non-bound protein (non-immune complex sample components) 
from the precipitated complex by washing gel support with additional sample 
buffer. 
4.  Boil gel support in reducing SDS-PAGE sample loading buffer. 
5.  Recover sample eluted in loading buffer from gel support and analyze by SDS-
PAGE. 
6.  Perform Western blot analysis, probing with antigen-specific antibody. 
  
Figure 3.12. Summary of a traditional immunoprecipitation procedure. 
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Co-IP vs. IP 
Co-immunoprecipitation (Co-IP) is a popular technique for protein interaction 
discovery. Co-IP is conducted in essentially the same manner as an IP. However, in a 
co-IP (Figure 3.13) the target antigen precipitated by the antibody “co-precipitates” a 
binding partner/protein complex from a lysate, i.e., the interacting protein is bound to 
the target antigen, which becomes bound by the antibody that becomes captured on the 
Protein A or G gel support. The assumption that is usually made when associated 
proteins are co-precipitated is that these proteins are related to the function of the target 
antigen at the cellular level. This is only an assumption, however, that is subject to 
further verification. 
 
  
 
Figure 3.13. Summary of a traditional co-immunoprecipitation. 
 
Thus an immunoprecipitation allows for the partial purification of a specific protein 
from a complex protein mixture that is present in a total cell lysate. In addition, co-
immunoprecipitations may identify any protein-protein associations that exist in any 
given circumstance. 
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Chapter 4 
The role of 
99mTechnetium-depreotide in the management of 
neuroendocrine tumours 
 
 
 
The role of 
99mTechnetium-depreotide in the management of 
neuroendocrine tumours. 
Tahir Shah, Ilona Kulakiene, Ann-Marie Quigley, Victoria S Warbey, Rajaventhan 
Srirajaskanthan, Christos Toumpanakis, Daniel Hochhauser, John Buscombe, Martyn 
E Caplin.  
Nuclear Medicine Communications 2008 May; 29(5): 436-40. 
 
Study previously presented at: 
American Gastroenterological Association annual meeting  
Digestive Diseases Week Los Angeles 2006 
British Society of Gastroenterology annual meeting 
Birmingham 2006 
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4.1  Introduction: 
Somatostatin is a hormone with multiple physiological effects including inhibition of 
secretion of other hormones and peptides. Somatostatin binds and acts through cell 
surface somatostatin receptors, of which there are 5 subtypes (SSTRs 1-5) (Chen C 
1992, Buscail L et al 1994, Buscail L et al 1995, Liebmann C 2001). The majority of 
NETs express SSTRs, which can be utilised not only for tumour imaging but also for 
tumour targeted radiotherapy. ¹¹¹In-pentetreotide (OctreoScan®) binds to SSTR2 with 
high  affinity  and  SSTR3/5  with  lower  affinity  (table  4.1).  It  is  widely  used  for 
localisation and staging of NETs with a reported sensitivity of 60-100% (De Herder 
WW et al 2005). It may also identify lesions not clinically suspected or apparent on 
planar radiology.  
Those patients displaying moderate to strong uptake with ¹¹¹In-pentetreotide (Krennig 
score ≥ 2 i.e. uptake greater than normal liver tissue [De Herder WW et al 2005) are 
deemed suitable for treatment with SSTR2 targeting agents such as 
90Y-[DOTA]
0-
Tyr
3-octreotide or 
177Lu-[DOTA]
0-Tyr
3-octreotate. However, some lesions may not be 
OctreoScan®  positive  while  other  lesions  may  potentially  become  OctreoScan® 
negative  with  time  due  to  tumour  dedifferentiation.  Although  a  study  directly 
comparing  ¹¹¹In-pentetreotide  and 
99mTechnetium-depreotide  demonstrated  ¹¹¹In-
pentetreotide to be a superior form of imaging (Lebtahi R et al 2002), we postulated 
that 
99mTc-depreotide may be useful in the subset of NET patients who have negative 
or  only  weakly  positive  ¹¹¹In-pentetreotide  scans,  due  to  its  significantly  higher 
binding affinity for SSTR3 (table 4.1). Here we present our experience relating to this 
sub-group of patients.  
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4.2  Patients, methods, and materials 
This  was  a  prospective  study  of  25  patients  with  histologically  confirmed 
neuroendocrine  tumours.  They  had  either  negative  or  weakly  positive  ¹¹¹In-
pentetreotide imaging (Krenning scale ≤ 1; measured on a scale range 0-4), and were 
consecutively  enrolled  from  our  NET  clinic.  They  underwent  either  paired  ¹¹¹In-
pentetreotide  and 
99mTc-depreotide  imaging,  or  just 
99mTc-depreotide  imaging  if 
within 6 months of the initial ¹¹¹In-pentetreotide scan. Histology was available for 20 
patients, enabling tumours to be graded as low (Ki67 <2%), intermediate (Ki67 2 – 
20%), and high grade (Ki67 >20%) (Table 4.2). The results from the two imaging 
agents  were  compared  and  confirmed  radiologically  using  triple-phase  CT  in  17 
patients, MRI in 2 patients and a combination of CT and MRI imaging in 7 patients. 
Patients  receiving  long-term  long-acting  somatostatin  analogue  therapy  continued 
with their treatment and were scanned 1 week prior to receiving their next injection. 
All  the  clinical  scans  were  performed  within  the  legal  requirements  of  the  UK’s 
Administration  of  Radionuclide  Substance  Advisory  Committee  (ARSAC).  Only 
patients in whom both sets of imaging had been performed at our institution were 
included. 
 
111In-PentetreotideImaging  
Whole-body and tomographic imaging was performed 24 hours after administration 
of 220 MBq of 
111In-pentetreotide, using a double or triple-headed gamma camera 
fitted  with  medium-energy  collimators  (Phillips  Prism  2000XP  and  Phillips  Irix, 
Phillips Medical Technology, Cleveland, Ohio, USA) and the two energy windows set 
at 173 and 247 keV ± 10%. Tomographic imaging was performed of the chest and/or 
abdomen as appropriate using the following parameters: angular range 180°, steps 60,  
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25 second acquisition per projection on the double-headed camera or angular range 
120°,  steps  40,  30  second  acquisition  per  projection  on  the  triple-headed  camera, 
employing a 64 x 64 matrix. The tomographic images were reconstructed using an 
iterative  ordered-subset  expectation  maximization  (OSEM)  programme  with  six 
iterations  and  post-filtered  with  a  count-optimized  Butterworth  filter.  The  images 
were displayed as a full data set of orthogonal slices each of 9 mm thickness. 
 
99mTc-DepreotideImaging  
Whole-body  and  tomographic  imaging  was  performed  at  1  and  4  hours  post 
administration  of  555  MBq  of 
99mTc-Depreotide,  using  a  double  or  triple-headed 
gamma  camera  fitted  with  low-energy  high  resolution  collimators  (Phillips  Prism 
2000XP and Phillips Irix, Phillips Medical Technology, Cleveland, Ohio, USA) with 
a single energy window set at 140 keV ± 10%. Tomographic imaging was performed 
of the chest and/or abdomen as appropriate using the following parameters: angular 
range  180°,  steps  60,  25  second  acquisition  per  projection  on  the  double-headed 
camera or angular range 120°, steps 40, 30 second acquisition per projection on the 
triple-headed camera, employing a 128 x 128 matrix. The tomographic images were 
reconstructed  using  an  iterative  ordered-subset  expectation  maximization  (OSEM) 
programme with six iterations and post-filtered with a count-optimized Butterworth 
filter. The images were displayed as a full data set of orthogonal slices each of 9 mm 
thickness. 
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Scintigraphy reporting 
All images were read from the computer reporting station by at least two trained 
readers. The images obtained from the two modalities were read on different days as a 
means of blinding the readers to the results from the alternate imaging agent. Any site 
of focal uptake of either radiopharmaceutical outside of the expected physiological 
distribution of tracer was identified and noted as abnormal.  In addition any areas of 
focal increased uptake within the liver, spleen, thyroid or colon was also recorded as 
abnormal. For the 
111In-pentreotide imaging any lesions in the liver were assessed 
using the Krenning grading system (De Herder WW et al 2005). 
A  direct  lesion-by-lesion  comparison  was  then  made  between  the  two 
radiopharmaceuticals. Any site of abnormal uptake was also compared with any sites 
of abnormality seen with anatomical imaging (normally triple phase CT or MRI). 
 
 
4.3  Results: 
20  of  25  patients  with  Krenning  score  ≤  1,  for 
111In-pentetreotide  imaging,  had 
histology available for further detailed analysis: of these 40% had high grade tumours, 
a further 35% had intermediate tumours, with the remainder 25% being low grade 
tumours (table 4.3). 13 of the 25 patients had completely negative ¹¹¹In-pentetreotide 
scans whereas the other 12 patients had weakly positive (Krenning score = 1) ¹¹¹In-
pentetreotide  scans  (table  4.3).  The  same  patients,  when  imaged  with 
99mTc-
depreotide, had strongly positive scans (Krenning score ≥ 2) in 8 cases (figure 4.1), 
with the majority of these patients having intermediate or high-grade tumours. 6 of 25 
patients  had  weakly  positive 
99mTc-depreotide  scans  (Krenning  score  =  1).  The 
remainder  11  of  25  patients  had  completely  negative 
99mTc-depreotide  scans  
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(Krenning score = 0) despite the clinical, radiological, and histological confirmation 
of  neuroendocrine  tumours  (table  4.2).  Wilcoxon  Signed  Ranks  Test  confirmed  a 
statistically  significant  difference  between  the  two  scintigraphy  modalities,  with 
99mTc-depreotide  scan  providing  better  imaging  in  this  selected  group  of 
neuroendocrine patients (Z = –2.311; Asymp. Sig. [2-tailed] 0.021).  
Correlations were sought between the tumour grade and scintigraphy results. These 
revealed a negative correlation between tumour grade and Krenning score for 
111In-
pentetreotide scans (Spearman’s rho: –0.446; Sig (2-tailed) 0.049), i.e. the higher the 
tumour  grade  the  lower  the  Krenning  score,  whereas  no  statistically  significant 
correlation  was  found  between  tumour  grade  and  the  Krenning  scores  for 
99mTc-
depreotide imaging. 
The ability of the three imaging modalities to highlight tumour lesions was compared 
(table 4.4). This revealed the two scintigraphic techniques had the ability to highlight 
different lesions within same patients (table 4.4).  
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4.4  Discussion:  
111In-pentetreotide is a well-established scintigraphic agent with high sensitivity and 
specificity  in  NETs.  Further  advances  in  functional  molecular  imaging  are  being 
achieved through the development of positron emission tomography (PET) scanning, 
in particular 
18F-dopa PET/CT and 
68Ga PET/CT, although its use is severely limited 
by availability at present (Ambrosini V et al 2007, Win Z et al 2007). Additional 
information can also be gleaned from detailed analysis of currently available imaging 
techniques.  Indeed  a  large-scale  study  comparing 
111In-pentetreotide  to 
123I-MIBG 
scintigraphy demonstrated that some lesions express appropriate receptors for 
111In-
pentetreotide but not for MIBG whilst others have uptake for MIBG but not for 
111In-
pentreotide (Quigley AM et al 2005). The information thus gained helps individualise 
treatment  with  the  most  appropriate  receptor  targeted  radio-therapeutic  agent,  and 
helps justify the increased costs associated with molecular imaging. 
This  study  compares 
99mTc-depreotide,  an  imaging  agent  with  higher  affinity  for 
SSTR3 than 
111In-pentetreotide, in patients with negative or weakly positive 
111In-
pentetreotide scans. Radiological imaging is also included as an independent means of 
confirming scintigraphy findings. High-resolution triple-phase-contrast  CT was the 
preferred imaging modality, as it is readily available and has high sensitivity  and 
specificity for NET lesions. MRI was used, in selected cases, either because of the 
need for repeated imaging in young patients or in order to visualise suspected tumour 
lesions not visible on CT.  
Our experience with 
99mTc-depreotide in this subset of NET patients demonstrated 
that a significant proportion (8 of 25; 32%) of OctreoScan®-negative patients were 
significantly positive (Krenning score ≥ 2) when imaged using
 99mTc-depreotide. We 
also demonstrated a negative correlation between tumour grade and 
111In-pentreotide  
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scan Krenning scores, i.e. high tumour grade was linked to weaker images. Lack of 
correlation between tumour grade and 
99mTc-depreotide scans highlights the fact that 
99mTc-depreotide imaging is not SSTR2 dependent, as well as indicating that loss of 
SSTR2/5 does not imply loss of other SSTRs.   
These findings imply that: 
i) 
99mTc-depreotide may be able to follow changes in tumour phenotype of 
NET  patients,  i.e.  loss  of  SSTR  subtypes  in  conjunction  with  tumour 
progression from low grade to high grade. 
ii) 
99mTc-depreotide  may  improve  the  sensitivity  of  SSTR  targeted 
scintigraphy for highlighting tumours which do not express SSTR2/5.  
iii) 
99mTc-depreotide may have the ability to highlight tumours suitable for 
treatment with agents with an expanded SSTR subtype affinity, such as 
SOM-230.  
 
In  conclusion, 
111In-pentetreotide  is  highly  sensitive  for  detecting  NETs.  However 
some tumours are 
111In-pentetreotide negative at presentation or become negative with 
time. This study demonstrated that 
99mTc-depreotide, is a significantly better imaging 
agent for detecting NETs in this subgroup of patients, and provides a theoretical basis 
for  targeted  therapy  to  be  performed  with  agents  possessing  an  expanded  SSTR 
subtype  affinity  such  as  SOM230  or 
90Y-DOTA-lanreotide.  Other  experimental 
imaging  techniques  based  on  either  newer  somatostatin  analogues  or  imaging 
modalities, e.g. PET scanning, may also be useful for imaging the higher grade NETs.   
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Radioligand     SSTR1    SSTR2    SSTR3    SSTR4    SSTR5 
¹¹¹In-pentetreotide   >10,000    1.5      30      >1000      1.0       
99mTc-depreotide    >1000      1.0      1.5      >1000      2 
90Y-DOTA-lanreotide     215     4.3      5.1         3.8      10 
SOM230         9.3      1.0      1.5      >1000      0.16 
Table 4.1: Affinity of radiolabelled ligands for SSTR subtypes. Values are listed in nmol/l and indicate the binding affinity 
in terms of the inhibitory constant causing 50% inhibition of specific somatostatin receptor binding (IC50). [Virgolini I et al 
2002, Schmid HA2004]. 
 
 
 
 
Grade           Mitotic count 
a(10 HPF)            Ki-67 index 
b(%) 
G1            <2                  ≤2 
G2               2 – 20                   3 – 20 
G3            >20                  >20 
Table 4.2: Grading proposal for foregut neuroendocrine tumours (Rindi G et al 2006) 
a10 HPF: high powered field = 2mm
2, at least 40 field (at 40x magnification) evaluated in areas of high mitotic density 
bMIB1 antibody: % of 2,000 tumour cells in area of highest nuclear labelling  
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Patient  Diagnosis  ¹¹¹In-
pentetreotide 
(strength) 
99mTc-
depreotide 
(strength) 
Histology 
grade 
1  MTC  1  2  Intermediate 
2  MTC  1  3  - 
3  Hindgut  1  0  Low 
4  Pancreatic  0  1  Intermediate 
5  Hindgut  0  0  High 
6  Bronchial  1  1  Intermediate 
7  Midgut  0  0  High 
8  MTC  1  2  Intermediate 
9  Unknown 
primary 
0  2  High 
10  Midgut  1  2  Intermediate 
11  Hindgut  1  0  Low 
12  Midgut  0  0  Low 
13  Bronchial  0  0  High 
14  Pancreatic  0  0  High 
15  Pancreatic  1  0  Low 
16  MTC  1  1  High 
17  Midgut  0  1  - 
18  Unknown 
primary 
0  2  High 
19  Pancreatic  0  0  Low 
20  Pancreatic  0  0  - 
21  Midgut  0  0  Intermediate 
22  Midgut  0  1  high 
23  Pancreatic  1  1  Intermediate 
24  Thymic  1  3  - 
25  MTC  1  3  - 
 
Table 4.3: Data on the 25 patients assessed. The imaging strength was measured using the Krenning scale [range 0-4]. Tumour grade was 
assigned using the criteria set out in the ENETS consensus document (Rindi G et al 2006). MTC = medullary thyroid carcinoma  
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            Neck             Chest          Spine        Right arm     Left arm         Liver        Abdomen       Pelvis        Right leg        Left leg            Total 
Pt   d  o  ct  d  o  ct  d  o  ct  d  o  ct  d  o  ct  d  o  ct  d  o  ct  d  o  ct  d  o  ct  d  o  ct  d  o  ct 
1  0  0  0  4  5  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  4  5  0 
2  0  0  0  10  3  10  3  0  10  0  0  0  0  0  0  0  0  3  0  0  0  0  0  10  0  0  0  0  0  0  13  3  33 
3  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  1  0  0  0  0  0  0  0  0  0  0  0  1  1 
4  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  3  2  0  0  0  0  0  0  0  0  0  0  0  2  0  3 
5  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
6  0  0  0  1  1  0  0  2  10  1  0  0  1  0  0  0  0  0  0  0  0  0  0  10  1  0  2  1  0  3  5  3  25 
7  0  0  0  0  0  10  0  0  0  0  0  0  0  0  0  0  0  1  0  0  10  0  0  0  0  0  0  0  0  0  0  0  21 
8  1  0  0  2  0  10  1  0  10  0  0  0  0  0  0  3  3  10  0  0  10  0  0  0  0  0  0  0  0  0  7  3  40 
9  0  0  0  0  0  10  5  0  10  3  0  3  3  0  3  0  0  2  0  0  0  0  0  0  3  0  3  3  0  3  17  0  34 
10  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  1  2  1  1  1  0  0  0  0  0  0  2  2  3 
11  0  0  0  0  0  0  0  0  2  0  0  0  0  0  0  0  1  6  0  0  0  0  1  0  0  0  0  0  0  0  0  2  8 
12  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  10  0  0  4  0  0  0  0  0  0  0  0  0  0  0  15 
13  0  0  0  1  2  2  0  0  0  0  0  0  0  0  0  0  0  10  1  1  0  0  0  0  0  0  0  0  0  0  2  2  0 
14  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  1 
15  0  3  0  0  0  10  0  0  0  0  0  0  0  0  0  0  2  10  0  0  10  0  0  0  0  0  0  0  0  0  0  5  30 
16  0  0    2  1    0  0    0  0    0  0    0  0    0  0    0  0    0  0    0  0    2  2   
17  0  0    0  0    0  0    0  0    0  0    1  0  9  0  0    0  0    0  0    0  0    1  0   
18  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  1  0  1  1  0  1  0  0  0  0  0  0  2  0  3 
19  0  0  1  0  0  1  0  0  0  0  0  0  0  0  0  0  0  3  0  0  2  0  0  0  0  0  0  0  0  0  0  0  7 
20  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  2  0  0  0  0  0  0  0  0  0  0  0  2 
21  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  10  0  0  1  0  0  0  0  0  0  0  0  0  0  0  12 
22  0  0  0  0  0  2  0  0  0  0  0  0  0  0  0  2  0  6  0  0  3  0  0  1  0  0  0  0  0  0  2  0  12 
23  0  0  0  0  0  2  0  0  0  0  0  0  0  0  0  0  1  10  0  1  1  1  1  0  0  0  0  0  0  0  1  3  13 
24  0  0  0  1  1  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  1  1 
25  3  3  0  0  0  10  0  0  0  0  0  0  0  0  0  0  0  3  0  0  0  0  0  0  0  0  0  0  0  0  3  3  13 
 
Table 4.4: Site based comparison of lesions detected by each imaging modality. 
d – depreotide; o – octreotide; ct – CT or MRI scan; Pt – patient number. 
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Figure 4.1: 71-year old female patient 
with thymic carcinoid tumour. The 
111In-pentetreotide scan (A) 
demonstrating low-grade uptake in 
the mediastinum (arrow) with 
intensity lower than that in the liver. 
The patient went on to have a 
99mTc-
Depreotide scan (B) illustrating high 
grade uptake in the mediastinum 
(arrows) with intensity greater than 
that in the liver.  
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CHAPTER 5                                          
Alpha-fetoprotein and human chorionic gonadotrophin-β as 
prognostic markers in neuroendocrine tumour patients 
 
 
 
 
 
The role of alpha fetoprotein and β-human chorionic gonadotrophin as 
tumour markers in neuroendocrine tumours. 
T. Shah, M. E. Caplin.  Br J Cancer. 2008; 99: 72-7.  
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human chorionic gonadotrophin subunit beta; hCGβ; chromogranin-A; ChA; Ki-
67 / MIB-1.  
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5.1  Introduction 
Neuroendocrine tumours (NETs) comprise a heterogeneous group of tumours 
classified as being either functional, with symptoms due to hormone secretion, 
or  non-functional  due  to  an  apparent  lack  of  hormone-associated  symptoms 
(Solcia et al 2000). The functional tumours may produce specific hormones the 
measurement  of  which  can  aid  diagnosis  and  management;  for  example 
serotonin with midgut carcinoid tumours, insulin with insulinoma, and gastrin in 
gastrinoma. Currently, the most useful “general” NET marker is plasma CgA 
and recent guidelines recommending that all patients with NETs should have 
CgA measured (Ramage et al 2005, Rindi et al 2006b).  
 
Tumour markers can provide valuable information on tumour functionality and 
presumed  tumour  burden  in  relation  to anti-tumour  therapy.  For example an 
indolent non-functioning NET may produce increased amounts of CgA as the 
first sign of a switch to a more progressive course. Alternatively, anti-tumour 
therapy may not display tumour response as determined radiologically, using 
the  RECIST  criteria,  since  tumour  cells  may  be  replaced  by  fibrosis  with  a 
resultant  lack  of  change  in  overall  tumour  size;  However,  there  may  be  a 
significant  decline  in  the  level  of  circulating  tumour  markers  together  with 
significant  symptomatic  improvement.  Additionally,  tumour  markers  can  have 
prognostic  value:  plasma  neurokinin-A  has  been  shown  to  be  an  accurate 
marker  of  prognosis  in  midgut  NETs,  with  rising  neurokinin-A  levels  despite 
somatostatin analogue therapy, shown to be associated with poorer prognosis 
(Turner et  al  2006); patients  with  CgA  greater  than  5000µg/l  have  a  5  year 
survival of only 22% as opposed to 63% for patients with serum chromogranin-
A levels of less than 5000µg/l (Janson et al 1997). Absolute plasma CgA levels 
may also help to differentiate between localised and diffuse NET spread, as 
well as between chronic active gastritis and NETs (Campana et al 2007). 
 
There  is  a  continuing  need  for  tumour  markers  that  can  provide  further 
diagnostic and prognostic information in NET patients. AFP and hCGβ have 
previously been reported as being elevated in some NET patients, however, the 
utility of these markers in NET patients has not been determined (Ramage et al 
2005). Lokich reported, in a small series, that AFP may be raised in a small 
proportion  of  NET  patients  and  that  it  may  provide  some  useful  information   118 
(Lokich et al 1987).  However this initial report has not been further explored. 
AFP  is  reactivated  in  numerous  cancers,  including  hepatocellular  carcinoma 
and teratocarcinomas. The basis of this reactivation is not well understood, but 
may involve changes in the level or activity of transcriptional regulators (Spear 
et al 1999).  
 
hCGβ  belongs  to  the  glycoprotein  hormone  family  that  also  comprises 
luteinizing  hormone  (LH),  follicle-stimulating  hormone  (FSH),  and  thyroid-
stimulating hormone (TSH). All members are heterodimers consisting of an α 
and a β subunit. The α-subunit, which is common to all glycoprotein hormones, 
contains  92  amino  acids.  The  β chains  determine  the  biological  activity  and 
display  extensive  homology,  with  that  between  hCGβ  and  LHβ  being  about 
80%. Human chorionic gonadotropin (hCG) is mainly used for detection and 
monitoring  of  pregnancy,  pregnancy-related  disorders  and  as  an  extremely 
sensitive and specific marker for trophoblastic tumours of placental and germ 
cell origin (Stenman et al 2006).  
 
The  aims  of  this  study  were  to  determine  the  role  of  AFP  and  hCGβ  as 
diagnostic and prognostic markers, their relationship to other tumour markers, 
as well as their value in predicting disease progression in NET patients. 
 
 
 
5.2  Patients and methods 
We have developed a database of neuroendocrine tumour patients, containing 
biochemical,  radiological,  histological  and  survival  data  available  for  360 
patients. Patients had been consented for approval of utilisation of blood and 
tissue results for research purposes. Pre-treatment biochemical data included 
tumour markers α-fetoprotein, hCGβ, and CgA. Histology data was collected in 
order  to  determine  tumour  grade.  NET  histological  grading  was  assessed 
according to the new TNM classification, including differentiation of tumour and 
proliferation index Ki-67 (MIB-1): thus classified as low grade (G1) mitotic count 
<2 / 10 high powered fields (HPF) or Ki-67 <2%; intermediate grade (G2) mitotic 
count 2 - 20 / 10 HPF or Ki-67 3 - 20%;  and high grade (G3) mitotic count >20 / 
10 HPF or Ki-67 >20% (Rindi et al 2006). Of the 360 patients in the database,   119 
294 had been tested for α-fetoprotein. Of these 294 patients a subset of 28 
patients was identified with serum α-fetoprotein levels at least 1.5x the upper 
limit of normal. A further 40 patients with normal α-fetoprotein were randomly 
chosen from the database to act as an age and sex matched control for the α-
fetoprotein-high patients. 268 patients had been tested for hCGβ, of which 33 
patients had hCGβ levels at least 1.5x the upper limit of normal.  A further 33 
patients with normal hCGβ were randomly chosen from the database to act as 
an age and sex matched control for the hCGβ-high patients. 
 
A subset of 21 patients was derived from the AFP and hCGβ groups that had 
raised AFP and hCGβ in combination. This subset comprised 9.1% of patients 
in whom the 2 markers had been measured.  Control group had normal serum 
AFP and hCGβ levels. 
 
Statistical  Package  for  the  Social  Sciences  (SPSS)  was  utilised  in  order  to 
determine any  differences  between  the  two  tumour marker  groups  and  their 
respective controls [Mann-Whitney U test for non-parametric samples; table 5.1, 
5.3  &  5.5];  to  discover  any  correlations  between  the  parameters  recorded 
[Spearman's  rho;  tables  5.2,  5.4  &  5.6];  and  to  look  for  survival  differences 
[Kaplan-Meier survival curves; figures 5.1, 5.2 & 5.3].     
 
 
5.3  Results  
5.3.1  AFP group:  
28 of 294 patients (9.5%) had elevated AFP. The AFP-high and control groups 
were compared using Mann-Whitney-U test, for 2 non-parametric samples, in 
order to look for significant differences in age and gender make-up of the 2 
groups. This confirmed the 2 groups to be evenly matched for age and sex 
(table 5.1). There were significant differences between the two groups for the 
measured tumour markers AFP, hCGβ, CgA, MIB-1 (table 5.1), and survival as 
measured from the time of diagnosis (figure 5.1; table 5.1).  
The data from the 2 groups was then combined for further statistical analysis in 
order  to  determine  possible  correlations  between  the  5  parameters  studied: 
absolute levels of AFP, MIB-1, hCGβ, CgA, and patient survival. Spearman's 
rho test was applied to the data (table 5.2). Serum AFP levels were discovered   120 
to correlate with the 4 parameters measured. Thus, rising serum AFP levels 
strongly  and  positively  correlated  with  rising  hCGβ,  CgA  levels,  and  MIB-1 
scores. There was an additional strongly negative correlation with survival from 
the time of diagnosis (significant at the 0.01 level) (table 5.2).  
 
 
5.3.2  hCGβ group:  
33 of 268 patients (12.3%) had elevated hCGβ. The hCGβ-high and control 
groups  were  compared  using  Mann-Whitney-U  test,  for  2  non-parametric 
samples, in order to look for significant differences in age and gender make-up 
of the 2 groups. This confirmed the 2 groups to be evenly matched for age and 
sex (table 5.3). There were significant differences between the two groups for 
the  measured  levels  of  tumour  markers  hCGβ,  AFP,  CgA,  and  survival  as 
measured  from  the  time  of  diagnosis  (table  5.3;  figure  5.2);  but  not  MIB-1 
scores (table 5.3).  
The data from the 2 groups was then combined for further statistical analysis in 
order  to  determine  possible  correlations  between  the  5  parameters  studied: 
absolute levels of hCGβ, AFP, MIB-1, CgA, and survival from time of diagnosis. 
Spearman's rho test was applied to the data (table 5.4).  
Serum  hCGβ  levels  were  discovered  to  be  correlated  with  3  of  4  other 
parameters measured. That is: rising serum hCGβ levels strongly and positively 
correlated  with  rising  AFP,  and  CgA,  levels.  Rising  hCGβ  levels  negatively 
correlated with survival from the time of diagnosis. (significant at the 0.01 level) 
[table 5.4]. No correlation was found between hCGβ levels and MIB-1 score. 
 
 
5.3.3  Combined AFP/hCGβ group:  
21 of 230 patients (9.1%) had combined elevation of serum AFP and hCGβ. 
The combined AFP/hCGβ-high and control groups were compared using Mann-
Whitney-U test, for 2 non-parametric samples, in order to look for significant 
differences in age and gender make-up of the 2 groups. This confirmed the 2 
groups to be evenly matched for age and sex (table 5.5). There were significant 
differences between the two groups for the measured levels of tumour markers 
hCGβ, AFP, CgA, and survival as measured from the time of diagnosis (table 
5.5; figure 3); but not MIB-1 scores (table 5.5).    121 
The data from the 2 groups was then combined for further statistical analysis in 
order  to  determine  possible  correlations  between  the  5  parameters  studied: 
absolute levels of hCGβ, AFP, MIB-1, CgA, and survival from time of diagnosis. 
Spearman's rho test was applied to the data (table 5.6).  
These statistical tests discovered the serum AFP levels to correlate with the 4 
parameters measured. That is: rising serum AFP levels strongly and positively 
correlated with rising hCGβ, CgA levels, and MIB-1 scores; Rising serum AFP 
strongly  and  negatively  correlated  with  survival  from  the  time  of  diagnosis 
(significant at the 0.01 level) (table 5.6). Serum hCGβ levels correlated with 3 of 
4 other parameters measured. That is: rising serum hCGβ levels strongly and 
positively  correlated  with  rising  AFP,  and  CgA,  levels.  Rising  hCGβ  levels 
negatively correlated with survival from the time of diagnosis. (significant at the 
0.01 level) [table 5.6]. No correlation was found between hCGβ levels and MIB-
1 score (table 5.6). 
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5.4   Discussion: 
A number of putative tumour markers are measured in NET patients, with CgA 
having the highest expression in NETs and being considered the most useful 
diagnostic  and  prognostic  marker  (Turner  et  al  2006,  Janson  et  al  1997, 
Campana et al 2007). Tumour markers are measured at regular intervals and 
may  be  useful  for  monitoring  disease  progression.  Often  a  rise  in  tumour 
marker levels may precede clinical indicators of disease progression such as 
worsening  diarrhoea,  facial  flushing,  and  weight  loss,  as  well  as  objective 
indicators of disease progression as determined radiologically. Furthermore, an 
increase  in  the  number  of  expressed  tumour  markers  is  associated  with 
worsening prognosis (Ardill & Erikkson 2003).  
 
To date there are only limited data on most tumour markers measured in NET 
patients, which has thus created uncertainty about their role. Clinical impression 
of a linkage between high-grade, aggressive tumours and a rise in serum AFP 
and hCGβ levels led us to perform a systematic review of the utility of AFP and 
hCGβ measurement in our NET patients. Although, very little is known about 
AFP in NETs, some useful data already exists on the expression and value of 
alpha  and  beta  subunits  of  hCG  (Nobels  et  al  1997,  Heitz  et  al  1987, 
Grossmann et al 1994, and Eriksson et al 1989). These subunits have been 
shown to be raised in a significant proportion of NET patients and to have the 
ability  to  differentiate  between  benign  and  malignant  gastroenteropancreatic 
tumours (Grossmann et al 1994, Eriksson et al 1989, and Heitz et al 1987). 
However, neither AFP nor sub-units of hCG are able to differentiate between 
NETs and other tumours (Nobels et al 1997, Yuen & Lai 2005).  
 
This analysis of a large NET patient database demonstrates, for the first time, 
the ability of two easily measurable agents to prognosticate in NET patients. 
Both  AFP  and  hCGβ  are  shown  to  be  related  to  poorer  survival,  with  the 
clearest difference being seen between the group of patients with combined rise 
in AFP and hCGβ in comparison to controls matched for age at diagnosis and 
sex. However, only AFP associated with Ki-67. This can be explained by the 
fact that there are significant differences in the disease stage between the AFP-  123 
high  group  and  its  control  group,  whereas  no  significant  differences  in  the 
disease  stage  existed  between  the  hCGβ-high  group  and  its  control  group 
(tables 5.1 & 5.3). 
 
Although overall AFP is only elevated in a minority of NET patient, this data 
analysis demonstrates the ability of AFP to highlight a group of NET patients 
with  aggressive,  high-grade  tumours  and  poor  prognosis.  Interestingly,  four 
patients  with  raised  AFP  did  not  have  liver  metastases  but  did  have  large 
volume disease elsewhere (neck, peritoneum, and chest). Thus AFP is likely to 
be a marker of tumour cell de-differentiation rather than a marker of hepatic 
metastases from NETs.    
 
hCGβ  also  provides  prognostic  information  with  its  demonstrated  correlation 
with impaired survival and other markers of a poor outcome, namely CgA and 
AFP. When hCGβ is high, as defined by levels > 1.5 x upper limit of normal, the 
Mann Witney U test applied to these values demonstrates a clear difference in 
survival  between  the  2  groups  (table  5.3).    On  determining  a  correlation 
between  the  absolute  hCGβ  level  and  degree  of  impairment  of  survival, 
although there is a trend to impaired survival this is not a statistically significant 
(table 5.4). The results of these analyses demonstrate that an abnormally high 
hCGβ  is  more  informative  than  the  absolute  level  itself.  Thus  hCGβ,  when 
raised, is a marker of poor prognosis (table 5.3, figure 5.2).  
 
The  clearest  predictions,  however,  can  be  made  for  those  patients  with  a 
combined  rise  in  both  serum  AFP  and  hCGβ  levels.  These  are  strongly 
associated with high CgA levels and worsening prognosis. Conversely, patients 
with normal AFP and hCGβ levels have low serum CgA levels and an excellent 
5 year prognosis (figure 5.3).  
 
Most NET patients have extensive metastases at the time of diagnosis. The 
indolent  nature  of  these  tumours  means  that  even  in  the  presence  of  liver 
metastases,  the  5  year  survival  rates  are  surprisingly  good.  However,  a 
proportion  of  patients  have  rapidly  progressive  disease,  at  diagnosis,  which   124 
requires  aggressive  management  with  cytoreductive  therapies,  hopefully 
resulting  in  better  symptom  control  and  improved  survival.  Predicting  the 
behaviour of NETs in individual cases has to date relied on tumour histology, 
serum CgA levels and serial radiology imaging. This data clearly demonstrates 
the utility of AFP, hCGβ, CgA, and possibly Ki-67 index in highlighting those 
patients,  with  WHO  stage  IV  disease,  that  are  going  to  require  intensive 
monitoring and possibly early and aggressive therapy. Conversely, patients with 
favourable results can be re-assured about their medium to long-term survival, 
and monitored less intensely with confidence, perhaps six monthly as opposed 
to three to four monthly for those patients with for example elevated AFP and 
hCGβ. 
 
This is a retrospective study and the results highlight the worth of performing a 
prospective study to assess these markers. 
 
In conclusion, this study has identified AFP and hCGβ to be capable of 
providing significant prognostic information relevant to the management of NET 
patients.   125 
 
 
  High AFP  Control  P value 
(Mann-Whitney-U 
test) 
Age at diagnosis  51  48  .597 
Sex (M/F)  15/13  18/22  .495 
DIAGNOSIS:        
Metastatic NET  
(of uknown 
primary) 
9  13   
Pancreatic NET  11  16   
Gastrinoma   1  2   
Bronchial   2  4   
Midgut NET  1  3   
Hindgut NET  1  0   
MTC  1  1   
Thymic NET  1  1   
Pelvic NET  1  0   
Mean AFP  
(0-11.3ng/ml) 
273.8  3.5  0.001 
Mean hCGβ  
(<2.5mIU/ml) 
21.3  1.6  0.001 
Mean CgA  
(0-60U/L) 
423  113  0.002 
Mean Ki-67  
(MIB-1)  
21   10   0.009 
Mean survival 
(months) 
37.6  69  0.001 
Stage IV disease 
(WHO 
classification) 
24 of 28 (86%)  25 of 40 (63%)  0.037 
Table 5.1: Comparison of demographic and tumour markers data for the 
raised-AFP and control groups demonstrating the two groups to be evenly 
matched for age, gender, and diagnosis. Significant differences between the 
two groups are apparent for the expression of tumour markers AFP, hCGβ, 
CgA, Ki-67 score, and survival from the time of diagnosis.  
 
       
Ki-67 
(MIB1)  hCGβ   CgA 
Survival 
in 
months 
Spearman's 
rho 
AFP  Correlation 
Coefficient  .381(**)  .558(**)  .451(**)  -.419(**) 
    Sig. (2-
tailed)  .007  .000  .000  .001 
**  Correlation is significant at the 0.01 level (2-tailed). 
Table 5.2: Correlation of AFP levels with Ki-67 score, serum hCGβ and CgA 
levels, as well as survival in NET patient.  
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  High hCGβ  Control  P value 
(Mann-Whitney-
U test) 
Age at diagnosis  55  54  .891 
Sex (M/F)  16/17  16/17   
DIAGNOSIS:        
Metastatic NET  
(of uknown primary) 
8  7   
Pancreatic NET  15  11   
Gastrinoma   2  1   
Bronchial   4  5   
Midgut NET  1  6   
Hindgut NET  1  1   
MTC  1  1   
Thymic NET  1  1   
Mean hCGβ  
(<2.5mIU/ml)  
198.7   2.0   0.001 
Mean AFP  
(0-11.3ng/ml) 
238.1  7.9  0.001 
Mean CgA  
(0-60U/L) 
414.2  180.3  0.02 
Mean Ki-67 (MIB-1)  
 
13   14  0.63 
Mean survival 
(months) 
48  57.3  0.037  
Stage IV disease 
(WHO 
classification) 
27 of 33 (82%)  24 0f 33 (73%)  0.382 
Table 5.3: Comparison of demographic and tumour markers data for the 
raised-hCGβ and control groups demonstrating the two groups to be evenly 
matched for age, gender, and diagnosis. Significant differences between the 
two groups are apparent for the expression of tumour markers AFP, hCGβ, 
CgA and survival from the time of diagnosis.  
 
     
Ki-67  
(MIB1)  AFP  CgA 
Survival 
in  
months 
Spearman's 
rho 
hCGβ  Correlation 
Coefficient  .012  .634 
(**)  .291(*)  -.229 
      Sig. (2-
tailed)  .931  .000  .019  .074 
**  Correlation is significant at the 0.01 level (2-tailed). 
*  Correlation is significant at the 0.05 level (2-tailed). 
Table 5.4: Correlation of hCGβ levels with AFP and CgA levels. There is also 
a trend towards a statistically significant correlation between hCGβ levels and 
survival, but clear absence of linkage between hCGβ levels and Ki-67 score.  
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  Combined raised 
AFP and hCGβ 
Control  P value 
(Mann-Whitney-
U test) 
Age at diagnosis   55.4  55.4  0.691 
Sex (M/F)  13/8  15/13   
DIAGNOSIS:        
Metastatic NET  
(of uknown primary)                                                                                                                                                                
6   6   
Pancreatic NET  10  10   
Gastrinoma   0  0   
Bronchial   2  5   
Midgut NET  0  5   
Hindgut NET  1  1   
MTC  1  2   
Thymic NET  1  1   
Mean AFP  
(0-11.3ng/ml) 
371.7  35.4  0.001 
Mean hCGβ  
(<2.5mIU/ml) 
283.6  2.2  0.001 
Mean CgA  
(0-60U/L) 
511  210  0.014 
Mean Ki-67  
(MIB-1)  
15.6  11.9  0.283 
Mean survival 
(months) 
29.9  61.2  0.001 
Stage IV disease 
(WHO 
classification) 
18 of 21   (86%)                                                                            20 of 28 (71%)  0.240 
Table 5.5: Comparison of demographic and tumour markers data for the 
combined raised serum hCGβ/AFP levels and control groups demonstrating 
the two groups to be evenly matched for age, gender, and diagnosis. 
Significant differences between the two groups are apparent for the 
expression of tumour markers AFP, hCGβ, CgA and survival from the time of 
diagnosis.  
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Ki-67 
(MIB1)  AFP  hCGb  CgA 
Survival 
in 
months 
Spearman's 
rho 
AFP  Correlation 
Coefficient  .330(*)  1.000  .778(**)  .413(**)  -.486(**) 
    Sig. (2-
tailed)  .035  .  .000  .004  .001 
Spearman's 
rho 
hCGb  Correlation 
Coefficient  .090  .778(**)  1.000  .310(*)  -.410(**) 
    Sig. (2-
tailed)  .575  .000  .  .032  .005 
**  Correlation is significant at the 0.01 level (2-tailed). 
*  Correlation is significant at the 0.05 level (2-tailed). 
Table 5.6: Correlation of AFP levels with Ki-67 score, serum hCGβ and CgA 
levels, as well as survival in NET patient.  
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Figure 5.1: Kaplan-Meier graph comparison of 5-year survival between 
the high-AFP and control (normal-AFP) groups (p=0.001).   130 
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Figure 5.2: Kaplan-Meier graph comparison of 5-year survival between 
the high-hCGb and control (normal-hCGb) groups (p=0.037) 
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Figure 5.3: Kaplan-Meier graph comparison of 5-year survival between 
the combined high-AFP/hCGb and control (normal-AFP/hCGb) groups 
(p=0.001). 
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CHAPTER 6 
CONCLUSIONS AND FUTURE WORK  
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Neuroendocrine tumours are rare cancers therefore there have been major logistical 
difficulties in studying them. Recently the care of these patients has started to be 
centralised  which  is  providing  the  basis  for  the  evaluation  and  development  of 
diagnostic  techniques,  the  study  of  neuroendocrine  tumour  biology  as  well  as  the 
assessment of novel therapeutic approaches.  
This  thesis  provides  new  insights  into:  the  diagnostic  and  prognostic  value  of 
biochemical tumour markers; the role of scintigraphic agent depreotide for tumour 
staging  and  determining  suitability  for  targeted  radiotherapy;  as  well  as  tumour 
biology and novel targets for therapy in neuroendocrine tumours. 
 
Chapter 2: The traditional DNA-damaging cytotoxic agents are of limited
 efficacy in 
the  treatment  of  neuroendocrine  tumours  of  the  gastrointestinal
  tract  (NETs). 
Characterization of specific molecular features
 of various cancer types has prompted a 
new era of molecular
 therapeutics with the development of more selective targeted
 
agents.  Within  this  new  setting,  there  is  a  great,  as  yet  unexploited,
  therapeutic 
potential in the field of NETs. One possible new therapeutic target showing promise 
in  various  common  tumour  types,  including  head  and  neck  and  colon  cancer,  is 
epidermal growth factor receptor (EGFR). This cell surface receptor is over-expressed 
in most tumour types and is associated with resistance to anti-tumour therapy and 
poor prognosis. Study of EGFR activation and signalling in various cell types has 
demonstrated the activation of downstream pathways that ultimately lead to enhanced 
cell-survival, proliferation, and tumour metastases. This work had been applied to the 
NET  field  with  demonstration  of  activation  of  ERK1/2  and  Akt/PKB  (2  tyrosine 
kinases  which  are  important  components  of  EGFR-related  intra-cellular  signalling 
pathways) in NET cell lines.  
This chapter details a large-scale immunohistochemical study performed on tumour 
tissue  obtained  from  98  NET  patients.  The  expression  of  EGFR  and  its  activated 
form, pEGFR, was studied using specific high affinity antibodies raised against these 
two forms. The expression of phosphorylated forms of ERK1/2 and Akt/PKB was 
also studied. This large scale study of EGFR expression, activation and activation of 
member  enzymes  of  downstream  pathways  is  the  first  such  study  in  NET  tissue 
samples. We demonstrated not only the presence of these signalling molecules in their 
activated forms in NET tissue but also a correlation between EGFR activation and the 
activation of ERK1/2 and Akt/PKB.   134 
This  study  provides  strong  scientific  basis  for  the  testing  of  available  EGFR 
inhibitors,  such  as  cetuximab  and  gefitinib,  in  patients  with  NETs.  It  also  invites 
further  research  into  the  mechanisms  underlying  the  observed  effects  of  EGFR, 
particularly in NET tissue and NET cell-lines. 
 
Chapter  3:  In  several  cancers,  EGFR  is  an  important
  determinant  of  treatment 
response  to  anti-tumour  therapy.  Thus,  it  is  imperative  to  understand  how  EGFR 
mediates these responses. There is evidence that ionising radiation-induced activation
 
of  EGFR  increases  tumour  cell  proliferation  through  the  activation
  of  the 
EGFR/RAS/mitogen-activated  protein  kinase/extracellular
  signal-regulated  kinase 
kinase pathway (Reardon DB et al 1999, Suy S et al 1997), which is thought
 to result 
in rapid repopulation after radiation exposure (Withers HR et al 1988, Dent P et al 
2003, Schmidt-Ullrich RK et al 1997).
 EGFR may also promote survival through the 
activation  of  the
  phosphatidylinositol  3-kinase  and  protein  kinase  B/AKT  kinase
  
(Contessa JN et al 2002, Toulany M et al 2005). A third mechanism implicates a 
direct role of EGFR
 as a mediator in the repair of IR-induced DNA damage. Recent 
evidence  demonstrates  ionising  radiation  induced  rapid  EGFR  translocation  to  the 
nucleus
 and subsequent binding to both the catalytic and regulatory subunits of the
 
DNA-dependent protein kinase (DNA-PK) (Dittmann K
b et al 2005). DNA-PK is a 
critical
  component  of  the  nonhomologous  end-joining  (NHEJ)  repair  pathway
  that 
plays a dominant role in repair of IR-induced DNA damage
 in higher eukaryotes. 
DNA-PK comprises three subunits, the 465-kDa
 catalytic subunit, DNA-PKcs, and 
two regulatory subunits, Ku70
 (70-kDa) and Ku80 (80-kDa), which associate with 
XRCC4, DNA
 ligase IV, and Artemis at sites of double-strand breaks (DSB)
 to bring 
about the physical rejoining of DSB ends. Thus, EGFR interactions
 with DNA-PKcs 
seem crucial to the repair of DNA damage induced by DNA-damaging anti-tumour 
therapy.  
EGFR/DNA-PKcs interactions are only partially understood in general and have not 
been studied in relation to neuroendocrine tumours.   
Initial work on EGFR/DNA-PKCS interactions was carried out by Bandyopadhay et al 
who showed a direct interation between EGFR and DNA-PKCS upon EGFR inhibition 
with the anti-EGFR antibody ‘cetuximab’. Further work performed by Friedmann et 
al  confirmed  increased  associations  between  EGFR  and  DNA-PKCS  upon  EGFR 
inhibition with small-molecule tyrosine kinase inhibitor ‘gefitinib’. EGFR inhibition   135 
by gefitinib led to delayed repair of cisplatin and etoposide induced DNA damage. 
This  was  felt  to  be  at  least  partly  due  to  the  sequestration  of  DNA-PKCS  in  the 
cytoplasm due to its direct binding to EGFR upon EGFR inhibition with gefitinib. 
Reduction  in  DNA-PKCS  activity  has  also  been  noted  in  conjunction  with  EGFR 
inhibition. Other mechanisms likely to play a role in sensitising to DNA damaging 
therapy are the attenuation of signalling through the EGFR/RAS/mitogen-activated 
protein kinase and Akt pathways.  
This chapter details work carried out to determine EGFR/DNA-PKCS interactions, and 
the effects of EGFR inhibition on these interactions, in NET cell-lines. Five cell lines 
with neuroendocrine features were used to assess the expression of EGFR and DNA-
PKCS, direct EGFR/DNA-PKCS interactions and their modulation by EGFR inhibition, 
the effects of EGFR inhibition on DNA-PKCS sub-cellular localisation. 
It was demonstrated that: 
1.  EGFR is expressed by all NET cell lines, though to various extent. 
2.  DNA-PKCS is expressed in very large quantities by all NET cell lines. 
3.  There are baseline EGFR/DNA-PKCS interactions seen in all cell lines, 
which  can  be  increased  by  EGFR  inhibition  in  NCI  and  BON  cell 
lines. 
4.  EGFR inhibition with gefitinib led to redistribution of DNA-PKCS from 
the nucleus to the cytoplasm in SHP and BON cell lines.  
5.  EGFR inhibition led to a marked decrease in DNA-PKCS expression in 
all but the RIN cells. 
6.  No  increase  in  EGFR/DNA-PKCS  interactions  was  observed  upon 
EGFR inhibition with cetuximab.  
Thus it is apparent that EGFR inhibition has a role to play in NETs. This work has 
uncovered  some  of  the  mechanisms  of  EGFR/DNA-PKCS  interactions  and  their 
modulation by EGFR inhibition. The work outlined in chapters 2 and 3 provides a 
strong scientific basis for the trial of EGFR inhibitors in NET patients. In view of the 
synergistic effects of EGFR inhibition with DNA-damaging therapy, as observed in-
vitro as well as in-vivo, it makes sense to use EGFR inhibition in combination with a 
DNA-damaging agent.  
A  successful  mode  of  DNA-damaging  treatment  given  to  NET  patients  is  SSTR-
targeted radiotherapy. However, its efficacy is limited by repopulation of tumour by 
radio-resistant  cells.  We  postulate  that  combining  EGFR  inhibition  with  SSTR-  136 
targeted radiotherapy will sensitise these tumours to radiotherapy treatment, leading 
to enhanced responses and hopefully prolonged survival in NET patients. For these 
reasons  a  phase  II  clinical  trial  of  combined  EGFR  inhibitor  therapy  and  SSTR-
targeted radiotherapy is planned. 
Further in-vitro work is also being performed in order to determine the effects of 
EGFR inhibition on irradiated NET cell-lines and to understand the various actions of 
EGFR on intra-cellular cell survival pathways, as well as its translocation within the 
cell and its interactions with DNA-PKCS.  
 
Chapter 4: Somatostatin is a peptide hormone which binds and acts through cell 
surface somatostatin receptors, of which there are 5 subtypes (SSTRs 1-5) (Chen C 
1992, Buscail L et al 1994, Buscail L et al 1995, Liebmann C 2001). Majority of 
NETs express SSTRs, particularly SSTR 2 and 5, which can be utilised not only for 
tumour  imaging  but  also  for  tumour  targeted  radiotherapy.  ¹¹¹In-pentetreotide 
(OctreoScan®),  based  on  a  somatostatin  analogue,  binds  to  somatostatin  receptor 
subtype 2 (SSTR2) with high affinity and is the most widely used as well as being the 
most  sensitive  scintigraphic  agent  for  localisation  and  staging  of  NETs,  with  a 
reported sensitivity of 60-100% (De Herder WW et al 2005). However, not all NETs 
express SSTR2 while others may express it initially while becoming SSTR2 negative 
through  the  course  of  disease,  either  due  to  SSTR2  targeted  radiotherapy  or  in 
conjunction with transformation of tumour grade from low to high. Unfortunately, the 
lack of SSTR2 expression not only lowers the sensitivity of somatostatin receptor 
scintigraphy, but since a strongly positive scan is a pre-requisite for SSTR-targeted 
radiotherapy it also deprives some patients of a valuable treatment modality.  
This chapter provides evidence for the usefulness of 
99mTc-depreotide, a scintigraphic 
agent  with  an  expanded  SSTR-subtype  affinity,  in  improving  the  sensitivity  of 
scintigraphic imaging. 
99mTc-depreotide had previously been compared, head to head, 
with OctreoScan® and found to be less sensitive. We therefore opted to concentrate 
on  patients  with  negative  or  weakly  positive  OctreoScan®  and  performed 
99mTc-
depreotide scans in this subgroup of NET patients.  
It was discovered that: 
1)  OctreoScan® negativity correlated with increasing tumour grade. 
2)  1/3
rd  of  OctreoScan®-negative  patients  were  significantly  positive  when 
imaged using 
99mTc-depreotide.   137 
 
This study demonstrates the feasibility of improving the sensitivity of SSTR-targeted 
scintigraphy  using  agents  with  an  expanded  spectrum  of  SSTR-subtype  affinities. 
This not only improves NET diagnosis and staging but will lead to better treatment 
options for NET patients. 
 
Chapter 5: Extensive use is made of a battery of tumour markers for diagnosis and 
follow-up in NET patients. However, the evidence to define the usefulness and role 
has  been  lacking  for  some  of  these  markers,  including  for  AFP  and  hCGβ.  This 
chapter details the prognostic values of biochemical tumour markers AFP and hCGβ 
in neuroendocrine tumour patients. Data was extracted from the NET patient database 
and  analysed  to  determine  any  relationships  between  these  markers  and  clinically 
significant outcomes such as patient survival.  
This  study  reveals  AFP  and  hCGβ  to  be  elevated  in  high-grade  neuroendocrine 
tumours with a rapidly progressive course and poorer survival. They are also found to 
correlate with chromogranin-A, which is known to be a marker of tumour burden and 
to have prognostic value. Thus AFP and hCGβ are clinically important in NETs and 
should be routinely measured. They are also likely to be useful in helping to plan 
treatment and in determining prognosis. 
 
 
 
In conclusion, NETs are rare cancers that are difficult to diagnose, prognosticate on or 
treat. Because of the rare nature of these tumours their pathophysiology is not well 
studied. Their relative chemo-resistance means that innovative methods of treatment 
have been applied in order to control symptoms and prolong survival. This research 
contributes significantly to diagnostic sensitivity, prognostic ability, and is likely to 
lead to improved treatment options in the mode of combined EGFR inhibition and 
targeted radiotherapy. Furthermore, it contributes to the better understanding of NET 
pathophysiology, through the discovery of activated EGFR signalling pathways, and 
contributes  to  a  better  understanding  of  the  effects  of  EGFR  inhibition  on 
EGFR/DNA-PKCS interactions which are important in cellular repair and survival.     138 
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